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Under the Direction of Binghe Wang, PhD 
ABSTRACT 
Prodrug is an often-used approach to facilitate the delivery of an active drug to an 
appropriate site with targeted release whenever possible. Proper prodrug design often relies on a 
few essential requirements: prodrug stability, triggered release, and selectivity. In the last few 
decades, there have been impressive progress in prodrug development. However, the delivery of 
gasotransmitters and ensuring linker stability while allowing drug release at the desired site of 
action are among remaining challenges.  The dissertation work focuses on developing new 
chemical strategies to address these two issues using   hydrogen sulfide (H2S) as a model for 
gasotransmitters and doxorubicin as a model for anticancer compounds. In the gasotransmiter part 
of the project, we developed a “trimethyl lock”-lactonization based approach to deliver pure H2S, 
an esterase-sensitive acetal approach to deliver persulfide, and an enrichment-triggered release 
method to deliver doxorubicin. The therapeutic effects of these prodrugs were evaluated in a 
combination of in vitro and in vivo models.  The concepts described should be generally applicable 
and should be very useful to those interested in prodrug design. 
INDEX WORDS: Hydrogen sulfide, Persulfide prodrugs, Prodrug activation, Drug delivery, 
Click and release, Enrichment to release, Kinetic control drug release.  
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1 DEVELOPMENT OF ESTERASE-SENSITIVE PRODRUGS WITH TUNABLE 
RELEASE RATES AND DIRECT GENERATION OF HYDROGEN SULFIDE 
Abstract: This chapter is mainly based on my publications: Angew. Chem. Int. Ed. in 2016 
from page 4514-4518, Med. Res. Rev. in 2017, DOI: 10.1002/med.21433.  Hydrogen sulfide (H2S) 
is an endogenously produced signaling molecule in mammals and is critical to human health and 
disease. Prodrugs that release hydrogen sulfide upon esterase-mediated cleavage of an ester group 
followed by lactonization are described herein. By modifying the ester group and thus its 
susceptibility to esterase, and structural features critical to the lactonization rate, H2S release rates 
can be tuned. Such prodrugs directly release hydrogen sulfide without the involvement of perthiol 
species, which are commonly encountered with existing H2S donors. Additionally, such prodrugs 
can easily be conjugated to another non-steroidal anti-inflammatory agent, leading to easy 
synthesis of hybrid prodrugs. As a biological validation of the H2S prodrugs, the anti-inflammatory 
effects of one such prodrug were examined by studying its ability to inhibit LPS-induced TNF-α 
production in RAW 264.7 cells. This type of H2S prodrugs shows great potential as both research 
tools and therapeutic agents. 
1.1 INTRODUCTION  
Hydrogen sulfide (H2S) is most widely known as a poisonous gas with the smell of rotten 
eggs. However, research in recent years has convincingly demonstrated the role of H2S as an 
endogenous gasotransmitter with importance on par with that of nitric oxide (NO) and carbon 
monoxide (CO).1-2 H2S has been shown to have anti-inflammation,
3-7 anti-tumor,8-12 ion channel 
regulation,13-16 cardiovascular protection4, 17-20 and anti-oxidation effects.21-22 Along with these 
physiological roles, H2S is emerging as a potential therapeutic agent much the same way as NO
23-
24 and CO.25 
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There have been numerous research publications demonstrating the tremendous 
therapeutic potential of H2S,
3, 26-32 With the demonstrated therapeutic effect, the development of 
H2S-based therapeutics relies on the ability to deliver hydrogen sulfide to the desired location(s), 
at the appropriate concentrations, and with the appropriate pharmacokinetics. Because H2S is an 
endogenous gaseous signaling molecule, it is recognized that low levels of H2S (nanomolar) may 
be tolerated indefinitely.33 On the other hand, it is commonly accepted that H2S dose-response 
curves are generally bell shaped with a very narrow therapeutic window.34 Thus delivery of 
precisely controlled-doses is a critical issue in the development of H2S-based therapeutics. Direct 
inhalation obviously would not be an acceptable approach for many reasons including smell, 
irritation, enhanced local concentrations at the first point of administration (lung), difficulties in 
controlling dosage, and dependence on patient’s lung functions and physical states.  Some of the 
same issues are true with simple administration of fast-releasing H2S donors such as NaHS and 
Na2S.  In addition, H2S has many unique properties, which present a special set of challenges in 
the development of therapeutics.  
 
1.1.1 The homeostasis of hydrogen sulfide and its pharmacological effect 
To appropriately discuss delivery and developability issues, it is important to understand 
the fundamentals of hydrogen sulfide homeostasis in normal physiology. Very different from most 
other signaling molecules is the chemical properties of H2S, which contribute to its biological 
activities and homeostasis.  For example, most signaling molecules that act on receptors and/or 
enzymes do so by simple binding without chemical reactions. However, for H2S, its chemical 
reactivity is an important part of its biological functions and fate. Thus any analysis of H2S-based 
therapeutics needs to take into consideration its unique properties and reactivity. H2S is a small 
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molecule, slightly larger than water with the following properties: (1) acidity, (2) reducing ability, 
(3) high affinity to iron-containing molecules such as heme, (4) easy convertibility among species 
of different oxidation states, (5) polymerizability and existence in various oligomeric states, (6) 
volatility, and (7) high water solubility (up to 80 mM at 37 °C35).  Specifically, H2S is a weak acid 
with pKa values (37 °C) for the first and second dissociation steps being around 6.88 and 19 
respectively.36 Thus under physiological conditions (pH = 7.4), H2S largely exists in two forms: 
the neutral molecular form (H2S) and the mono-ionized form (HS
-). Sulfide (S2-) is a very minor 
component simply because of the second pKa being very high. Further complicating the picture is 
the fact that hydrogen sulfide, and its oxidized forms such as SO2
37-38 and persulfide39-42 may all 
have their own biological activities. Thus detailed mechanistic understanding will depend on the 
ability to deliver a “clean” species with well-defined concentration and delivery rates.  
 
1.1.1.1 H2S redox in biology: production, metabolism and signaling pathways  
 
In mammals, enzyme-catalyzed endogenous H2S production is well understood.
43-46 
Basically, these processes are part of cysteine metabolism, with cystathionine β-synthase (CBS), 
cystathionine γ-lyase (CSE), and 3-mercaptopyruvate sulfurtransferas(3MST) (Figure 1.1) being 
the key enzymes involved. CBS catalyzes a β substitution reaction of serine to form cystathionine, 
and then CSE catalyzes the elimination of cystathionine to form cysteine, α-ketobutyrate and NH3. 
CBS and CSE also directly catalyze H2S release from cysteine or homocysteine. Cysteine 
aminotransferase (CAT) transfers the amino group from cysteine to a keto acid, typically α-
ketoglutarate, forming 3-mercaptopyruvate (3MP). Then 3MST produces H2S from 3MP. The 
expression of these enzymes is tissue specific, with CBS being found predominantly in the nervous 
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system and liver, and CSE activity being higher than CBS activity in the aorta, portal vein and 
other vascular tissues.47 3MST is expressed in the central nervous system, mostly in glial cells, 
hippocampal pyramidal neurons, cerebellar Purkinje cells, and mitral cells in the olfactory bulb. 
In addition to the expression and distribution of these enzymes, endogenous production of H2S 
also depends on availability of substrates and enzyme activity, which might be affected by many 
properties of the intracellular environment such as the redox state.  
 
Figure 1.1 Enzymatic pathways of H2S production in mammalian cells 
 
H2S is metabolized via the sulfide oxidation pathway in the mitochondria.
48-50 Basically, a 
membrane-bound sulfide:quinone oxidoreductase (SQR) oxidizes H2S to a SQR persulfide 
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intermediate. In the presence of O2 and water, sulfur dioxygenase (SDO) oxidizes the persulfide 
intermediate to sulfite.51-53 Then Rhodanese transfers a sulfane sulfur (SQR persulfide) to sulfite 
to form thiosulfate (S2O3
−2)54  (Figure 1.2), which reacts with glutathione (GSH) via catalysis by 
thiosulfate sulfurtransferase (TST) to produce GSSH. Subsequently, GSSH is used as a substrate 
by SDO to generate sulfite, which is further metabolized to sulfate by sulfite oxidase (SO). In 
addition, H2S can be converted to dimethylsulfide by cytosolic methylation. Another possible 
pathway for H2S removal is related to the interaction of H2S with myoglobin (Mb) and hemoglobin 
(Hb) to form the sulfheme complex.55-57 One cannot help but wonder whether the various 
intermediates have their own regulatory roles, which would be a good reason for nature to use such 
a complex transformation process.   
 
Figure 1.2 H2S metabolism in the mitochondrion. 
 
Besides the enzymatic regulation of H2S production and metabolism, H2S could also be 
stored in proteins by forming persulfide through persulfidation (S-sulfhydration).58-60 Most, if not 
all, S-sulfhydration occurs at reactive cysteine residues in proteins and results in the conversion of 
the thiol (-SH) group of a cysteine to a persulfide group (-SSH), which is also the major pathway 
of sulfide signaling.58-59, 61-63 The formation of persulfide in cysteine residues of a protein can cause 
structural changes, which alter protein activity and lead to a cellular and physiological responses 
14 
to H2S.  For instance, in 2011, Mustafa et al. observed that S-sulfhydration of Cys-43 in the Kir 
6.1 subunit of the ATP-sensitive potassium channels (KATP) reduces ATP binding and enhances 
phosphatidylinositol 4,5-bisphosphate (PIP2) binding, which leads to KATP channel activation.
64 S-
sulfhydration of the calcium-dependent intermediate conductance potassium channel (IKca) 
contributes to H2S-dependent hyperpolarization of endothelial cells. All these findings indicate 
that H2S is an important Endothelial Derived Hyperpolarizing Factor (EDHF) and dysregulation 
of the pathway may be a critical factor in the development of vascular diseases such as 
hypertension. As an additional example, in 2013 Yang and co-workers65 demonstrated that S-
sulfhydration of Kelch-like ECH-associated protein 1 (Keap1) at Cys-151 enhances nuclear 
translocation of Nuclear Factor (erythroid-derived 2)-like 2 (Nrf2), antioxidant gene transcription, 
and GSH production; and thus protects cells from oxidative stress and premature senescence. 
These findings point to an important function of H2S against cellular aging via the post-
translational modification of the Keap1/Nrf2 axis and associated oxidative stress. All these studies 
show that persulfide formation is a posttranslational modification of the cysteine residue. 
However, it needs to be noted that the sulfur atom of H2S as well as thiols (R-SH) possesses the 
same oxidation state (-2); thus direct persulfide formation via H2S is not possible. There are two 
proposed persulfide formation mechanisms. One is the addition of SH− to a sulfenic (S-OH) group 
in proteins to form persulfide. Since protein thiolate (R-S-) is a strong nucleophile, it readily reacts 
with H2O2 to yield the corresponding sulfenic group, which, in turn, reacts with SH
− to yield the 
corresponding persulfide.66-67 The other mechanism relies on polysulfides. Some recent studies 
showed that polysulfides can be synthesized endogenously by 3MST,68-70 and are much more 
potent in inducing persulfide formation. 
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Sulfide-hemeprotein interactions are also involved in sulfide signaling. Sulfide has strong 
affinity for hemeproteins such as cytochrome c oxidase (CcO), Mb, and Hb, and can convert the 
high spin ferric center of heme protein to a low spin ferric-sulfide complex, reducing the central 
metal from the ferric to ferrous state, or forming ferrous-sulfide complexes. The effects of sulfide 
on hemeproteins are concentration-dependent. For example, at high concentrations, H2S binds 
directly to the ferric heme α3 center and completely inhibits CcO activity, leading to inhibition of 
the mitochondrial respiration and subsequent toxicity; however at low concentrations (nearly 
stoichiometric), H2S stimulates O2 consumption without having an inhibitory effect.
71 There have 
been studies72 showing that the interaction of H2S with hemeproteins would decrease cellular ATP 
concentration and activate KATP channels. These interactions can also regulate the function of 
hemeproteins, produce bioactive sulfide metabolites and protect against heme-induced oxidative 
stress, which plays an important role in sulfide signaling.  
All indications are that the redox chemistry of H2S and its affinity to iron are the key 
characteristics that contribute to its biology.  
 
1.1.2 Current Challenges. 
It is clear that there is growing understanding of sulfide signaling pathways and its various 
biological effects including the relaxation of blood vessels, cytoprotection against oxidative stress, 
and anti-inflammatory actions that would warrant significant efforts in translating the known 
pharmacological effects of H2S to the development of H2S-based therapeutics. A major issue is 
the development of H2S donors or prodrugs as potential therapeutics.  This is because there are 
obvious concerns with using H2S or its salt forms.  For example, the volatile nature and stench 
odor make H2S or its salts very unlikely delivery forms for pharmaceutical uses. Beyond the 
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superficial, there are also mechanistic reasons for the development of donors and prodrugs that can 
afford sustained release of H2S. First, as discussed above, the dose-response curves in almost all 
known pharmacological experiments for H2S are bell-shaped with a narrow therapeutic window.  
Thus there is a need to deliver precise amounts of H2S.  However, there are complex processes of 
maintaining H2S homeostasis in living system and H2S is volatile.  Thus bolus administration of 
H2S would only lead to a spike of H2S concentration. Although there have been no systematic 
studies of the effect of duration of H2S treatment, one can assume that a sustained and constant 
level of H2S for certain duration would be far more desirable than a quick spike for therapeutic 
applications.  Second, much of hydrogen sulfide’s effect resides with its redox chemistry. A quick 
bolus administration of H2S is likely to change the cellular redox states and the effect may go well 
beyond H2S-specific functions. Third, at high H2S concentrations after bolus administrations, the 
distribution of various sulfur species may be very different from that of the physiologic state.  It is 
well known that persulfide species may have activities of their own.69, 73  Some studies already 
showed that polysulfides formed in solutions of H2S mediate protein thiol oxidation, which 
converts cysteinyl thiolates (Cys-S−) to persulfides (Cys-S-S−).69 There are suggestions that 
polysulfides/thiosulfates rather than H2S itself are the actual active molecules responsible for 
persulfide formation, and thus mediate sulfide signaling.69  Depending on the release rates and 
their own oxidation states, using different H2S donors at the same concentration might lead to the 
generation of different concentrations of various sulfur species. Thus this change in distribution 
could make mechanistic studies very hard, or even physiologically irrelevant. Meanwhile, “pure” 
polysulfide donors are highly desired in this field, but it is still quite a challenge for synthetic 
chemists to make such molecules at high purity. Another difficulty in H2S research is the lack of 
understanding of the ideal concentration of H2S in physiology and in therapy, including the 
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question of the normal endogenous H2S concentration range in circulation.  This is largely due to 
the lack of sensitive methods for the detection of H2S and the lack of H2S donors with well-defined 
release rates that would allow a detailed examination of the H2S concentration-effect relationship 
issue. Although there are many methods for detecting H2S including the colorimetric methylene 
blue method, ion-selective or polarographic electrodes, gas chromatography with flame 
photometry, the monobromobimane assay, and assays using various fluorescent probes,74-75 none 
quite comes to the needed sensitivity and response time for the near real time detection of H2S at 
physiological concentrations. A wide physiological concentration range has been reported: from 
0.1 μM to more than 300 μM.3 As a conservative estimate, plasma H2S levels in healthy humans 
or animals might be in the high nanomolar to low micromolar range.3 The lack of methods for 
accurately monitoring H2S levels in circulation or in the targeted organs and systems makes it hard 
to estimate the therapeutic dosages. Thus prodrugs, which directly release H2S without involving 
redox chemistry, will be important research tools for dissecting many of the remaining issues.  
Even in developing H2S prodrugs, there are unique challenges as compared to prodrugs of 
other small molecules.  Much of these challenges are associated with H2S’s volatility and rapid 
metabolism.  For example, for a prodrug of a small molecule drug with a half-life in hours, the 
dosage of the prodrug can be easily translated into a stoichiometric concentration because the drug 
released would persist within the circulation for a reasonable period of time. However, for a 
gasotransmitter, this is very different. Because of its volatility and thus its constant 
evaporation/exhalation, H2S concentration is a balance between exhalation and production. If one 
takes into consideration the cellular metabolism of H2S, then it becomes easy to understand why 
the concentration of the administered prodrug may not have a linear relationship with H2S 
concentration. In one study, it was found that for a series of H2S prodrugs with different release 
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rates at 200 μM, the highest peak H2S concentration achieved was only 50% of the prodrug 
concentration in a solution experiment when the release half life is short (13 min).76 Then the 
concentration quickly drops. On the other hand, another prodrug in the same series with a slower 
release rate (t1/2, 100 min) provided a sustained concentration of H2S at 5% of its prodrug 
concentration for over 1 h. Therefore, one can see that H2S prodrug release rate plays a very 
important role in determining the concentration of the drug.  In addition, to address the biological 
effect of H2S prodrugs, well-defined control compounds are also necessary. With polysulfide 
compounds, this is hard to achieve.  
 
1.1.2.1 Developability issues related to H2S donors or prodrugs 
In drug discovery and development, assessing developability is a critical step.77-79 Prodrugs 
are no exceptions,80 however, with unique features, which are discussed in later sections. Drug 
developability is a complex issue; it is well known that there are many examples of drugs in the 
market that do not fit the model of modern day criteria. Nevertheless, literature developability 
criteria are very important reference points. When judgment calls are made, there is a need to have 
a clear understanding of why one needs to deviate from the “standard” developability criteria.  
In assessing drug developability, one typically needs to consider pharmacokinetics, 
metabolism, permeability, protein binding, toxicity, efficacy, chemical tractability, and drug-drug 
interactions, among other important factors.77-78 When it comes to criteria that can guide the design 
of new chemical entities (NCE), there are many specific factors to consider. The most well-known 
is the Lipinski’s “Rule of Five.” When it comes to specific molecular properties to assess, 
experiments commonly include determinations of solubility, stability, membrane permeability, 
19 
p450/microsomal metabolism, cytotoxicity, mutagenicity, hERG inhibition (cardiotoxicity), p450 
inhibition and induction, and protein binding.  
In applying drug developability assessment to a prodrug project, there are unique issues to 
consider.  This is especially true for prodrugs of a gasotransmitter. First, the potency and efficacy 
issues are no longer the same as in a typical small molecule drug discovery project. This is because 
the active drug itself is already fixed. In the case of hydrogen sulfide, its potency and efficacy are 
defined by the parent drug already. Second, for a gasotransmitter prodrug such as H2S, the drug 
permeability issue is very different from that of a typical small molecule drug. The prodrug itself 
actually does not necessarily need to penetrate any barrier as long as the parent drug can reach the 
site of action.  With a gasotransmitter, the parent drug itself is very permeable across cellular 
barriers. Thus the prodrug does not even need to get into the intracellular space in order to be 
effective. In a way, sometimes it might be preferred that the prodrug not get into the cell in order 
to minimize side effect and toxicity issues. This aspect is very different from that of a traditional 
small molecule drug discovery project. Another unique issue for a prodrug of a gasotransmitter is 
the dose-response issue. As discussed above, the relationship between the drug effective dose and 
the prodrug dose is not necessarily a linear relationship because of the volatility and rapid 
metabolism of H2S. The relationship among release rates, volatility, and rate of metabolism defines 
the “steady state” concentration, if any. Thus having well-defined release rates is very important 
for the future development of H2S prodrugs. Additional developability issues unique to hydrogen 
sulfide include odor and ready inter-conversions of various species. The first would be expected 
to significantly affect patient compliance, dispensing, and storage; and the second would be 
expected to affect chemical tractability in process chemistry, quality control, dosage 
determination, and the overall approval process by the US Food and Drug Administration (FDA). 
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Thus developing prodrug forms that can overcome these issues are also very critical to the future 
of H2S-based therapeutics.  
 
1.1.2.2 Ideal Hydrogen sulfide prodrugs 
 
With the above discussions of developability issues and associated challenges, we layout 
some ideal characteristics of H2S donors or prodrugs for therapeutic applications (Figure 1.3), 
which could serve as reference points in evaluating existing donors and in guiding future efforts.  
First of all, tunable and controllable H2S release rates are essential properties.  The release rate of 
H2S prodrugs directly affects the effective concentration of the parent drug and thus their functions. 
Therefore, designing H2S prodrugs with a range of controllable release rates is highly desired.  
Along this line, the use of well-defined triggering mechanisms for release will be very much 
desired for certain applications. Second, stability during storage, drug preparation, or formulation 
is required. Third, water solubility is essential for the eventual drug delivery and absorption. It is 
well known that drugs need to have certain water solubility in order to be absorbed and to be 
effective.79 Water solubility is also an important factor that could affect formulability and 
pharmacokinetic issues. Fourth, chemical tractability is critical to all small molecule drugs. The 
ability to prepare and characterize the prodrug with sufficient purity and well-defined distribution 
of various species is critical to the viability of a drug discovery and development project.  Fifth, 
the presence of aversive odor and taste is a developability issue for all drugs. This issue is 
especially prominent with H2S prodrugs because of its known unpleasant odor, which is expected 
to not only affect patient compliance, but also storage and delivery. Thus finding ways to 
ameliorate the undesirable odor will be important. Lastly, unique to prodrug development is the 
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issue of tractability of the side product(s) after drug release from the prodrug. This issue is 
important at the research stage so that there is a proper control compound. More importantly, at 
the clinical development stage there needs to be a good understanding of the chemical species 
introduced into the human body and a reasonable level of assurance that the “side product(s)” does 
not have undesirable effects.   
 
Figure 1.3 Ideal characteristics of H2S prodrugs 
 
1.1.3 Current H2S donors 
In the past several years, many series H2S prodrugs have been developed. We summarize 
the prodrugs which was discovered before 2016.(Scheme 1.1)  
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Scheme 1.1 Current H2S donors (Before 2016) 
In studying the physiological and pathological properties of H2S, H2S gas or inorganic 
sulfide salts such as Na2S and NaHS have been widely used. However, the uncontrollable release 
of H2S from sulfide salts and the toxic effects of excessive H2S limit their potential as possible 
therapeutic agents.81-82 Moreover, inorganic sulfide salts could not mimic the slow and continuous 
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H2S production in the biological system, which further limits their usage. Therefore, new H2S 
releasing agents (H2S donors) are of great clinical and research interests.
26, 81-83 Currently, there 
are seven types of H2S donors that have been reported:
84 1) garlic and related sulfur compounds;85 
2) Lawensson's reagent and analogs (GYY4137);4 3) 1,2-dithiole-3-thiones (DTTs) and hybrids of 
H2S and non-steroidal anti-inflammatory drugs;
86-88 4) thiol-activated H2S donors;
89-91 5) photo-
induced H2S donors;
92-93 and 6) thiol amino acid;94 and 7) polysulfide (SG-1002).95 There are some 
obvious limitations among these H2S donors. First of all, the release rates of H2S from most donors 
such as GYY4137 and DTTs are hard to control, and the effect of their byproducts associated with 
H2S release is unclear. Furthermore, existing H2S donor systems lack well defined negative 
controls. Some H2S donors, such as thiol-activated H2S donors would generate the perthiol 
intermediates, which may also have certain physiological effect, making it hard to deconvolute the 
experimental results. Almost all existing donors release precursors of H2S. Thus the correlation of 
H2S release and the amount of donor added is difficult.  H2S donors that can mimic endogenous 
H2S production through a single enzymatic step are currently not available. Recently, Moore et al 
96 tested the effect of GYY4137 on the release of pro- and anti-inflammatory mediators in 
lipopolysaccharide (LPS)-treated murine RAW264.7 macrophages, and found that the effects of 
H2S on inflammatory processes are complex and dependent not only on H2S donor concentration 
but also on the rate of H2S generation. Therefore, there is a need for new H2S prodrugs, which 
directly generate H2S with well-defined and tunable release rates that are not directly affected by 
the redox balance of the cellular environment and the presence of other thiol species. Such H2S 
donors/prodrugs will be very important research tools in delineating the functions of H2S and lay 
a foundation for the future development of H2S-based therapeutics 
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1.2 Results and Discussions 
Our lab has long-standing interests in prodrugs based on intramolecular cyclizations.97-99. 
We took advantage of one such lactonization prodrug systems (Scheme 1.2), and designed 
esterase-sensitive prodrugs of H2S. Specifically, the nucleophilic hydroxyl or amino group can be 
masked as an ester or amide, and the drug, H2S, can be conjugated to the carbonyl carbon in the 
form of a thioacid. After hydrolysis of the masking group, the nucleophile can attack the carbonyl 
group and undergo a lactonization reaction, and thus release hydrogen sulfide. 
 
Scheme 1.2. The general concept of cyclization driven prodrugs of hydrogen sulfide 
 
To test the idea, we first synthesized prodrug BW-HP-101, which uses a “trimethyl lock” 
and thus stereochemical control to facilitate lactonization.97, 100-104 The synthesis of BW-HP-101 
was accomplished by treating compound 1,105 with Lawensson's reagent under microwave 
conditions,106  followed by reaction with one equivalent of sodium hydroxide  (Scheme 1.3). 
  
 
Scheme 1.3. Synthesis of “trimethyl lock”-based H2S prodrug HP-101 and the mechanism of 
esterase triggered H2S release 
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The novel BW-HP-101 is a very stable white and odorless solid, and has very good water 
solubility, allowing 10 mM stock solutions to be prepared in aqueous buffer. The prodrug showed 
no obvious decomposition during storage at room temperature for 3 days and at -20 °C for 3 month.  
 
To examine the feasibility of concept described in Schemes 1 and 2, we studied whether 
esterase can catalyze H2S release from BW-HP-101 by using a H2S-selective microelectrode, and 
found time-dependent H2S release in the presence of porcine liver esterase (PLE) (Figure 1.4) with 
a peak concentration at about 15 min. H2S release was further confirmed by using a well-known 
hydrogen sulfide fluorescent probe WSP-5107 (Figure 1.5). Strong fluorescence was detected when 
WSP-5 was incubated with the prodrug in the presence of PLE in phosphate buffer saline (PBS) 
or cell culture media containing fetal bovine serum (FBS). Such results indicate that BW-HP-101 
indeed releases H2S in PBS with esterase catalysis, or cell culture media containing FBS. In 
contrast, incubation in PBS alone did not lead to H2S formation, indicating the chemical stability 
of the prodrug. Lactone formation was also confirmed by NMR (SI). As another piece of evidence 
on the stability of the thioacid group, thioactic acid was incubated in aqueous solution; no 
decomposition was observed within 48 h. 
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Figure 1.4. H2S generation from BW-HP-101. 200 μM the prodrug in PBS (1% DMSO) 
at 37 °C with 1 unit/mL of PLE. (p=0.95, n=3.) 
 
 
Figure 1.5. Qualitatively detection of hydrogen sulfide releasing from BW-HP-101 by 
WSP-5.The concentration of WSP-5 is 50 uM, and the intensities of fluorescence were recorded 
after 5 min of incubation of WSP-5 with different substrates at room temperature. a: WSP-5 only 
in PBS; b: WSP-5+ 200 μM prodrug in PBS; c: WSP-5+ 200 μM prodrug in DMEM (No FBS), 
no cells; d: WSP-5+ 200 μM prodrug in DMEM (with FBS)+ cells e: WSP-5+ 200 μM prodrug 
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in DMEM (with FBS), no cells; f: WSP-5+ 200 μM prodrug + 1 unit/mL of esterase; g: WSP-
5+200 μM GYY1437; h: WSP-5+1unit/mL esterase. 
 
All these studies demonstrate the expected enzyme-catalyzed release of hydrogen sulfide 
from the prodrug system. We then further studied the tunability of the release rates by varying the 
ester group and factors controlling the lactonization step. Variations of the ester group allows for 
tuning the rate of the unmasking step. For ester hydrolysis, it has been shown that increasing the 
size of the acyl moiety results in decreased catalytic hydrolysis rate.108-109 Thus we reasoned that 
modifying the acyl moiety should help tune the hydrolysis rates. The second direction in tuning 
H2S releasing rates is based on controlling the lactonization rate by varying the number of methyl 
groups in the system. It is well known that the lactonization of compound 1 is much faster than 
that of o-hydroxydihydrocinnamic acids 3 and 4, which lack pendant methyl groups (Scheme 1.4) 
and thus has decreased entropic control of the conformation favorable for lactonization.101 
Therefore, BW-HP-102, -103, and -104 were synthesized to tune the release rates. BW-HP-102 
and BW-HP-104 contain a large acyl moiety cyclopropanecarbonyl ester and BW-HP-103 and 
BW-HP-104 lack two methyl groups on phenyl ring. 
 
 
Scheme 1.4. Relative rate constants for lactonization of various hydroxydihydrocinnamic acids. 
110-113 
 
H2S release from these prodrugs was studied (Figure 1.6). As designed, these prodrugs 
show very different H2S release rates. For 200 μM of the prodrug in PBS at 37 °C with 1unit/mL 
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PLE, the peak H2S concentration for the fastest one, BW-HP-101, was about 95 μM at 15 min; and 
for the slowest one, BW-HP-104, it was about 13 μM at 43 min. Such results bring out an important 
issue, i.e. the same concentration of the prodrug may mean very different effective H2S 
concentrations, depending on the release rates. This issue is especially important in delivering a 
gaseous molecule because of its volatility nature and the lack of “accumulation,” which is in direct 
contrast to the delivery of non-volatile drugs. In the latter case, a slower release may only affect 
the onset time, but not the final concentration. With a gaseous molecule, release rates affect the 
onset time, the peak concentration, and the eventual concentration significantly. Thus when 
comparing the results using various H2S prodrugs/donors, particular attention needs to be paid to 
the release rate and effective concentration issue.  
 
  
Figure 1.6. H2S generation curves.200 μM prodrugs in PBS (1% DMSO) with 1 unit/mL esterase 
at 37 °C. (p=0.95, n=3.) 
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We also monitored the lactone product formation by HPLC (Table 1.1), and found t1/2 
ranging from 13 to 99 min for 200 μM prodrugs in the presence of PLE. Such results further 
demonstrated the concept of tuning the H2S release rates.  
 
Table 1.1 The half-lives of various prodrugs. 200 μM prodrugs in PBS with esterase 1 
unit/mL at 37 °C, p=0.95, n=3. 
 BW-HP-101 BW-HP-102 BW-HP-103 BW-HP-104 
T1/2 (min) 13.0 ±2.4  28.7±1.5   44.5±2.1  99.0 ±8.9  
   
The conjugation of two drugs with the same therapeutic indication, but different 
mechanisms, is attracting a great deal of attention in the hybrid drug field.114 Especially interesting 
is the idea of conjugating a non-steroidal anti-inflammatory drug (NSAID) to a H2S donor,
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which has known anti-inflammatory effects. H2S-NSAIDs have shown remarkable improvements 
in activity and tolerability as compared with the related parent compounds.114 However, few of the 
hydrogen sulfide prodrugs could be successfully applied to hybrid drug preparation for chemistry 
reasons, and existing H2S-NSAIDs also suffer from the lack of control in H2S release.  Because 
most NSAIDs have a free carboxyl group, their conjugation to one of our prodrugs is not only 
easy, but also leads to a hybrid prodrug, which uses the same mechanism to release both drugs. 
This is very unique among all known H2S hybrid drugs. Thus, we also synthesized BW-HP-105, 
which is formed by coupling the novel H2S release system to naproxen (Figure 1.7). HPLC kinetic 
studies showed that BW-HP-105 could generate naproxen and H2S by treatment with an esterase. 
Compared to other H2S prodrugs with the same stereochemical control (BW-HP-101, 102), BW-
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HP-105 showed a slower hydrolysis rate as expected because of the larger masking group 
(naproxen as the acyl group). The H2S-NSAID hybrid shown here is the first example of 
controllable H2S release employing the same mechanism to “activate” both drugs, and will be a 
very useful research tool and potential therapeutic agent.  
 
 
Figure 1.7.  200 μM HP-105 in PBS  with PLE 20unit/mL. (37 °C, 1% DMSO, p=0.95, n=3) 
 
We next tested whether such compounds also produced H2S-associated biological effects 
in vitro. For such studies, negative control compounds are always important. However, there are 
no good control compounds for existing H2S prodrugs. To address this issue, we used the inactive 
oxyacid version of the prodrugs (iHPs, Figure 1.6) as the control compounds. Compared to thioacid 
prodrugs, iHPs have the same chemical structural frame except replacing sulfur with oxygen.  
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We first tested the cytotoxicity of these prodrugs on RAW264.7 macrophages. None 
showed any toxicity at 200 μM. We then examine the effect of the prodrugs on TNF-α production 
after co-treatment of the cell with the prodrugs and 1 μg/mL LPS for one hour, using an ELISA 
kit (Figure 1.8). The results showed that only the prodrugs and GYY 4137 effectively inhibited 
TNF-α secretion, and Na2S showed pro-inflammatory effect, which is similar to literature results.96 
None of the iHPs showed the same effect, which clearly demonstrated that the inhibition effect on 
TNF-α production came from the H2S released from the respective prodrug.   
                                          ○A                                                       
  
                     ○B  
 
Figure 1.8.  TNF-α concentrations of RAW 264.7cell culture media after 1-hour co-
treatment with H2S prodrugs and LPS.(A) Treatment with 50 μM HPs, iHPs Na2S and GYY4137. 
(B) Treatment with various concentrations of BW-HP-101 and iHP-101 (n=4 *: p<0.05) 
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1.3  Conclusion 
In conclusion, we successfully investigated a new strategy of making H2S prodrugs by 
using an esterase catalyzed lactonization prodrug system. Compared to existing H2S 
prodrugs/donors, the new H2S prodrugs described show several unique features. First of all, they 
have controlled H2S release rates. This aspect seems to be the most challenging and important 
issue in the field of H2S donors.  Secondly, the trigger is an enzyme ubiquitous in the biological 
system.[23] Thirdly, the prodrugs require a specific type of enzyme to trigger H2S release, which 
afford the potential for controlled release at preferred sites. Fourthly, as research tools, the 
prodrugs described have well-defined negative controls. Fifthly, this strategy provides the first 
H2S-NSAIDs hybrids with controllable release rates. We believe that these new H2S prodrugs 
will be very useful research tools to others working in this field. 
1.4 Experimental part 
General Information: All reagents and solvents were of reagent grade and were purchased from 
Aldrich. 1H-NMR (400 MHz) and 13C-NMR (100 MHz) spectra were recorded on a Bruker Avance 
400 MHz NMR spectrometer. Mass spectral analyses were performed on an ABI API 3200 (ESI-
Triple Quadruple). HPLC was performed on a Shimadzu Prominence UFLC (column: Waters C18 
3.5 μM, 4.6×100 mm). UV-Vis absorption spectra were recorded on a Shimadzu PharmaSpec UV-
1700 UV-Visible spectrophotometer. Fluorescence spectra were recorded on a Shimadzu RF-
5301PC fluorometer. 96-Well plates were read and recorded on a PerkinElmer 1420 multi-label 




1.4.1 Synthesis of HPs 
 
Scheme  1.5 Synthesis of “trimethyl lock”-based H2S prodrug HP-101 
 
Synthesis of sodium 3-(2-acetoxy-4, 6-dimethylphenyl)-3-methylbutanethioate (HP-101). A 
solution of 3-(2-acetoxy-4,6-dimethylphenyl)-3-methylbutanoic acid (1, 78 mg, 0.3 mmol), 
Lawesson's reagent (60 mg, 0.15 mmol) and 1.5 mL CH2Cl2 in a sealed tube was subjected to 
microwave irradiation (100 °C , 6 min). After completion of reaction, the solution mixture was 
diluted with dichloromethane (DCM, 5 mL). The organic layer was washed by 1 N HCl and brine, 
and dried over anhydrous sodium sulfate. Then, after filtration, DCM was removed under vacuum. 
The residue was purified by flash column chromatography (hexane: ethyl acetate =10:1) to give 
an oily residue (59 mg). The oil product was dissolved in methanol, and a NaOH solution (8.4 mg 
in 2 mL methanol) was added at -78 °C. After 3 minutes, the methanol in the reaction mixture was 
removed by rotavapor. Diethyl ether was added into the crude product, and the final product was 
precipitated from diethyl ether as a white solid (57 mg, 67%). 1H NMR (CD3OD): δ 6.80 (s, 1H, 
Ph-H), 6.53 (s, 1H, Ph-H), 3.33 (s, -CH2-CO-), 2.58 (s, 3H, Ph-CH3), 2.32 (s, 3H, -CO-CH3), 2.21 
(s, 3H, Ph-CH3), 1.54 (s, 6H, Ph-C(CH3)2-); 
13C NMR (CD3OD): δ219.0, 172.4, 150.7, 139.4, 
137.0, 136.4, 132.9, 123.9, 64.4, 40.6, 31.8, 25.7, 22.0, 20.2.  HRMS calcd for C15H19O3S [M-H]
-  




Reagents and conditions (i) Et3N, DCM, 0 ℃-rt, 12 h, 46%; (ii) AcOH/H2O, THF, rt, 12 h, 91%; 
(iii) Pyridinium chlorochromate (PCC), DCM, rt, 2 h, 83%; (iv) NaClO2/NaH2PO4, 2-methylbut-
2-ene, t-BuOH, rt, 2 h, 52%; (v) 1) Lawesson’s reagent, DCM, microwave, 6 min; 2) NaOH, 
methanol, -78 ℃, 56% for the last two steps . 
Scheme  1.6 Systhesis of HP-102 
 
[0001] Synthesis of 2-(4-((tert-butyldimethylsilyl)oxy)-2-methylbutan-2-yl)-3,5-dimethylphenyl 
cyclopropanecarboxylate (7). To a solution of 2-(4-((tert-butyldimethylsilyl)oxy)-2-methylbutan-
2-yl)-3,5-dimethylphenol (5, 1.9 g, 5.9 mmol) and Et3N (1.2 ml, 8.8 mmol) in DCM (150 mL) was 
added dropwise cyclopropanecarbonyl chloride (6, 0.8 ml, 8.8 mmol) at 0 ℃ during a period of 
10 min. The mixture was allowed to warm to room temperature and was stirred for an additional 
12 h. Then the reaction was quenched with the addition of H2O (100 mL), and extracted with ethyl 
acetate (2 × 150 mL). The combined organic phase was dried over  anhydrous Na2SO4 and 
evaporated under reduced pressure to give the crude product, which was purified by column 
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chromatography (hexane: ethyl acetate =100:1) to give a colorless oil (1.04 g, 46%). 1H NMR 
(CDCl3): δ6.79 (s, 1H), 6.56 (s, 1H), 3.50 (t, J = 8.0Hz, 2H), 2.52 (s, 3H), 2.22 (s, 3H), 2.06 (t, J 
= 8.0Hz, 2H), 1.86-1.80 (m, 1H), 1.49 (s, 6H), 1.17-1.13 (m, 2H), 1.01-0.95 (m, 2H), 0.85 (s, 9H), 
-0.02 (s, 6H); 13C NMR (CDCl3): 174.1, 150.1, 138.4, 136.0, 134.3, 132.3, 123.2, 61.0, 46.1, 39.3, 
32.0, 26.1, 25.4, 20.3, 18.4, 13.7, 8.9, -5.2. HRMS calcd for C23H38O3Si [M+H]
+ 391.2663, found: 
391.2649. 
 
Synthesis of 2-(4-hydroxy-2-methylbutan-2-yl)-3,5-dimethylphenyl cyclopropanecarboxylate (8). 
To a solution of 2-(4-((tert-butyldimethylsilyl)oxy)-2-methylbutan-2-yl)-3,5-dimethylphenyl 
cyclopropanecarboxylate (7, 1.04 g, 2.7 mmol) in tetrahydrofuran (THF, 15 mL) was added H2O 
(15 mL) and AcOH (45 mL). The reaction mixture was stirred at room temperature for 4 h, 
quenched with H2O (50 mL), and extracted with ethyl acetate (2 × 150 mL). The combined organic 
phase was dried over anhydrous Na2SO4, evaporated under reduced pressure, and purified by silica 
gel column chromatography (hexane: ethyl acetate =6:1) to give a colorless oil (680 mg, 91%). 1H 
NMR (CDCl3): δ 6.81 (s, 1H), 6.55 (s, 1H), 3.54 (t, J = 8.0 Hz, 2H), 2.52 (s, 3H), 2.22 (s, 3H), 
2.06 (t, J = 8.0 Hz, 2H), 1.87-1.82 (m, 1H), 1.51 (s, 6H), 1.18-1.14 (m, 2H), 1.04-0.99 (m, 2H); 
13C NMR (CDCl3): 174.8, 150.0, 138.5, 136.3, 134.1, 132.5, 123.4, 60.7, 45.9, 39.3, 32.2, 25.5, 
20.3, 13.7, 9.1. HRMS calcd for C17H24O3 [M+H]
+277.1798, found: 277.1789. 
 
Synthesis of 3,5-dimethyl-2-(2-methyl-4-oxobutan-2-yl)phenylcyclopropanecarboxylate (9). To a 
solution of PCC (1.5 g, 7.0 mmol) in DCM (20 mL) was added dropwise 2-(4-hydroxy-2-
methylbutan-2-yl)-3,5-dimethylphenyl cyclopropanecarboxylate (8, 0.96 g, 3.5 mmol) in DCM 
(25 mL) at room temperature. After 2 h, the mixture was directly subjected to column 
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chromatography (hexane: ethyl acetate =10:1) to obtain the pure product as colorless oil (0.8 g, 
83%). 1H NMR (CDCl3): δ 9.55 (t, J = 4Hz, 1H), 6.84 (s, 1H), 6.61 (s, 1H), 2.84 (d, J = 4.0 Hz, 
2H), 2.53 (s, 3H), 2.23 (s, 3H), 1.86-1.80 (m, 1H), 1.57 (s, 6H), 1.17-1.14 (m, 2H), 1.05-1.00 (m, 
2H); 13C NMR (CDCl3): 203.3, 174.1, 149.7, 137.9, 136.9, 132.8, 132.7, 123.5, 56.8, 38.3, 31.7, 
25.5, 20.4, 13.6, 9.1.  HRMS calcd for C17H22O3 [M+H]
+275.1642, found: 275.1632. 
 
Synthesis of 3-(2-((cyclopropanecarbonyl)oxy)-4,6-dimethylphenyl)-3-methylbutanoic acid (10). 
To a solution of 3,5-dimethyl-2-(2-methyl-4-oxobutan-2-yl)phenyl cyclopropanecarboxylate (9, 
200 mg, 0.73 mmol) in t-BuOH (4 mL) and 2-methylbut-2-ene (0.7 mL), NaClO2 (98 mg, 1.08 
mmol) in 0.67 M NaH2PO4 (0.8 mL) was added dropwise at room temperature. After 2 h, the 
reaction mixture was quenched with H2O (10 mL), and extracted with ethyl acetate (2 × 50 ml). 
The combined organic phase was dried over anhydrous Na2SO4 and then evaporated under reduced 
pressure to give the crude product, which was purified by column chromatography (hexane: ethyl 
acetate =5:1) to yield a white solid (110 mg, 52%). 1H NMR (CDCl3): δ 6.80 (s, 1H), 6.59 (s, 1H), 
2.86 (s, 2H), 2.53 (s, 3H), 2.22 (s, 3H), 1.89-1.83 (m, 1H), 1.58 (s, 6H), 1.18-1.14 (m, 2H), 1.03-
0.98 (m, 2H); 13C NMR (CDCl3): 177.5, 174.2, 149.7, 138.1, 136.4, 133.5, 132.5, 123.2, 47.7, 
38.9, 31.4, 25.4, 20.4, 13.6, 9.1. HRMS calcd for C17H22O4  [M+H]
+291.1591, found: 291.1580. 
 
Synthesis of Sodium 3-(2-((cyclopropanecarbonyl)oxy)-4,6-dimethylphenyl)-3-methy 
lbutanethioate (HP-102). To a solution of 3-(2-((cyclopropanecarbonyl)oxy)-4,6-
dimethylphenyl)-3-methylbutanoic acid  (10, 110 mg, 0.38 mmol) in DCM (5 mL) was added 
Lawesson’s reagent (77 mg, 0.19 mmol). The mixture was heated in a microwave at 100 ℃ for 6 
min. The mixture was directly subjected to column chromatography (hexane: ethyl acetate =25:1) 
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to obtain the pure product as colorless oil, which was then dissolved in 5 ml methanol. Then 2.5 
ml of 0.1 M NaOH methanol solution was added at -78 ℃. After 5 min, the mixture was allowed 
to warm to room temperature and the solvent was removed by vacuum. The final product was 
achieved by precipitation from ether as a white solid (70 mg, 56%). 1H NMR (400 MHz, CD3OD): 
δ 6.77 (d, J = 0.8 Hz, 1H), 6.46 (d, J = 0.8 Hz, 1H), 3.35 (s, 2H), 2.56 (s, 3H), 2.18 (s, 3H), 1.99-
1.98 (m, 1H), 1.53 (s, 6H), 1.09-1.04  (m, 4H); 13C NMR (CDCl3): 196.1, 174.0, 149.8, 138.1, 
136.7, 133.0, 132.6, 123.3, 58.5, 39.9, 31.5, 25.6, 20.4, 13.7, 9.2. HRMS calcd for C17H21NaO3S 
[M+H]+329.1182, found: 329.1168. 
 
 
Reagents and conditions: (i) tert-Butyldimethylsilyl chloride(TBDMSCl), Dimethylformamide 
(DMF), imidazole, 92%; (ii) acetic anhydride, 4-Dimethylaminopyridine(DMAP), 3 h, 91%; (iii) 
AcOH/H2O, THF, rt, 12 h, 91%; (iv) PCC, DCM, rt, 2h, 92%; (v) NaClO2/NaH2PO4, 2-methylbut-
2-ene, t-BuOH, rt, 2 h; 79% (vi) 1) Lawesson’s reagent, DCM, microwave, 6 min; 2) NaOH, 
methanol, -78 ℃, 60% for the last two steps. 
Scheme  1.7 Synthesis of HP-103. 
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Synthesis of 2-(4-((tert-butyldimethylsilyl)oxy)-2-methylbutan-2-yl)phenol (12). To a 20-ml vial 
was added 2-(4-hydroxy-2-methylbutan-2-yl)phenol (11, 2.5 g, 14 mmol), imidazole (2.8 g, 42 
mmol), TBDMSCl  (4.2 g, 28 mmol ) and DMF (7 ml). The mixture was stirred for 5 min at room 
temperature, then quenched with the addition of H2O (100 mL), and extracted with ethyl acetate 
(2×150 mL). The combined organic phase was washed by saturated NaHCO3 (2×150 mL) and 
dried over anhydrous Na2SO4 and evaporated under reduced pressure to give the crude product, 
which was purified by recrystallization in methanol to give a white solid (3.8 g, 92%). 1H NMR 
(400 MHz CDCl3): δ 7.19 (d, J = 7.6 Hz, 1H), 7.08-7.04 (m, 1H), 6.86-6.83 (m, 1H), 6.66 (d, J = 
7.6 Hz, 1H), 6.10 (s, 1H), 3.51 (t, J = 7.6 Hz, 2H), 2.17 (t, J = 7.6 Hz, 2H), 1.42 (s, 6H), 0.88 (s, 
9H), 0.02 (s, 6H). 13C NMR (CDCl3) δ 154.9, 134.1, 127.7, 127.3, 120.2, 116.9, 61.7, 43.3, 36.7, 
29.0, 26.1, 18.5, -5.1. HRMS calcd for C17H30O2Si [M+H]
+295.2088, found: 295.2075. 
 
Synthesis of 2-(1-((tert-butyldimethylsilyl)oxy)-2-methylpropan-2-yl)phenyl acetate (13). To a 
solution of 2-(4-((tert-butyldimethylsilyl)oxy)-2-methylbutan-2-yl)phenol (12, 1.53 g, 5.6 mmol) 
in DCM (10 mL), was added acetic anhydride (1.63 g, 3 mmol), Et3N (1.62 g, 16 mmol ) and 
DMAP (0.29 g, 2.4 mmol). The mixture was stirred at room temperature for 2 h. The reaction was 
quenched with H2O (10 mL) and extracted with ethyl acetate (2 × 50 mL). The combined organic 
phase was dried over anhydrous Na2SO4 and evaporated under reduced pressure to give the crude 
product, which was then purified by column chromatography (hexane: ethyl acetate =100:1)  to 
obtain colorless oil (1.6 g, 91%). 1H NMR (CDCl3): δ 7.33 (dd, J = 7.6 Hz, 1.2 Hz, 1H), 7.25-7.21 
(m, 1H), 7.18-7.14 (m, 1H), 7.00 (dd, J = 7.6 Hz, 1.2 Hz, 1H), 3.41 (t, J = 7.6 Hz, 2H), 2.33 (s, 
3H) 2.01 (t, J = 7.6 Hz, 2H), 1.37 (s, 6H), 0.84 (s, 9H), -0.04 (s, 6H). 13C NMR (CDCl3) δ 169.5, 
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149.2, 139.0, 128.2, 127.2, 125.8, 124.1, 60.6, 44.5, 36.9, 29.3, 26.1, 21.8, 18.4, -5.2. HRMS cald 
for C19H32O3Si [M+H]
+337.2193, found: 337.2201. 
 
Synthesis of 2-(4-hydroxy-2-methylbutan-2-yl)phenyl acetate (14). To a solution of 2-(1-((tert-
butyldimethylsilyl)oxy)-2-methylpropan-2-yl)phenyl acetate (13) in 3 ml THF (1.50 g, 4.46 
mmol), was added H2O (3 mL) and AcOH (9 mL). The reaction mixture was stirred at room 
temperature for 4 h, quenched with H2O (10 mL), and extracted with ethyl acetate (2×50 mL). The 
combined organic phase was dried over anhydrous Na2SO4 and evaporated under reduced pressure 
to give the crude product, which was purified by column chromatography (hexane: ethyl acetate 
=2:1) to obtain colorless oil (900 mg, 91%). 1H NMR (CDCl3): δ 7.32 (dd, J = 7.6 Hz, 1.6 Hz, 
1H), 7.25-7.21 (m, 1H),7.18-7.14 (m, 1H), 6.98 (dd, J = 7.6 Hz, 1.6 Hz, 1H), 3.40 (t, J = 7.6 Hz, 
2H), 2.34 (s, 3H), 1.99 (t, J = 7.6 Hz, 2H), 1.37 (s, 6H). 13C NMR (CDCl3) δ 169.9, 149.1, 138.8, 




Synthesis of 2-(2-methyl-4-oxobutan-2-yl)phenyl acetate (15). To a solution of PCC (1.55 g, 7.2 
mmol) in DCM (5 mL), a solution of (2-(4-hydroxy-2-methylbutan-2-yl)phenyl acetate (14, 710 
mg, 3.20 mmol) in DCM (5 mL) was added dropwise at room temperature.  After 2 h, the mixture 
was directly subjected to column chromatography (hexane: ethyl acetate =10:1) to obtain the pure 
product as colorless oil (650 mg, 92%). 1H NMR (CDCl3): δ 9.45 (t, J = 2.8 Hz, 1H), 7.38 (dd, J 
= 7.6 Hz, 1.6 Hz, 1H), 7.30-7.26 (m, 1H), 7.22-7.18 (m, 1H), 7.05 (dd, J = 7.6 Hz, 1.6 Hz, 1H), 
2.79 (d, J = 2.8 Hz, 2H), 2.36 (s, 3H), 1.46 (s, 6H). 13C NMR (CDCl3): δ 202.8, 169.3, 149.0, 
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137.5, 128.0, 127.8, 126.2, 124.5, 54.6, 36.3, 29.1, 21.8. HRMS calcd for C13H16O3 
[M+H]+221.1172, found: 221.1178. 
 
Synthesis of 3-(2-acetoxyphenyl)butanoic acid (16). To a solution of 2-(2-methyl-4-oxobutan-2-
yl)phenyl acetate (15, 600 mg, 2.73 mmol) in t-BuOH (12 mL) and 2-methylbut-2-ene (2.5 mL) 
was added dropwise NaClO2 (564 mg, 6.27 mmol) in 0.67M NaH2PO4 (2.0 mL) at room 
temperature. After 2 h, the reaction was quenched with H2O (20 mL), and extracted with ethyl 
acetate (2×50 ml). The combined organic phase was dried over anhydrous Na2SO4 and evaporated 
under reduced pressure to afford the crude product, which was purified by column chromatography 
(hexane: ethyl acetate =5:1) to obtain a white solid (510 mg, 79%). 1H NMR (CDCl3): δ 7.38 (dd, 
J = 8.0 Hz, 1.6 Hz, 1H), 7.27-7.23 (m, 1H), 7.19-7.15 (m, 1H), 7.03 (dd, J = 8.0 Hz, 1.6 Hz, 1H), 
2.79 (s, 2H), 2.35 (s, 3H) 1.47 (s, 6H). 13C NMR (CD3OD) δ 175.2, 171.0, 150.4, 139.9, 128.9, 
128.2, 126.7, 125.2, 46.6, 37.4, 29.1, 21.6. HRMS calcd for C13H16O4 [M+Na]
+ 259.0941, found: 
259.0945. 
Synthesis of sodium 3-(2-acetoxyphenyl)-3-methylbutanethioate (HP-103). A solution of 3-(2-
acetoxyphenyl)butanoic acid (16, 100 mg, 0.42 mmol) and Lawesson’s reagent (85 mg, 0.21 
mmol) in DCM (5 mL) in a sealed tube was subjected to microwave irradiation (100 °C , 6 min). 
The mixture was directly subjected to column chromatography (hexane: ethyl acetate =20:1) to 
obtain the pure product as colorless oil, which was then dissolved in 5 ml methanol. To this 
solution 3 ml of 0.1 M NaOH methanol solution was added at -78 ℃. After 5 min, the mixture was 
allowed to warm to room temperature and the solvent was removed by vacuum. The final product 
was achieved by recrystallization in ether as a white solid (70 mg, 60%). 1H NMR (CD3OD): δ 
7.39 (dd, J = 8.0Hz, 1.6 Hz, 1H), 7.26-7.22 (m, 1H), 7.19-7.15 (m, 1H), 7.04 (dd, J = 8.0Hz, 1.6 
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Hz, 1H), 3.18 (s, 2H), 2.36 (s, 3H) 1.44 (s, 6H). 13C NMR (CDCl3) δ 195.7, 169.3, 148.9, 137.5, 
128.0, 127.8, 126.0, 124.2, 56.2, 37.5, 28.4, 21.8.  HRMS calcd for C13H15NaO3S [M-Na]
- 
251.0747, found: 251.0742. 
  
  
Reagents and conditions (i) TBDMSCl , imidazole, DMF, rt, 92%; (ii) Et3N, DCM, 0 ℃-rt, 12 h, 
73%; (iii) AcOH/H2O, THF, rt, 12 h, 85%; (iv) PCC, DCM, rt, 2 h 88%; (v) NaClO2/NaH2PO4, 2-
methylbut-2-ene, t-BuOH, rt, 2 h 65%; (vi) 1) Lawesson’s reagent, DCM, microwave, 6 min; 2) 
NaOH, methanol, -78 ℃, 65% for the last two steps . 
Scheme  1.8 Synthesis of HP-104. 
 
Synthesis of 2-(4-((tert-butyldimethylsilyl)oxy)-2-methylbutan-2-yl)phenol (18). To a 20-ml vial 
was added 2-(4-hydroxy-2-methylbutan-2-yl)phenol (11, 2.5 g, 14 mmol), imidazole (2.8 g, 42 
mmol), TBDMSCl (4.2 g, 28 mmol ) and DMF (7 ml). The mixture was stirred for 5 min at room 
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temperature, then quenched with the addition of H2O (100 mL), and extracted with ethyl acetate 
(2×150 mL). The combined organic phase was washed by saturated NaHCO3 (2×150 mL), dried 
over anhydrous Na2SO4, and evaporated under reduced pressure to give the crude product, which 
was purified by recrystallization in methanol to give a white solid (3.8 g, 92%). 1H NMR (CDCl3): 
δ 7.19 (d, J = 7.6 Hz, 1H), 7.08-7.04 (m, 1H), 6.86-6.83 (m, 1H), 6.66 (d, J = 7.6 Hz, 1H), 6.10 (s, 
1H), 3.51 (t, J = 7.6 Hz, 2H), 2.17 (t, J = 7.6 Hz, 2H), 1.42 (s, 6H), 0.88 (s, 9H), 0.02 (s, 6H). 13C 
NMR (CDCl3) δ 154.9, 134.1, 127.7, 127.3, 120.2, 116.9, 61.7, 43.3, 36.7, 29.0, 26.1, 18.5, -5.1. 
HRMS calcd for C17H30O2Si [M+H]
+295.2088, found: 295.2075. 
 
Synthesis of 2-(4-((tert-butyldimethylsilyl)oxy)-2-methylbutan-2-yl)phenyl 
cyclopropanecarboxylate (19). To a solution of 2-(4-((tert-butyldimethylsilyl)oxy)-2-
methylbutan-2-yl)phenol (18, 2.0 g, 6.8 mmol) and Et3N (1.4 g, 13.6 mmol) in DCM (150 mL) 
was added dropwise cyclopropanecarbonyl chloride (6, 1.46 g, 13.6 mmol) at 0 ℃. The mixture 
was allowed to warm to room temperature and stirred for 12 h. Then the reaction was quenched 
with the addition of H2O (100 mL), and solution was extracted with ethyl acetate (2×150 mL). The 
combined organic phase was dried over anhydrous Na2SO4 and evaporated under reduced pressure 
to give the crude product, which was purified by column chromatography (hexane: ethyl acetate 
=50:1) to give a colorless oil (1.8 g, 73%). 1H NMR (CDCl3): δ 7.32 (dd, J = 7.6 Hz, 1.6 Hz, 1H), 
7.23-7.19 (m, 1H), 7.16-7.12 (m, 1H), 6.98 (dd, J = 7.6 Hz, 1.6 Hz, 1H), 3.41 (t, J = 7.6 Hz, 2H), 
2.03 (t, J = 7.6 Hz, 2H), 1.92-1.85 (m, 1H), 1.38 (s, 6H), 1.19-1.18 (m, 2H), 1.05-1.00 (m, 2H), 
0.84 (s, 9H), -0.04 (s, 6H). 13C NMR (CDCl3) δ 173.5, 149.4, 139.1, 128.1, 127.1, 125.6, 124.2, 





Synthesis of 2-(4-hydroxy-2-methylbutan-2-yl)phenyl cyclopropanecarboxylate (20). To a solution 
of 2-(4-((tert-butyldimethylsilyl)oxy)-2-methylbutan-2-yl)phenyl cyclopropanecarboxylate (19, 
1.7 g, 4.69 mmol）in THF (20 mL) was added H2O (20 mL) and AcOH (60 mL). The reaction 
mixture was stirred at room temperature for 4 h, quenched with H2O (50 mL), and extracted with 
ethyl acetate (2 × 150 mL). The combined organic phase was dried over anhydrous Na2SO4 and 
evaporated under reduced pressure, and purified silica gel column chromatography (hexane: ethyl 
acetate =10:1)   as colorless oil (1.1 g, 95%). 1H NMR (400 MHz CDCl3): δ 7.32 (dd, J = 7.6 Hz, 
1.6 Hz, 1H), 7.24-7.20 (m, 1H), 7.18-7.13 (m, 1H), 6.96 (dd, J = 7.6 Hz, 1.6 Hz, 1H), 3.42 (t, J = 
7.6 Hz, 2H), 2.03 (t, J = 7.6 Hz, 2H), 1.93-1.87 (m, 1H), 1.39 (s, 6H), 1.21-1.17 (m, 2H), 1.07-
1.02 (m, 2H). 13C NMR (CDCl3) δ 174.1, 149.4, 139.0, 128.1, 127.3, 125.9, 124.3, 60.3, 44.4, 
36.9, 29.2, 13.6, 9.2. For C15H20O3 [M+H]
+249.1485, found: 249.1485. 
 
Synthesis of2-(2-methyl-4-oxobutan-2-yl)phenyl cyclopropanecarboxylate (21). To a solution of 
PCC (2.2 g, 10.0 mmol) in DCM (20 mL) was added dropwise 2-(4-hydroxy-2-methylbutan-2-
yl)phenyl cyclopropanecarboxylate (20, 1.1 g, 4.4 mmol) in DCM (25 mL) at room temperature. 
After 2 h, the mixture was directly subjected to column chromatography (hexane: ethyl acetate 
=20:1) to obtain the pure product as colorless oil (0.95 g, 88%). 1H NMR (CDCl3): δ 9.45 (t, J = 
2.8 Hz, 1H), 7.38 (dd, J = 8.0 Hz, 1.6 Hz, 1H), 7.29-7.25 (m, 1H), 7.21-7.17 (m, 1H), 7.03 (dd, J 
= 8.0 Hz, 1.6 Hz, 1H), 2.81 (d, J = 2.8 Hz, 2H), 1.93-1.86 (m, 1H), 1.47 (s, 6H), 1.21-1.17 (m, 
2H), 1.08-1.04 (m, 2H). 13C NMR (CDCl3): δ 202.9, 173.4, 149.2, 137.6, 127.9, 127.7, 126.0, 
124.5, 54.5, 36.3, 29.1, 13.5, 9.2. HRMS calcd for C15H18O3 [M+Na]
+269.1148, found: 269.1149. 
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Synthesis of 3-(2-((cyclopropanecarbonyl)oxy)phenyl)-3-methylbutanoic acid (22). To a solution 
of 2-(2-methyl-4-oxobutan-2-yl)phenyl cyclopropanecarboxylate (21, 900 mg, 3.6 mmol) in t-
BuOH (20 mL) and 2-methylbut-2-ene (4 mL) NaClO2 (496 mg, 5.4 mmol) in 0.67 M NaH2PO4 
(4 mL) was added dropwise  at room temperature. After 2 h, the reaction mixture was quenched 
with H2O (20 mL), and extracted with ethyl acetate (2 × 100 ml). The combined organic phase 
was dried over anhydrous Na2SO4 and then evaporated under reduced pressure to give the crude 
product, which was purified by column chromatography (hexane: ethyl acetate =10:1)  to yield a 
white solid (610 mg, 65%). 1H NMR (MeOH): δ 7.42 (dd, J = 7.6 Hz, 1.6 Hz, 1H), 7.23-7.14 (m, 
2H), 6.97 (dd, J = 7.6 Hz, 1.6 Hz, 1H), 2.80 (s, 2H), 1.99-1.93 (m, 1H), 1.47 (s, 6H), 1.13-1.07 (m, 
4H). 13C NMR (CDCl3) δ 177.6, 173.6, 149.1, 138.2, 127.8, 127.5, 125.8, 124.1, 45.8, 36.7, 28.4, 
13.5, 9.2. HRMS calcd for C15H18O4 [M+H]
+263.1278, found: 263.1279. 
 
Synthesis of sodium 3-(2-((cyclopropanecarbonyl)oxy)phenyl)-3-methylbutanethioate (HP-104). 
To a solution of 3-(2-((cyclopropanecarbonyl)oxy)phenyl)-3-methylbutanoic acid (22, 120 mg, 
0.46 mmol) in DCM (5 mL) was added Lawesson’s reagent (92 mg, 0.23 mmol). The mixture was 
heated in a microwave at 100℃  for 6 min. The mixture was directly subjected to column 
chromatography (hexane: ethyl acetate =20:1) to obtain the pure product as colorless oil, which 
was then dissolved in 5 ml methanol. Then  2.5 ml of 0.1 M NaOH methanol solution was added 
to the reaction solution at -78 ℃ . After 5 min, the mixture was allowed to warm to room 
temperature and the solvent was removed by vacuum. The final product was achieved by 
recrystallization in ether as a white solid (90 mg, 65%). 1H NMR (CDCl3): δ 7.38 (d, J = 7.2 Hz, 
1H), 7.28-7.17 (m, 2H), 7.04 (d, J = 8.0 Hz, 1H), 4.41 (s, 1H),  3.11 (s, 2H), 1.97-1.90 (m, 1H), 
1.48 (s, 6H), 1.22-1.20 (m, 2H), 1.09-1.06 (m, 2H); 13C NMR (CDCl3): 195.8, 173.4, 149.1, 137.6, 
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128.0, 127.7, 125.9, 124.2, 56.3, 37.5, 28.4, 13.5, 9.3. HRMS calcd for C15H17NaO3S 
[M+H]+301.0869, found: 301.0871. 
 
Reagents and conditions (i) EDC/DMAP, DCM, rt, 2 h, 88%; (ii) AcOH/H2O, THF, rt, 12 h, 
87%; (iii) PCC, DCM, rt, 2 h, 81%; (iv) NaClO2/NaH2PO4, 2-methylbut-2-ene, t-BuOH, rt, 2 h, 
66%; (v) 1) Lawesson’s reagent, DCM, microwave, 6 min; 2) NaOH, methanol, -78 ℃, 65% for 
the last two steps  
Scheme  1.9 Synthesis of HP-105. 
 
Synthesis of 2-(4-((tert-butyldimethylsilyl)oxy)-2-methylbutan-2-yl)-3,5-dimethylphenyl (S)-2-(6-
methoxynaphthalen-2-yl)propanoate (23). To a solution of 2-(4-((tert-butyldimethylsilyl)oxy)-2-
methylbutan-2-yl)-3,5-dimethylphenol (5, 1.27 g, 3.9 mmol), (S)-2-(6-methoxynaphthalen-2-
yl)propanoic acid (1.00 g, 4.4 mmol) and DMAP (100 mg, 0.8 mmol) in DCM (50 mL) was added 
EDC (1.62 g, 8.7 mmol). The mixture was stirred at room temperature for 2 h, then quenched with 
the addition of H2O (50 mL), and extracted with DCM (2×50 mL). The combined organic phase 
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was dried over anhydrous Na2SO4 and evaporated under reduced pressure to give the crude 
product, which was purified by column chromatography (hexane: ethyl acetate =50:1) to give a 
colorless oil (1.86 g, 88%). 1H NMR (CDCl3): δ 7.77-7.72 (m, 3H), 7.50 (dd, J = 8.4 Hz, J = 1.6 
Hz, 1H), 7.17-7.14 (m, 2H), 6.74 (d, J = 1.2 Hz, 1H), 6.32 (d, J = 1.2 Hz, 1H), 4.04 (q, , J = 7.2 
Hz, 1H), 3.93 (s, 3H), 3.40 (t, J = 7.2 Hz, 2H), 2.48 (s, 3H), 2.14 (s, 3H), 1.91 (t, J = 7.2 Hz, 2H), 
1.69 (d, J = 7.2 Hz, 3H), 1.36 (d, J = 7.2 Hz, 6H), 0.84 (s, 9H), -0.06 (s, 6H); 13C NMR (CDCl3): 
173.7, 157.8, 150.2, 138.3, 136.0, 134.9, 134.2, 134.0, 132.3, 129.5, 129.1, 127.4, 126.6, 126.5, 
122.7, 119.2, 105.7, 60.9, 55.4, 46.3, 45.9, 39.2, 31.9, 31.9, 26.1, 25.4, 20.3, 18.6, 18.3, -5.2. 
HRMS calcd for C33H46O4Si  [M+H]
+535.3238, found: 535.3239. 
 
Synthesis of 2-(4-hydroxy-2-methylbutan-2-yl)-3,5-dimethylphenyl (S)-2-(6-methoxynaphthalen-
2-yl)propanoate (24). To a solution of (2-(4-((tert-butyldimethylsilyl)oxy)-2-methylbutan-2-yl)-
3,5-dimethylphenyl (S)-2-(6-methoxynaphthalen-2-yl)propanoate (23, 1.86 g, 3.5 mmol)in THF 
(15 mL) was added H2O (20 mL) and AcOH (45 mL). The reaction mixture was stirred at room 
temperature for 12 h, quenched with H2O (50 mL), and extracted with ethyl acetate (2 × 100 mL). 
The combined organic phase was dried over anhydrous Na2SO4 and evaporated under reduced 
pressure. Silica gel column chromatography (hexane: ethyl acetate =2:1) gave the product as 
colorless oil (1.27 g, 87%). 1H NMR (CDCl3): δ 7.79-7.74 (m, 3H), 7.52 (dd, J = 8.4 Hz, J = 1.6 
Hz, 1H), 7.19-7.15 (m, 2H), 6.77 (d, J = 1.2 Hz, 1H), 6.35 (d, J = 1.2 Hz, 1H), 4.08 (q, J = 7.2 Hz, 
1H), 3.93 (s, 3H), 3.44 (t, J = 7.2 Hz, 2H), 2.49 (s, 3H), 2.16 (s, 3H), 1.92-1.80 (m, 2H), 1.72 (d, 
J = 7.2 Hz, 3H), 1.37 (s, 6H); 13C NMR (CDCl3): 174.2, 157.9, 150.2, 138.4, 136.3, 134.6, 134.0, 
134.0, 132.5, 129.4, 129.1, 127.5, 126.7, 126.5, 122.8, 119.3, 105.7, 60.6, 55.4, 46.3, 45.6, 39.2, 
32.0, 25.5, 20.2, 18.5. HRMS calcd for C27H32O4 [M+Na]
+443.2193, found: 443.2192. 
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Synthesis of 3,5-dimethyl-2-(2-methyl-4-oxobutan-2-yl)phenyl (S)-2-(6-methoxynaphthalen-2-
yl)propanoate (25). To a solution of PCC (1.2 g, 5.6 mmol) in DCM (15 mL) was added dropwise 
the solution of 2-(4-hydroxy-2-methylbutan-2-yl)-3,5-dimethylphenyl (S)-2-(6-
methoxynaphthalen-2-yl)propanoate (24, 1.2 g, 2.8 mmol) in DCM (20 mL) at room temperature. 
After 2 h, the mixture was directly subjected to column chromatography (hexane: ethyl acetate 
=5:1) to obtain the pure product as colorless oil (0.97 g, 81%). 1H NMR (CDCl3): δ 9.36 (d, J = 
2.4 Hz, 1H), 7.77-7.73 (m, 3H), 7.49 (dd, J = 8.8 Hz, J = 1.6 Hz, 1H), 7.19-7.14 (m, 2H), 6.79 (s, 
1H), 6.43 (s, 1H), 4.06 (q, J = 7.2 Hz, 1H), 3.93 (s, 3H), 2.54 (t, J = 2.4 Hz, 2H), 2.48 (s, 3H), 2.18 
(s, 3H), 1.71 (d, J = 7.2 Hz, 3H), 1.40 (s, 3H), 1.35 (s, 3H); 13C NMR (CDCl3): 203.22, 173.5, 
157.9, 149.9, 137.8, 136.9, 134.3, 134.0, 132.9, 132.7,129.4, 129.1, 127.6, 126.7, 126.4, 123.0, 
119.4, 105.7, 56.4, 55.4, 46.3, 38.2, 31.6, 31.4, 25.6, 20.3, 18.4.  HRMS calcd for C27H30O4  
[M+Na]+441.2036, found: 441.2033. 
 
Synthesis of (S)-3-(2-((2-(6-methoxynaphthalen-2-yl)propanoyl)oxy)-4,6-dimethylphenyl)-3-
methylbutanoic acid (26). To a solution of 3,5-dimethyl-2-(2-methyl-4-oxobutan-2-yl)phenyl (S)-
2-(6-methoxynaphthalen-2-yl)propanoate (25, 0.96 g, 2.3 mmol) in t-BuOH (18 mL) and 2-
methylbut-2-ene (3 mL) was added dropwise NaClO2 (330 mg, 3.4 mmol) in 0.67 M NaH2PO4 
(3.6 mL) at room temperature. After 2 h, the reaction mixture was quenched with H2O (20 mL), 
and extracted with ethyl acetate (2 × 50 ml). The combined organic phase was dried over 
anhydrous Na2SO4 and then evaporated under reduced pressure to give the crude product, which 
was purified by column chromatography (hexane: ethyl acetate =2:1) to yield a white solid (650 
mg, 66%). 1H NMR (CDCl3): δ7.77-7.72 (m, 3H), 7.50 (dd, J = 8.8 Hz, J = 2.0 Hz, 1H), 7.16-7.13 
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(m, 2H), 6.75 (s, 1H), 6.40 (s, 1H), 4.09 (q, , J = 7.2 Hz, 1H), 3.92 (s, 3H), 2.68-2.55 (m, 2H), 2.49 
(s, 3H), 2.15 (s, 3H), 1.70 (d, J = 7.2 Hz, 3H), 1.44 (s, 3H), 1.38 (s, 3H); 13C NMR (CDCl3): 
176.8, 173.7, 157.9, 150.0, 138.1, 136.4, 134.5, 134.0, 133.5, 132.5,129.5, 129.1, 127.5, 126.7, 
126.5, 122.7, 119.2, 105.7, 55.4, 47.2, 46.3, 38.8, 31.4, 31.2, 25.5, 20.3, 18.4.   HRMS calcd for 
C27H30O5  [M+Na]
+457.1985, found: 457.1983. 
 
Synthesis of Sodium (S)-3-(2-((2-(6-methoxynaphthalen-2-yl)propanoyl)oxy)-4,6-
dimethylphenyl)-3-methylbutanethioate (HP-105). To a solution of (S)-3-(2-((2-(6-
methoxynaphthalen-2-yl)propanoyl)oxy)-4,6-dimethylphenyl)-3-methylbutanoic acid (26, 180 
mg, 0.41 mmol) in DCM (5 mL) was added Lawesson’s reagent (83 mg). The mixture was heated 
in a microwave at 100 ℃ for 6 min. The mixture was directly subjected to column chromatography 
(hexane: ethyl acetate =15:1) to obtain the pure product as colorless oil, which was then dissolved 
in 5 ml methanol. Then 2.6 ml 0.1 M NaOH methanol solution was added at -78 ℃. After 5 min, 
the mixture was allowed to warm to room temperature and the solvent was removed by vacuum. 
The final product was achieved by recrystallization in ether as white solid (140 mg, 72%) 1H NMR 
(CDCl3): δ 7.81-7.74 (m, 3H), 7.52 (dd, J = 8.8 Hz, J = 2.0 Hz, 1H), 7.20-7.15 (m, 2H), 6.76 (d, J 
= 1.6 Hz 1H), 6.49 (d, J = 1.6 Hz 1H), 4.14 (q, J = 7.2 Hz, 1H), 3.94 (s, 3H), 2.80-2.64 (m, 2H), 
2.48 (s, 3H), 2.18 (s, 3H), 1.74 (d, J = 7.2 Hz, 3H), 1.38 (s, 3H), 1.30 (s, 3H); 13C NMR (CDCl3): 
196.2, 173.4, 158.0, 150.1, 138.1, 136.5, 134.4, 134.1, 132.8, 132.6, 129.5, 129.1, 17.7, 126.8, 
126.5, 122.8, 119.4, 105.8, 58.1, 55.4, 46.4, 39.7, 31.5, 31.3, 25.6, 20.4, 18.3. HRMS calcd for 
C27H29O4SNa [M+H]
+: 473.1757, found: 473.1756. 
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1.4.2 H2S release from HPs 
Stock solution preparation. HPs stock solution: HPs were dissolved in DMSO to afford 20 mM 
HPs stock solutions. Esterase stock Solution: 6.0 mg Esterase (18 unit/mg esterase from porcine 
liver, PLE, Aldrich, E3019) was dissolved in 1.080 ml PBS to provide a 100 unit/mL esterase 
stock solution. WSP-5 stock solution: WSP-5 was dissolved in DMSO to prepare a 2.5 mM stock 
solution. CTAB was dissolved in ethanol to prepare a 100 mM stock solution.   
H2S concentration measurement by an electrode probe ISO-H2S-2. 
HPs (Final Conc. 200 μM) was added to an incubation chamber (World Precision Instruments; 
WPI) containing phosphate buffer (10 mM; pH 7.4, 10 mL), and esterase (1 unit/ mL) at 37 °C.  
H2S formation was detected with the use of a 2-mm H2S-selective microelectrode (ISO-H2S-2; 
WPI) attached to an Apollo 1100 Free Radical Analyser (WPI) and shown as picoamps current 
generated. A standard curve (using Na2S·9H2O) was generated by following literature 
procedures,89 but using PBS containing esterase at 37 °C .  
H2S measurement by a fluorescent probe WSP-5. 
HP-101 (final concentration: 200 μM) or other control compounds were added to PBS (10 mL) 
buffer containing esterase (1 unit/ mL) at 37 °C. After 15 minutes, aliquots of 100 μL samples 
were taken out and added into 100 μL PBS containing 50 uM WSP-5 and 100 μM CTAB in 96-
well plate.  After mixing and standing for 5 min at room temperature, the fluorescent intensities at 
535 nm were recorded by a plate reader with excitation at 485 nm.  
 
H2S release from HP-101 in cell culture media 
HP-101 (200 μM) was added to an incubation chamber (World Precision Instruments; WPI) 
containing cell culture media (10mL) at 37 °C.  H2S formation was detected with the use of a ISO-
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H2S-2 attached to an Apollo 1100 Free Radical Analyser and shown as picoamps current generated 
(Figure 1.4.1). A standard curve (using Na2S·9H2O) was also generated under the same 
conditions.89 The results (Figure 1. 9) indicated that HP-101 in the DMEM did not release H2S; 
however, when HP-101 was added into the media collected after overnight of cell culturing, H2S 
was released at a moderate rate, presumably due to the presence of esterases produced by the cells. 
 
Figure 1.9. H2S release from HP-101(200 μM) in cell culture media with or without FBS 
as detected using an electrode probe. (n= 3, p= 0.95) 
 
H2S release from HP-105 measurement 
To 9.9 mL phosphate buffer (pH 7.4) solution was added 11.1 mg (200 unit) PLE, followed by the 
addition of 100 μL 20 mM HP-105 stock solution (Final Conc.: 200μM). The resultant solution 
was sealed and stirred at 37 °C.  At every 30 min, 200 μL of reaction solution was taken into a 1.5 
mL vial containing 200 μL zinc acetate (1 %, w/v).  Then the vial was centrifuged for 10 min. 
(14.5 × 1000 rp). Removed the supernatant and washed the precipitation with PBS solution (100 
μL × 2). Then 600μL  N,N-dimethyl-1,4-phenylenediaminesulfate (0.2% w/v in 20% H2SO4  
solution) and 50 μL ferric chloride (10% w/v in 0.2%  H2SO4 solution) was added to the vial. Then 
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the vial was centrifuged for 5 min (14.5 × 1000 rp). The absorbance (at 740 nm) of the resulting 
solution was measured (after stirring for 10 min). H2S concentration was calculated based on a 
calibration curve of NaHS. 
 
 
Figure 1.10. H2S release from HP-105 (200 μM) in PBS at 37 °C with 20 unit/ mL PLE. (n= 3, 
p= 0.95) 
 
1.4.3 Kinetic studies of esterase trigger lactone formation 
Esterase triggered lactone formation from HP-101 as monitored by LC-MS/MS (Figure 8) 
HP-101 (final Conc. 200 μM) was added to PBS (10 mL) with 1 unit/mL esterase at 37 °C. 
Reaction mixture (10 μL) was taken out every 3 minutes and added into a vial containing 990 uL 
methanol at -78°C for 5 minutes. The mixture (14.5 ×1000 rp) was centrifuged, and the supernatant 
was used as the sample for LC-MS/MS analysis (Agilent 1100 LC, 6410 TripleQ MS/MS, Ion 
transition: 205.0/135.0, positive mode). 
All LC-MS/MS samples were analyzed using liquid chromatography tandem mass spectrometric 
method (Agilent 6410 series). Auto-sampler temperature was set at 10 °C, a positive ionization 
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mode with multiple reaction monitoring (MRM, m/z Q1/Q3) of lactone (m/z 205.0/135.0, RT 
1.4min) was employed. The ion spray voltage was set at 3500 V, ionization temperature set as 300 
°C and drying gas flow rate at 10 L/min. Data acquisition and quantitation were performed using 
Mass Hunter software (Agilent Technologies). Separation was achieved using HP1100 series LC 
(Agilent Technologies, Wilmington, DE) equipped with a photodiode array (PDA) detector, using 
an Agilent Zorbax reversed-phase (SB-C18, 3.0×250 mm, 5.0 μm) column. A gradient method 
was employed to separate the individual GE components using mobile phase A (0.1% formic acid 
in water) and mobile phase B (ACN). The gradient elution method with 30% B at 0 min, 90% B 
at 20 min, held for 10 min, back to 30% B at 40 min with a flow rate of 0.4 mL/min. An injection 
volume of 10 μL was used for analysis.  
The results (Figure 1.11) showed that about 190 μM of the lactone product was formed after 
treatment with esterase for 25 min. Such results indicate that about 95% of H2S was released in 
that period. 
 
Figure 1.11. Esterase-triggered lactone formation from HP-101 as monitored with LC-MS/MS. 
(n= 3, p= 0.95)  
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Esterase triggering lactone formation from HPs as monitored with HPLC 
HPs (final Conc. 200 μM) was added to PBS (10 mL) with 1 unit/mL esterase at 37 °C. 200 μL 
reaction mixture was taken out every 10 minutes and added into a vial containing 600 μL ethanol 
at -78 °C for 5 minutes. The mixture (14.5 ×1000 rp, 90 seconds) was centrifuged, and the 
supernatant was used as the sample for HPLC. 200 μL HPLC samples were injected into Shimadzu 
Prominence UFLC (column: Waters C18 3.5 μM, 4.6×100 mm, injection loop volume: 20μL). The 
mobile phase was acetonitrile (ACN)/H2O (pH=4.0) with ratios defined in the table below. (Table 
1.2) 
Table 1.2 HPLC monitored esterase triggering lactone formation of HPs.  (n= 3, p= 0.95) 
 HP-101 HP-102 HP-103 HP-104 HP-105 
Eluent conditions 50% ACN  
0~20 min 
60% ACN 
 0~20 min 
45% ACN  
0~20 min 
55% ACN  
0~20min 
Method b 
Retention time of HPs 
(min) 
13.6 ± 0.2 9.7 ± 0.2 7.7 ± 0.2 8.3 ± 0.2 20.7 ± 0.3 
Retention time of the 
lactones (min) 
10.7 ± 0.2 5.5 ± 0.2 8.5 ± 0.2 6.1 ± 0.2 9.6 ± 0.3 
Method b: 45% ACN, 0~10min; 45%~75% ACN, 10~15 min; 75% CAN, 15-20min; 75%~45% 
CAN, 20~25min. 
 
1.4.4 Stability Studies of the thioacid group 
To a solution of 5 mL deuterated PBS (1X pH=7.4), 50.0 mg of potassium thioacetate (0.438 
mmol) and 4.0 mg of acetic acid (0.0658 mmol) were added. The mixture was incubated at 37 °C 
for 48 hours. The mixture was analyzed by 1H NMR at 0- and 48-hour time points, respectively. 
The spectrums were shown below (Figure1.12 ). At 0 h, the integration ratio between the methyl 
protons in thioacetate (CH3: 2.48 ppm) and that of acetic acid (CH3: 1.94 ppm) is 6.7, which is 
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consistent of the ratio of the compounds we added, and after 48 hours, the ratio did not change. 
Such results indicate that the thioacid group is stable under the conditions of the study.  
 
 
Figure 1.12. 1H NMR spectra of reaction mixture at the 0- and 48-hour time points. 
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1.4.5 Cell culture 
 
      RAW 264.7 (ATCC® TIB-71™) mouse macrophage cells were used in the studies. The RAW 
264.7 cells were maintained in DMEM (Dulbecco’s Modified Eagle’s Medium) supplemented 
with 10% fetal bovine serum (MidSci; S01520HI) and 1% penicillin-streptomycin (Sigma-
Aldrich; P4333) at 37 °C with 5% CO2.  
 
1.4.5.1 Cytotoxicity study 
   The RAW 264.7 cells were seeded in 96-well plate one day before the experiment. Different 
concentrations of HP or iHP compounds was directly dissolved in cell culture media and added 
into the RAW 264.7 cell culture. The cells were then incubated with the compound for 24 hours 
at 37 °C with 5% CO2. The cell viability was tested by the MTT assay. Specifically, after 24 hr of 
incubation, 0.5 mg/mL MTT (3-(4, 5-Dimethylthiazol-2-yl)-2, 5-Diphenyltetrazolium Bromide) 
was added into the cell culture for 4 hours. Thereafter, the supernatant was removed and 100 μL 
DMSO was added into the wells containing the cells. After shaking gently for 3 minutes, 




Figure 1.13. Cytotoxicity of HPs. (n= 4, p=0.95) 
 
1.4.5.2 Anti-inflammation study 
   The RAW 264.7 cells were seeded in the 48-well plate one day before the experiment. 
Lipopolysaccharide was added into the cell culture to initiate the inflammatory response in RAW 
264.7 cells and to trigger the expression of cytokines. RAW 264.7 cells were co-treat with HPs or 
iHPs, 1unit/mL esterase and 1 μg/mL of LPS for 1 hour. Thereafter, the cell culture supernatant 
was collected. The concentrations of TNF-α in the cell culture supernatant was quantified by a 
commercial ELISA kit (ELISA Ready-SET-Go!® -eBioscience. 
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2 DEVEPMENT OF A NOVEL ESTERASE-SENSITIVE PRODRUG APPROACH 
FOR CONTROLLABLE DELIVERY OF PERSULFIDE SPECIES 
Abstract: This chapter is mainly based on my publications: Angew. Chem. Int. Ed. in 2017, 
from page 11749–11753. A new strategy to deliver a well-defined persulfide species in a biological 
medium is described herein. Under near physiological conditions, the persulfide prodrug can be 
activated by an esterase to generate a “hydroxyl methyl persulfide” intermediate, which rapidly 
collapses to form a defined persulfide. Such persulfide prodrugs can be used either as chemical 
tools to study persulfide chemistry and biology or for future development as H2S-based therapeutic 
reagents. Using the persulfide prodrugs developed in this study, the reactivity between S-methyl 
methanethiosulfonate (MMTS) with persulfide was unambiguously demonstrated. In addition, a 
representative prodrug exhibited potent cardioprotective effects in a murine model of myocardial 
ischemia-reperfusion (MI/R) injury with a bell shape therapeutic profile. 
2.1 Introduction  
The physiologic and potentially therapeutic roles of hydrogen sulfide (H2S) and related 
sulfur species are well accepted.117-123 However, the detailed mechanism(s) of action for these 
sulfur species is far from clear. Further, even the question of the “active” sulfur species is not 
always clear for a given biological response.  To complicate this further, different donors of sulfur 
species without defined chemistry are often used in various studies, leading to difficulty in result 
interpretation and comparison. For example, polysulfides and garlic-derived sulfur species are 
often used in biological studies.124-125 The chemistry of such sulfur donors is not well defined; 
consequently, it is not always clear what the “active” species is and the relative ratio of the various 
species. To advance the field of sulfur biology, it is important to devise chemical strategies that 
allow for the precise production of various specific sulfur species for mechanistic studies at the 
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molecular level and for understanding the biology. Several labs have made significant 
contributions in developing prodrugs of hydrogen sulfide4, 126-128 and COS129-133 as well as sulfur 
donors at various oxidation states.95, 134-136 Along this line, one molecular pathway is known to 
play an important role in sulfur-mediated signaling, S-sulfhydration.137 Clearly, this is not the kind 
of chemistry that can be achieved with hydrogen sulfide per se. It would require sulfur species at 
the oxidation state of a persulfide or polysulfide. Indeed, perthiol species have drawn growing 
attention owing to its potentially dominant roles in H2S-related signaling pathways.
123, 138-139 There 
are already many studies that explore persulfide chemistry in biology. For example, it was reported 
that persulfide species such as glutathione persulfide (GSSH) have much stronger “reducing” 
ability for ferric-cytochrome c than H2S and GSH.
140 Such results are puzzling in terms of the 
redox chemistry because chemically it is hard to understand how a persulfide species can be 
stronger reducing agents than sulfide. Such findings suggest that more work is needed at the 
molecular level to elucidate the mechanism of action. Other examples include the findings that 
reactive sulfur species (RSS) such as sulfane sulfurs or polysulfides are more effective in S-
sulfhydration than H2S.
123, 141-142  There is a clear need for investigation of persulfide chemistry 
and chemical biology in this field.138 However, there are two major challenges that face the 
chemistry field. The first one is a lack of good persulfide precursors/prodrugs that allow for easy 
and reliable access to persulfides as research tools; and the second one is the limited availability 
of ‘easy to use’ detection methods for protein S-sulfhydration.138 There has been reported work to 
address the second issue.123, 137, 143-146 We herein focus on developing novel and easy to handle 
persulfide prodrugs to address the first issue. 
The difficulty in developing persulfide prodrugs comes from the unstable nature of 
persulfide species, which can rapidly decompose to disulfides, polysulfides, elemental sulfur and 
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H2S.
147 This is especially true if there is an exposed free sulfhydryl group (-SH). To achieve 
controlled delivery of persulfide in biological studies, the free sulfhydryl group has to be protected, 
and then regenerated when needed. One class of existing persulfide precursors contains the acyl 
disulfide group.126, 145 They were cleverly designed to release the persulfides through nucleophilic 
attack by a thiol group. However, the release of persulfide relies on the addition of an excess 
amount of thiol in solution.126, 146 Therefore, there is a mix of various sulfur species present at any 
given time. An approach to directly achieve “pure” persulfide species under physiological 
conditions without using other sulfide or thiol species is needed. 
 
2.2  Results and Discussions 
Enzyme-sensitive prodrugs have been widely used in drug delivery.148 We are interested 
in designing esterase-sensitive persulfide prodrugs, which are stable under physiological 
conditions and can efficiently generate persulfide in the presence of an enzymatic trigger.  
Specifically, similar to the idea of using “hemiacetal” as an unstable intermediate in prodrug 
design,149 we were interested in exploiting the “hydroxyl methyl disulfide” (HOCHRSSR) analog 
as a key intermediate in our design. In this design, an ester group is introduced to mask the 
hydroxyl group, leading to a stable precursor. Activation of this prodrug thus relies on the cleavage 
of this ester bond, resulting in an unstable HOCHRSSR intermediate, which would collapse to 
give an aldehyde and a persulfide (Scheme 2.1) 
 
Scheme  2.1. General design of persulfide prodrugs, and their release mechanism. 
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To test our design, persulfide prodrug 1 (P1, BW-HP-201,Scheme 2.2 ) was synthesized 
by a one-step reaction between 1,2-dibenzyldisulfane and propionic acid using KMnO4 as the 
oxidant by following a similar literature procedure.150 P1 is a colorless oil without the 
characteristic smell of sulfide such as benzyl mercaptan and is stable at room temperature for 5 
days and at -20 °C for 3 months. P2~6 (BW-HP-202-206) were also synthesized using the same 
procedures. 
  
Scheme  2.2.  Structures of persulfide prodrugs. 
 
We first studied the ability for P1 to undergo the intended reaction by monitoring the 
formation of both benzyl persulfide and benzaldehyde by HPLC. It turned out that the benzyl 
persulfide (compound 32) (Scheme 2.3) was not sufficiently stable for detection on an HPLC time 
scale. This further affirms the rationale for designing these prodrugs, i.e., without the protection 
of the terminal sulfhydryl group, the persulfide species would not be stable enough for long-term 
storage. For detection purpose, we therefore, trapped benzyl persulfide using N-acetyl-L-cysteine 
(compound 33) to give compound 34, which is stable for HPLC detection. Specifically, 100 μM 
P1 was treated with porcine liver esterase (0.5 u/ml, PLE) for 10 min at 37 °C in the phosphate 
buffered saline (PBS, pH= 7.4) containing 500 μM compound 33 (Scheme 2.3). The results show 
that the amount of benzaldehyde 31 detected was the equivalent of 96% conversion. However, 
only 55% recovery of disulfide 34 were detected under such conditions, clearly indicating that the 
trapping reaction was not fast enough on the time scale of the study. By increasing the 
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concentration of 33 to 3 mM, we were able to detect about 95% recovery of disulfide 34 (Scheme 
2.3).  Such results clearly indicated that the release reaction occurred as designed.   
  
Scheme  2.3.  Benzyl persulfide was release from P1 and trapped by 33. 
 
Besides using HPLC to detect the formation of 31 and 34, we also used the standard 
methylene blue (MB) method to detect the H2S release from P1 (Figure 2.1) in the presence of 33. 
The results showed no obvious H2S generation in the absence of PLE, and only less than 5 µM 
H2S (5%) were formed in the presence of 500 µM compound 33, suggesting the possibility of a 
small percentage of the prodrug to undergo sulfur exchange.  However, with the addition of 0.5 
u/ml PLE at 37 °C in PBS P1 generated about 23 µM, 33 µM and 45 µM H2S in the presence of 0 
µM, 500 µM and 3 mM compound 33, respectively. Compared with H2S release, the formation of 
benzaldehyde was not affected by compound 33 (Figure 2.1). More than 90% benzaldehyde was 
detected in 2 min in PLE-containing solution with or without compound 33, and less than 5% 
benzaldehyde was detected in the solution with 500 µM compound 33 without the addition of PLE. 
Such results indicated that the prodrugs were most effectively activated by an esterase, which 
controlled the rate-determining step.  
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Figure 2.1. P1 hydrolysis at 37 °C in PBS (2% DMSO). □:100 μM P1; :100 μM P1 + 
500 μM Compound 3;  :100 μM P1 + PLE; :100 μM P1 + 500 μM Compound 3 + PLE;  
100 μM P1 + 3 mM Compound 3 + PLE. a) H2S release detection by MB method; b) 
Benzaldehyde formation detection by HPLC.  
 
For small molecule bioregulators (SMBs), release rate is a very important factor in 
determining the sustained effective concentration and thus biological effect. Donors at the same 
concentration could lead to different biological effects when the release rates are different. Our 
earlier work on H2S prodrugs demonstrated that varying the acyl moiety allows for tuning the 
esterase-catalyzed hydrolysis rates.76 Thus we reasoned that similarly designed persulfide 
prodrugs should also show different release profiles. Therefore, we next examined release kinetics. 
Specifically, we treated all these precursors (100 μM) with 0.5 u/ml PLE in PBS containing 500 
μM compound 33 at 37 °C. Aldehyde formation was monitored by HPLC (Table 2.1), and H2S 
release was tested by the MB method. 
Table 2.1 Total percentage of aldehyde formation (A%) and 50% aldehyde formation 
time (t1/2) 
Compound  P1 P2 P3 P4 P5 P6 
A% 96±3 ∆ 91±4 97±3 97±2 89±6 
t1/2 (s) 25±5 12±6
* 85±9 17±6 29±6 145±12 
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∆: not detectable because of low boiling point of acetaldehyde;*: 50% P2 remaining at the time of 
sampling.  n= 3 p=0.95.  
 
The results demonstrated that all the prodrugs were sensitive to PLE with hydrolysis half-
lives ranging from 12 to 145 s. As a consequence of their respective release rates, the peak 
concentrations and sustained concentrations are also different. For example, H2S level released 
from P1 reached a peak concentration of 33 µM within 30 s and then decreased slowly.  On the 
other hand, the slowest prodrug P6 showed a gradual increase in H2S concentration, reaching a 
maximum of 15 µM after 3 min.  
The above studies clearly demonstrated the chemical feasibility of the prodrug activation 
and allow for studies of reaction kinetics.  However, such studies used benzaldehyde and hydrogen 
sulfide as surrogates for product detection. Next, it was important to demonstrate persulfide 
formation without the added the thiol species, 33.  In the field of designing detection methods for 
protein S-sulfhydration, a key step is developing trapping reagents, which could efficiently trap 
the persulfide under physiological conditions.138 For this study, we used dinitrofluorobenzene 
(DNFB, Compound 35), which was known to trap persulfides (Scheme 2.4).151 Specifically, we 
incubated 100 μM of the prodrugs with 1u/ml PLE at 37 °C for 10 s and then added 4 mM of 
DNFB to the mixture. The resulting solution was further incubated for another 30 min. Then the 
formation of disulfide compound 36 was analyzed by HPLC (Table2.2). We were able to trap 
70%-82% of the persulfide released from the prodrugs. There could be several reasons for the 
incomplete “conversion” to 36. First, it is possible that the reaction rate between the released 
persulfide and 35 is not high enough for 100% conversion. However, the fact that all prodrugs 
gave similar percentages of 36 (Table 2.2) suggests that this is not controlled by reaction kinetics 
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at the trapping step because the various prodrugs gave substantially different peak concentrations, 
and trapping yields are not correlated with release rates. The second possible reason is the 
competition between trapping and disproportionation reaction of the persulfide released. We tend 
to think that the latter was the reason for the less than 100% conversion to 36.  To confirm this, 
we incubate 100 μM of the prodrug with 1u/ml PLE and 4 mM DNFB at r.t., and found that the 
trapping yields increased to 82%-93%. Clearly, at lower temperature (room temperature vs. 37 
°C), the disproportion reaction was slower, allowing for the improved trapping efficiency. The 
results demonstrated that the prodrugs could efficiently afford persulfide for further studies. 
  
Scheme  2.4.  Persulfide released from precursors and trapped by DNFB 
 
Table 2.2 Persulfide released from precursors and trapped by DNFB 
Prodrugs P1 P2 P3 P4 P5 P6 
A (%) 79±5 70±4 71±5 80±4 82±5 78±4 
B (%) 87±5 80±6 81±5 88±6 93±5 86±5 
 A: trapping yield at 37 °C, B: trapping yield at r.t. n= 3, p=0.95 
As a research tool, the system can provide relatively “pure” persulfide, which is very 
unique and important in the field of protein S-sulfhydration. In 2009, sulfide signaling through S-
sulfhydration was first demonstrated.137 A modified biotin switch technique, using S-methyl 
methanethiosulfonate (MMTS) as an alkylating reagent, was used to identify a large number of 
proteins that may undergo S-sulfhydration. The underlying chemical mechanism was based on the 
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assumption that MMTS would selectivity react with thiol groups (RSH), but not persulfide group 
(RSSH) (Scheme 2.5a).  
  
Scheme  2.5. Persulfides react with MMTS 
 
However, later studies suggested that this assumption on the lack of reactivity between 
MMTS with RSSH was questionable (Scheme 2.5a).146 One reported work in studying the 
reactivity between MMTS with RSSH used a mixture of GSSG and sodium sulfide (Scheme 2.5b). 
In doing so, a small peak of GSSSMe was indeed detected. However, the origin of this “trisulfide” 
peak could be interpreted in more than one way due to complexity of the mixture formed in the 
process of preparing GSSH (Scheme 2.5b). To further probe the reactivity between MMTS with 
RSSH, we conducted the reaction between MMTS and the persulfide released from P5. 
Specifically, 100 μM of the prodrug was incubated with 1u/ml PLE and 4 mM MMTS at r.t. for 
30 min (Scheme 2.5d). Then LC-MS was applied to analyze product formation. For comparison, 
we also incubated 4 mM of MMTS with 1 mM dibenzyl disulfide BnSSBn and 1 mM of Na2S 
(Scheme 2.5c). The results are shown in Figure 2.2a and 2.2b. The reaction in 2.5c led to BnSSMe 
as the major product, and only a small amount of BnSSSMe was formed. Such results are quite 
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similar to the product formation pattern in the reported reaction between MMTS with GSSG and 
Na2S.
146  However in the reaction of MMTS with benzyl persulfide released from P5 (Scheme 
2.5d, Figure 2.2b), BnSSSMe clearly formed as the dominant product, and other possible sulfide 
products were only observed in minute quantities. The results here clearly demonstrated that 
MMTS could react with persulfide. By taking advantage of the unique property of our persulfide 
prodrug system, we reconfirmed that MMTS can efficiently react with persulfide.  
 
 
Figure 2.2. HPLC chromatography. a) HPLC trace of BnSSBn reacting with Na2S and MMTS. b) 
HPLC trace of esterase mediate P5 hydrolysis and persulfide trapping by MMTS.  
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Besides using the prodrugs as chemical tools to study persulfide chemistry under near 
physiological conditions, we also examined their biological effects. We first assessed the 
cytotoxicity of these prodrugs using the H9c2 cell line. All prodrugs showed no obvious toxicity 
at up to 100 µM after 24 h of incubation. Various sulfur species have been shown to exhibit 
protective effects in heart myocardial infarction reperfusion (MI/R) injury studies.122, 126, 152 As a 
test of the biological relevance of the prodrugs designed, we selected P2, which has a relative good 
water solubility and low toxicity of side product (acetaldehyde), as a representative for 
examination of its protective effect in a murine model of MI/R injury. The compounds were tested 
in a mouse heart ischemia reperfusion injury model. Mice were subjected to 45 min of ischemia 
induced by left coronary artery (LCA) occlusion followed by 24 h of reperfusion of P2 (0, 12.5, 
50, 100, 500 μg/kg) or vehicle, administered by intracardiac injection at the time of reperfusion. 
The LCA was re-occluded at 24h of reperfusion at the same position. Then Evens Blue dye was 
injected through right common carotid artery to delineate the area-at-risk (AAR). Due to the 
occlusion of LCA, AAR did not receive blood flow nor the Evens Blue dye, while the remainder 
of the heart was stained blue. Therefore, AAR were the non-blue regions in the mid-ventricular 
slice (Figure 2.3a). The infarct size (INF) was stained white by triphenyltetrazolium chloride 
solution. Thus, the white regions in the mid-ventricular slice represent INF (Figure 2.3a). Left 
ventricle (LV) is the sum of blue and non-blue regions. All of the animal groups displayed similar 
area-at-risk per left ventricle (AAR/LV), suggesting that the surgical procedure produced the same 
degree of ischemic damage. Compared with vehicle-treated mice, those receiving the prodrug 
displayed significant reductions in infarct size per area-at-risk (INF/AAR) at the dosage of 50 or 
100 μg/kg (Figure 2.3b). It is well-known that sulfide’s protective effects are bell-shaped with 
regard to dosage.12, 127 It is important to note that indeed the prodrug’s protective effect had an 
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optimal concentration of 50-100 μg/kg. Substantially lower (12.5 μg/kg) or higher (500 μg/kg) 
doses showed no protective effects. Moreover, circulating cardiac troponin I levels, a marker for 
acute myocardial infarction, paralleled the results of infarction area measurements (Figure 2.3c). 
In addition to that, we also validated the sulfane sulfur production from the prodrug in vivo. As 
shown in Figure 2.3d, administration of P2 led to a significant increase of sulfane sulfur in blood. 
Such results strongly suggest that persulfide prodrug indeed serves as a persulfide donor.    
     
Figure 2.3. a) Representative photomicrographs of a mid-ventricular slice after MI/R and stained 
with Evan’s blue and 2,3,5-triphenyltetrazolium chloride for both vehicle- and prodrug-(P2) 
treated hearts. b) AAR/LV and INF/AAR for P2 treated or Vehicle treated mice. c) Circulating 
troponin I level for P2 treated, or Vehicle treated mice. d) Plasma sulfane sulfur levels at 5 minutes 
post intracardiac injection.  Values are means ± SEM. *P < 0.05, **P < 0.01, ***P < 0.001 the 
vehicle group, #P < 0.01 vs the 100 μg/kg of P2 treated group.  
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2.3  Conclusions 
In summary, we have developed a series of persulfide prodrugs with controllable release 
rates. These persulfide prodrugs release persulfide through an esterase-mediated hydrolysis 
mechanism. In the presence of the PLE, the prodrugs efficiently released persulfides under near 
physiological conditions. Using the prodrug, we reaffirmed the reactivity between persulfide and 
MMTS. The protective effects of P2 in a murine model of MI/R injury have also been 
demonstrated.  All the studies above demonstrate that this novel type of persulfide prodrugs not 
only can be used as research tools, but also are possible therapeutic agents. 
 
2.4 Experimental part 
General Information. All solvents were of reagent grade and were purchased from Fisher 
Scientific and Aldrich. Reagents and were purchased from Aldrich, Oakwood, or VWR. Silica gel 
(230 × 400 mesh, Sorbtech) was used for column chromatography unless otherwise noted. Silica 
gel TLC plate was purchased from Sorbtech. 1H-NMR (400 MHz) and 13C-NMR (100 MHz) 
spectra were recorded on a Bruker Avance 400 MHz NMR spectrometer. Mass spectral analyses 
were performed on an ABI API 3200 (ESI-Triple Quadruple). HPLC was performed on a 
Shimadzu Prominence UFLC (column: Waters C18 3.5 μM, 4.6×100 mm). UV-Vis absorption 
spectra were recorded on a Shimadzu PharmaSpec UV-1700 UV-Visible spectrophotometer. 
Fluorescence spectra were recorded on a Shimadzu RF-5301PC fluorometer. 96-Well plates were 
read and recorded on a PerkinElmer 1420 multi-label counter. Porcine liver esterase was purchased 
from Aldrich.WSP-5 was synthesized following literature procedures.1 CHNS analysis were 
conducted by Atlantic Microlab. 
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2.1.1 Synthesis  
2.4.1.1  synthesis of persulfide prodrugs 
 
P1: To a 20-ml vial was added 1,2-dibenzyldisulfane (40, 500 mg, 2.0 mmol), KMnO4 
(316 mg, 2.0 mmol) and 4 ml propionic acid. The oil bath was preheated to 140 °C and the mixture 
was stirred at this temperature for 5 min and then immediately cooled down to room temperature. 
The mixture was diluted with 100 ml ethyl acetate and then washed with 50 ml brine, 50 ml 
saturated NaHCO3 and finally 50 ml brine. The organic phase was then dried over Na2SO4 and 
then solvent was evaporated under reduced pressure to give the crude product, which was purified 
by column chromatography (hexane: ethyl acetate =200:1) to yield a colorless oil (Rf = 0.7 in 
hexane: ethyl acetate =20:1). The colorless oil was further subjected to vacuum at room 
temperature for 2 h to yield the pure product as a colorless oil (35 mg, 9.5%, 213 mg of 1,2-
dibenzyldisulfane was recovered). 1H NMR (MeOD): δ 7.38-7.24 (m, 10H), 6.76 (s, 1H), 3.75 (s, 
2H), 2.47 (q, J = 7.6 Hz, 2H), 1.17 (t, J = 7.6 Hz, 3H) ppm.  13C NMR (MeOD): δ 174.4, 138.2, 
138.0, 130.6, 130.0, 129.6, 128.6, 128.6, 127.8, 82.8, 44.2, 28.5, 9.4 ppm. HRMS calcd for 
C17H18O2S2Na [M+Na]
+ 341.0640, found: 341.0643. Elem. Anal.: calcd (%) for C17H18O2S2: C 





                          
P2: To a 20-ml vial was added 1,2-diethyldisulfane (41, 244 mg, 2.0 mmol), KMnO4 (316 
mg, 2.0 mmol) and 4 ml propionic acid. The oil bath was preheated to 140 ℃ and the mixture was 
stirred at this temperature for 5 min and then immediately cooled down to room temperature. The 
mixture was diluted with 100 ml ethyl acetate and washed with 50 ml brine, 50 ml saturated 
NaHCO3 and then 50 ml brine. The organic phase was dried over Na2SO4 and then evaporated 
under reduced pressure to give the crude product, which was purified by column chromatography 
(hexane: ethyl acetate =200:1) to yield a colorless oil (Rf = 0.6 in hexane: ethyl acetate =20:1). 
The colorless oil was further subjected to vacuum  at room temperature for 2 h to yield the pure 
product as a colorless oil (20mg, 9.6%, 113 mg 1,2-diethyldisulfane was recovered). 1H NMR 
(CDCl3): δ 5.99 (q, J = 6.4 Hz, 1H), 2.73 (q, J = 7.2 Hz, 2H), 2.35 (q, J = 7.6 Hz, 2H), 1.60 (d, J 
= 6.4 Hz, 2H), 1.31 (t, J = 7.2 Hz, 3H), 1.17 (t, J = 7.6 Hz, 3H) ppm.  13C NMR (CDCl3): δ 173.4, 
77.6, 33.7, 27.9, 20.3, 14.4, 9.1 ppm. HRMS calcd for C7H14O2S2Na [M+Na]
+ 217.0327, found: 
217.0325. Elem. Anal.: calcd (%) for C7H14O2S2: C 43.27, H 7.26, N 0.00, S 33.00; Found C 43.41, 





P3: To a 20-ml vial was added 1,2-dibenzyldisulfane (40,500 mg, 2.0 mmol), KMnO4 (316 
mg, 2.0 mmol) and 4 ml 3-methylbutanoic acid. The oil bath was preheated to 140 ℃ and the 
mixture was stirred at this temperature for 5 min and then immediately cooled down to room 
temperature. The mixture was diluted with 100 ml ethyl acetate and washed with 50 ml brine, 50ml 
saturated NaHCO3 and then 50ml brine. The organic phase was dried over Na2SO4 and then 
evaporated under reduced pressure to give the crude product, which was purified by column 
chromatography (hexane: ethyl acetate =200:1) to yield a colorless oil (Rf = 0.7 in hexane: ethyl 
acetate =20:1). The colorless oil was subjected to vacuum at 70℃ for 2 h to yield the pure product 
as a colorless oil (27 mg, 7.6 %, 248 mg 1,2-dibenzyldisulfane was recovered).  1H NMR (CDCl3): 
δ 7.40-7.31 (m, 8H), 7.25-7.24 (m, 2H), 6.78 (s, 1H), 3.70 (ABq, J = 12.4 Hz, ΔδAB = 0.04, 2H), 
2.34-2.27 (m, 2H), 2.21-2.16 (m, 1H), 0.99 (d, J = 3.2 Hz, 3H), 0.97 (d, J = 3.2 Hz, 3H) ppm.  13C 
NMR (CDCl3): δ 171.7, 136.7, 136.6, 129.6, 129.1, 128.7, 128.6, 127.8, 126.9, 81.3, 43.6, 43.6, 
25.9, 22.6 ppm. HRMS calcd for C19H23O2S2 [M+H]
+ 347.1134, found: 347.1303. Elem. Anal.: 





    
                 
P4: To a 20-ml vial was added 1,2-dibenzyldisulfane (40, 500 mg, 2.0 mmol), KMnO4 
(316 mg, 2.0 mmol), CH3COONa (600mg, 7.3 mmol) and 4 ml acetic acid. The oil bath was 
preheated to 140 ℃ and the mixture was stirred at this temperature for 5 min and then immediately 
cooled down to room temperature. The mixture was diluted with 100 ml ethyl acetate and washed 
with 50 ml brine, 50ml saturated NaHCO3 and then 50ml brine. The organic phase was dried over 
Na2SO4 and then evaporated under reduced pressure to give the crude product, which was purified 
by column chromatography (hexane: ethyl acetate =200:1) to yield a colorless oil (Rf = 0.7 in 
hexane: ethyl acetate =20:1). The colorless oil was further subjected to vacuum at room 
temperature for 2 h to yield the pure product as a colorless oil (35mg, 10.8 %, 237 mg 1,2-
dibenzyldisulfane was recovered). 1H NMR (CDCl3): δ 7.40-7.29 (m, 9H), 7.26-7.24 (m, 1H), 6.78 
(s, 1H), 3.73 (ABq, J = 12.0 Hz, ΔδAB = 0.04, 2H), 2.18 (s, 3H) ppm.  13C NMR (CDCl3): δ 169.6, 
136.6, 136.5, 129.6, 129.2, 128.7, 128.7, 127.8, 126.9, 81.6, 43.6, 21.3 ppm. HRMS calcd for 
C16H16O2S2Na [M+Na]
+ 327.0484, found: 327.0494. Elem. Anal.: calcd (%) for C16H16O2S2: C 




P5: To a 20-ml vial was added 1,2-dibenzyldisulfane (40,500 mg, 2.0 mmol), KMnO4 (316 
mg, 2.0 mmol) and 4 ml isobutyric acid. The oil bath was preheated to 140 ℃ and the mixture was 
stirred at this temperature for 5 min and then immediately cooled down to room temperature. The 
mixture was diluted with 100 ml ethyl acetate and washed with 50 ml brine, 50 ml saturated 
NaHCO3 and then 50ml brine. The organic phase was then dried over Na2SO4 and then evaporated 
under reduced pressure to give the crude product, which was purified by column chromatography 
(hexane: ethyl acetate =200:1) to yield a colorless oil (Rf = 0.7 in hexane: ethyl acetate =20:1).The 
colorless oil was further subjected to vacuum  at 55℃ for 2 h to yield the pure product as a colorless 
oil (20 mg, 5.6 %, 233 mg of 1,2-dibenzyldisulfane was recovered). 1H NMR (CDCl3): δ 7.42-
7.29 (m, 9H), 7.26-7.24 (m, 1H), 6.79 (s, 1H), 3.72 (ABq, J = 12.0 Hz, ΔδAB = 0.05, 2H), 2.73-
2.66 (m, 1H), 1.27 (d, J = 7.2 Hz, 3H), 1.24 (d, J = 7.2 Hz, 3H) ppm.  13C NMR (CDCl3): δ 175.6, 
136.7, 136.6, 129.6, 129.0, 128.7, 128.6, 127.8, 126.8, 81.2, 43.6, 34.4, 19.1, 19.0 ppm. HRMS 
calcd for C18H20O2S2Na [M+Na]
+ 355.0797, found: 355.0818. Elem. Anal.: calcd (%) for 





P6: To a 20-ml vial was added 1,2-dibenzyldisulfane (40, 1000 mg, 4.0 mmol), KMnO4 
(600 mg, 3.8 mmol) and 4 ml isobutyric acid. The oil bath was preheated to 140 ℃ and the mixture 
was stirred at this temperature for 5 min and then immediately cooled down to room temperature. 
The mixture was diluted with 100 ml ethyl acetate and washed with 50 ml brine, 50ml saturated 
NaHCO3 and then 50ml brine. The organic phase was then dried over Na2SO4 and then evaporated 
under reduced pressure to give the crude product, which was purified by column chromatography 
(hexane: ethyl acetate =200:1) to yield a colorless oil (Rf = 0.7 in hexane : ethyl acetate =20:1). 
The colorless oil was further subjected to vacuum at 70℃ for 2 h to yield the pure product as a 
colorless oil (20mg, 5.6 %, 233 mg 1,2-dibenzyldisulfane was recycled). 1H NMR (CDCl3): δ 7.40-
7.30 (m, 8H), 7.26-7.24 (m, 2H), 6.77 (s, 1H), 3.68 (ABq, J = 12.0 Hz, ΔδAB = 0.05, 2H), 1.29 (s, 
9H) ppm.  13C NMR (CDCl3): δ 177.0, 136.8, 136.6, 129.6, 129.0, 128.7, 128.6, 127.7, 126.8, 81.2, 
43.6, 39.2, 27.3ppm. HRMS calcd for C19H22O2S2Na [M+Na]
+ 369.0953, found: 369.0971. Elem. 
Anal.: calcd (%) for C19H22O2S2: C 65.86, H 6.40, N 0.00, S 18.50; Found C 65.96, H 6.38, N 
0.00, S 18.62. 
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2.4.1.2   Synthesis of N-acetyl-S-(benzylthio)cysteine 
 
N-acetyl-S-(benzylthio)cysteine (34): To a 20-ml vial was added benzyl mercaptan (42, 100 
mg, 0.8 mmol), acetylcysteine (33, 130 mg, 0.8 mmol), sodium acetate (131 mg, 1.6 mmol), 4 ml 
tetrahydrofuran and 2 ml water. The reaction mixture was stirred for 5 min and then iodine (101 
mg, 0.4 mmol) was added. After stirring for another 10 min, the mixture was diluted with 30 ml 
ethyl acetate and 10 ml water. To the mixture was then added saturated sodium thiosulfate solution 
until the solution became colorless. The organic phase was washed with 10 ml brine and then 
concentrated to give the crude product, which was purified by column chromatograph to yield the 
pure product as pale yellow oil (Rf = 0.7 in Methanol: Dichloromethane = 1:5, 150 mg, 66 %). 1H 
NMR (CD3OD): δ 7.36-7.24 (m, 5H), 4.64 (dd, J = 8.8 Hz, J = 4.4 Hz, 1H), 3.93 (ABq, J = 12.8 
Hz, ΔδAB = 0.02, 2H), 2.89 (dd, J = 14.0 Hz, J = 4.4 Hz, 1H), 2.71 (dd, J = 14.0 Hz, J = 8.8 Hz, 
1H), 1.99 (s, 3H) ppm.  13C NMR (CD3OD): δ 173.6, 173.3, 138.8, 130.5, 129.6, 128.5, 53.0, 44.1, 
40.5, 22.4 ppm. HRMS calcd for C12H16NO3S2
+ [M+H]+: 286.0566, found: 286.0569. 
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2.4.1.3   Synthesis of disulfide compound 36a and 36b 
 
1-benzyl-2-(2,4-dinitrophenyl)disulfane (36a): To a solution of 2,4-Dinitro-1-
fluorobenzene (DNFB, 186mg, 1mmol), compound 40 (50mg, 0.2 mmol) in 3 ml chloroform was 
added a solution of potassium thiolacetate (116mg , 1mmol) in 1ml DMF. The reaction was stirred 
at r.t for 15 min. Then compound 42 (500mg, 4mmol) was added to the reaction mixture. The 
reaction was stirred at r.t for another 10 min, then iodine (259mg, 1mmol) was added to the reaction 
mixture.  The reaction mixture was stirred at r.t for 2 h, diluted with ethyl acetate (30 ml), and 
washed with 1N HCl (20 ml), H2O (20 ml) and brine (10 ml). The organic layer was dried over 
NaSO4 and solvent was removed by rotavapor to afford a crude product, which was purified by 
column chromatograph (Rf = 0.6 in hexane : ethyl acetate =10:1) to yield the pure product as a 
yellow solid (31 mg, 10%).  1H NMR (CDCl3): δ 8.97 (d, J = 2.4 Hz, 1H), 8.13 (dd, J =2.4 Hz, H= 
9.2 Hz, 1H), 8.04 (d, J = 9.2 Hz, 1H), 7.13-7.25(m, 5H), 4.00(s, 2H). 13C NMR (CDCl3):  δ 146.1, 
145.2, 144.9, 135.5, 129.3, 128.9, 128.8, 128.1, 126.6, 121.1, 43.5. HRMS calcd for 
C13H10AgN2O4S2
+  [M+Ag]+: 428.9127, found: 428.9132 .  
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1-(2,4-dinitrophenyl)-2-ethyldisulfane (36b): Following the same procedure for preparing 
compound 36a, the product was obtained as a yellow solid (Rf = 0.5 in hexane : ethyl acetate 
=10:1,15 mg, 6%). 1H NMR (CDCl3): δ 9.12 (d, J= 2.4 Hz, 1H), 8.54 (d, J= 8.8 Hz, 1H), 8.47 (dd, 
J= 2.4 Hz, J= 8.8 Hz, 1H), 2.82 (q, J= 6.4 Hz, 2H), 1.36 (t, J= 6.4 Hz, 2H). 13C NMR (CDCl3):  
δ 147.0, 145.6, 145.2, 128.9, 127.4, 121.8, 32.7, 14.5. HRMS calcd for C8H8AgN2O4S2+  [M+Ag]+: 
366.8971, found: 366.8979. 
  
2.4.2 Kinetic studies of P1-6 (Ps) in the presence of esterase. 
Stock solution preparation preparation: HPs stock solution: HPs were dissolved in DMSO 
to afford 5 mM HPs stock solutions. Disulfide compound stock solution: Compound 36a and 36b 
were dissolved in DMSO to afford 5 mM stock solutions. Esterase stock solution: 6.0 mg Esterase 
(18 u/mg esterase from porcine liver, PLE, Aldrich, E3019) was dissolved in 108 ml phosphate 
buffer (PBS, pH 7.4) to provide a 1 u/ml PLE stock solution.  Acetylcysteine stock solution: 163 
mg acetylcysteine was dissolved in 100 ml PBS to afford 10mM stock solution; 50 mg 
acetylcysteine was dissolved in 2.0 ml DMSO to afford 150 mM stock solution. WSP-5 stock 
solution: WSP-5 was dissolved in DMSO to prepare a 2.5 mM stock solution. CTAB was dissolved 
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in ethanol to prepare a 100 mM stock solution. DNFB stock solution: DNFB was dissolved in 
DMSO to afford 200 mM stock solution.  
H2S release from HP detected by Methylene Blue Method.   At each time point, 100 μL of 
reaction solution was taken into a 1.5 mL vial containing 100 μL zinc acetate (1%, w/v).  Then the 
vial was centrifuged for 10 min (14.5 × 1000 rp). The supernatant was removed. Then 200 μL N,N-
dimethyl-1,4-phenylenediaminesulfate (0.2% w/v in 20% H2SO4  solution) and 200 μL ferric 
chloride (1% w/v in 0.2%  H2SO4 solution) were added to the vial. After 6 min, the absorbance (at 
740 nm) of the resulting solution was measured. H2S concentration was calculated based on a 
calibration curve of Na2S·9H2O.  
HPLC sample preparation. At each time point, 200 μL of reaction solution was taken into 
a 1.5 mL vial containing 600 μL acetonitrile (ACN). The mixture was incubated in an acetone dry 
ice bath (-78 °C) for 5 min, and centrifuged for 10 min (14.5 × 1000 rp). The supernatant was 
analyzed by HPLC with method A. 
HPLC with Method A: mobile phase A (10 mM NaH2PO4 in water, pH= 5.0) and mobile 
phase B (ACN), flow rate: 1mL/min, running time: 25min, the gradient elution method: 30% B 
from 0 to 8 min, 30% to 95% B from 8 to 15 min, 95% B from 15 to20 min, 95% to 30% B from 
20 to 24 min, 30% B from 24 to 25 min. Detection wavelength: 254 nm. Column: Waters C18 3.5 
μM, 4.6×100 mm. Injection volume: 20 µL 
HPLC with Method B: mobile phase A (H2O) and mobile phase B (ACN), flow rate: 
1mL/min, running time: 25min, the gradient elution method: 30% B from 0 to 8 min, 30% to 95% 
B from 8 to 15 min, 95% B from 15 to20 min, 95% to 30% B from 20 to 24 min, 30% B from 24 
to 25 min. Detection wavelength: 254 nm. Column: Waters C18 3.5 μM, 4.6×100 mm. Injection 
volume: 200 µL 
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HPLC with Method C: mobile phase A (H2O, pH = 3.0, CF3COOH) and mobile phase B 
(ACN), flow rate: 1 mL/min, running time: 35 min, the gradient elution method: 30% B from 0 to 
10 min, 30% to 80% B from 10 to 25 min, 80% to 30% B from 25 to 35 min. Detection wavelength: 
254 nm. Column: Waters C18 3.5 μM, 4.6×100 mm. Injection volume: 200 µL 
Table 2.3. Retention times table with Method A. 
Compound  P1 P2 P3 P4 P5 P6 31 6a 6b 
Time /min 15.9 4.3 16.6 15.2 16.3 16.6 5.8 14.7 15.4 
Time points at which samples were taken for kinetic studies: 10s, 30s, 1min, 1.5 min, 2min, 2.5 
min, 3min.  
Reaction set up procedure: To a 20-ml vial was added various volumes of PLE stock 
solution, acetylcysteine stock solution and pure PBS (Table 2.4.2). The mixture was stirred at 37 
ºC for 30 min. Then 100 µl HPs was added to the mixture. The reaction mixture was stirred at 37 
ºC, and at each time point, 100 µl or 200 µl reaction mixture was taken out for H2S release detection 
or HPLC sample preparation. 
Table 2.4 Reaction conditions. 





Pure PBS Substrates 
1 2.5 ml 250 µl 2.25ml 201 
2 2.5 ml 500 µl 2 ml  201 
3 2.5 ml 1.5 ml 1 ml 201 
4 0 250 µl 4.75 ml 201 
5 2.5 ml 0 2.5 ml 201 
6 2.5 ml 250 µl 2.25 ml 202 
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7 2.5 ml 250 µl 2.25 ml 203 
8 2.5 ml 250 µl 2.25 ml 204 
9 2.5 ml 250 µl 2.25 ml 205 
10 2.5 ml 250 µl 2.25 ml 206 
11 2.5 ml 0 2.5 ml 202 
12 2.5 ml 0 2.5 ml 203 
13 2.5 ml 0 2.5 ml 204 
14 2.5 ml 0 2.5 ml 205 
15 2.5 ml 0 2.5 ml 206 
Persulfide trapping reaction: To a 20-ml vial was added 5 ml PLE stock solution (1 unit/ml). The 
solution was incubated at 37 ºC for 30 min, then 100 µl HPs were added to the mixture. After 10 
s, 200 µl DNFB stock solution was added. The reaction mixture was stirred at 37 ºC for another 
30 min. 200 µl reaction mixture was taken out for HPLC sample preparation.  
 
2.4.3 Mechanism study of H2S release from “acetal” based H2S prodrugs using 
HPLC.  
For the H2S release mechanism study, HPLC with method C was used. 
Procedure: To a 20-ml vial was added 1.9 ml PLE stock solution (5 unit/ml) and 40 ul 150 
mM   acetylcysteine. Then 40 ul P1 (5 mM in DMSO) was added. The solution was incubated at 
37 ºC for 3 h. The 200 μL of reaction solution was taken into a 1.5 mL vial containing 600 μL 
ACN. The mixture was incubated in an acetone dry ice bath (-78 °C) for 5 min, and centrifuged 




Figure 2.4.Persulfide release mechanism study. a), 100 μM P1   in PBS. b), 100 μM P1 in 
PBS (4% DMSO) was incubated with 5 U/ml PLE and 3 mM L- acetylcysteine  at 37 ℃,   after 3 
hours the mixture was subjected to HPLC.    
 
2.4.4 Cell culture  
H9C2 (ATCC®CRL-1446™) cells were used in the studies. The H9C2 cells were 
maintained in DMEM (Dulbecco’s Modified Eagle’s Medium) supplemented with 10% fetal 
bovine serum (MidSci; S01520HI) and 1% penicillin-streptomycin (Sigma-Aldrich; P4333) at 37 
°C with 5% CO2.   
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2.4.4.1 Cytotoxicity study (Without added PLE) 
The H9C2 cells were seeded in 96-well plate one day before the experiment. Different 
concentrations of prodrugs were added into the H9C2 cells. The cells were then incubated with the 
compounds for 24 hours at 37 °C with 5% CO2. Cell viability was tested by the cell counting kit-
8 (Dojindo; KH677). Specifically, after 24 h of incubation, cell culture media was changed and 10 
ul cell counting kit-8 solution was added. Absorbance at 450 nm was read by a plate reader after 
















































































Figure 2.5. Cytotoxicity of various perthiol prodrugs. H9C2 cells were treated with perthiol 
prodrugs with various concentrations for 24h. 
 
2.4.4.2 Cytotoxicity studies (With adding PLE) 
The H9C2 cells were seeded in 96-well plate one day before the experiment. Cell was 
cultured in DMEM supplemented with 10% fetal bovine serum, 1% penicillin-streptomycin and 
1u/ml PLE. 
Different concentrations of prodrugs were added into the H9C2 cells. The cells were then 
incubated with the compounds for 24 hours at 37 °C with 5% CO2. Cell viability was tested by the 
cell counting kit-8 (Dojindo; KH677). Specifically, after 24 h of incubation, cell culture media was 
changed and 10 ul cell counting kit-8 solution was added. Absorbance at 450 nm was read by a 













































































Figure 2.6. Cytotoxicity of various perthiol prodrugs.H9C2 cells were treated with perthiol 
prodrugs with various concentrations for 24h. 
 
2.4.4.3 H2S release validation by fluorescent probe WSP-5 in cultured cell 
H9C2 cells were cultured in DMEM supplemented with 10% FBS (v/v), penicillin (100 
U/mL) and streptomycin (100 ug/mL) at 37 °C with 5% CO2. Cells were seeded to culture dished 
one day before use. Cells were washed by FBS free DMEM media before use. Cells were treated 
with 100 μM P5 or 100 μM Na2S or vehicle in PBS buffer (containing 300 μM L-cysteine) with 
PLE (5 U/ml) or without PLE for 10 min. The cell culture media was removed and washed by 
PBS. Cells were incubated with 10 μM WSP-5 in PBS (containing 100 μM CTAM) for 10 minutes. 











































































Figure 2.7. Fluorescence images of P5 in cultured cells.H9C2 cells were treated with different 
prodrugs under various conditions, and then washed and treated with 10 μM WSP-5 for 10 min. 
(a) P5 100 μM + esterase 5 u/ml (b) P5 100 μM (c) 100 μM Na2S·9H2O (d) No prodrug. 
 
2.4.5 LC-MS studies of persulfide reactivity with S-methyl methanethiosulfonate 
(MMTS).  
Sample preparation A: To a 20-ml vial was added 5 ml PBS containing 1u/ml PLE, 100 µl 
P5 stock solution (5 mM in DMSO), and 100 µl MMTS (200 mM in DMSO). The mixture was 
stirred at r.t for 30 min. Then 200 µl reaction mixture was taken out and added to a vial containing 
600 µl ACN, and the mixture was centrifuged for 4 min (14.5 × 1000 rp). The supernatant was 
analyzed by HPLC with method B. The fraction at 15.3 min retention time was collected. 1 ul of 
AgNO3 (1 mg/ml in ACN) solution was added to the fraction, and the mixture was injected to the 
MS.  
Sample preparation B: To a 20-ml vial was added 1 ml H2O, 100 µl dibenzyl disulfide 
(BnSSBn, 10 mM in DMSO), 100 µl Na2S solution (10 mM in H2O), and 100 µl MMTS (200 mM 
in DMSO). The mixture was stirred at r.t for 30 min. Then 200 µl reaction mixture was taken out 
and added to a vial containing 600 µl ACN, and the mixture was centrifuged for 4 min (14.5 × 
1000 rp). The supernatant was analyzed by HPLC with method B. The fractions at 14.6 min, 15.3 
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min, 15.8 min and 16.3 min was collected separately, and all samples was added 1 ul of AgNO3 
(1 mg/ml in ACN) solution and then was injected to the MS respectively.  
It needs to be noted that all spectrums shown below is the original spectrum before 
calibrated by the internal standards. The HRMS of these compounds are shown in Table 2.4.3: 
Table 2.5 HRMS of sulfide compounds 
Compound Formula Calcd. Found 
[BnSSMe+Ag]+ C8H10AgS2
+ 276.9269 276.9273 
[BnSSSMe+Ag]+ C8H10AgS3
+ 308.8990 308.8997 
[BnSSBn+Ag]+ C14H14AgS2
+ 352.9582 352.9588 
[BnSSSBn+Ag]+ C14H14AgS3
+ 384.9303 384.9307 
[BnSSSBn+Ag]+ C14H14AgS3




2.4.6 Methylene blue (MB) method to detect the H2S release from P1-P6 
To 4.9 mL 500 μM Compound 33 in phosphate buffer (pH 7.4) solution was added 5unit 
PLE, followed by the addition of 100 μL 5 mM prodrugs stock solution (Final Conc.: 100 μM). 
The resultant solution was stirred at 37 °C.  At each time point, 200 μL of reaction solution was 
taken into a 1.5 mL vial containing 200 μL zinc acetate (1 %, w/v).  Then the vial was centrifuged 
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for 10 min. (14.5 × 1000 rp). Removed the supernatant and washed the precipitation with PBS 
solution (100 μL × 2). Then 600μL N,N-dimethyl-1,4-phenylenediaminesulfate (0.2% w/v in 20% 
H2SO4  solution) and 50 μL ferric chloride (10% w/v in 0.2%  H2SO4 solution) was added to the 
vial. Then the vial was centrifuged for 5 min (14.5 × 1000 rp). The absorbance (at 740 nm) of the 
resulting solution was measured (after stirring for 10 min). H2S concentration was calculated based 
on a calibration curve of NaHS.  
 
Figure 2.8.H2S release from 100 µM P1 to P6at 37 °C in PBS in the presence of 500 µM compound 
33 (2% DMSO) and 0.5 u/ml PLE. The H2S concentrations were detected by MB method.   P1;  
P2;  P3;  P4;  P5 .P6.  
 
2.4.7 Myocardial Ischemia-Reperfusion Protocol 
Male c57/b6j mice (Jaxon Laboratory) were used at 10-12 weeks of age. The suregery was 
performed under aseptic conditions. Instruments were steam autoclaved or undergo cold 
sterilization (MaxiCide, Henry Schein). The surgical area was cleaned and wiped down with 70% 
ethanol before and after surgery. The mice were anesthetized with intraperitoneal injections of 
ketamine (50mg/kg) and sodium pentobarbital (60 mg/kg). Subsequent to anesthesia, the mice 
were orally intubated with polyethylene-60 (PE-60) tubing, connected via loose junction to a 
rodent ventilator (MiniVent Type 845, Hugo-Sachs Elektronik) set at a tidal volume 250 μL of and 
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a rate of ~130 breaths per minute, and supplemented with 100% oxygen (0.1-0.2 liters/minute flow 
rate). Body temperature was maintained at ~37 °C using a mouse monitor pad (Indus, 
MouseMonitor). Hair remover (i.e., Nair®) was placed on the chest with a cotton swab and then 
removed along with the chest hair. Betadine solution was placed on the chest wall prior to any skin 
incision. We applied alternating applications of betadine and alcohol to be applied with a cotton 
swab at least once each with a final application of betadine. An incision was made in the skin along 
the midline to expose the sternum. A median sternotomy was performed and the wound edges was 
cauterized with an electrocautery device. The proximal left coronary artery (LCA) wasvisualized 
and ligated for 45 min with 7-0 silk suture mounted on a tapered needle (BV-1, Ethicon). A short 
segment of PE-10 tubing was placed in between the LCA and the 7-0 silk suture to minimized 
damage to the coronary artery and allow for complete reperfusion following the ischemic period. 
Ischemia was confirmed by the appearance of hypokinesis and pallor distal to the occlusion, as 
well as ST segment elevation shown on the Mouse Monitor. Following the prescribed period of 
LCA occlusion, the ligature was removed, and reperfusion was visually confirmed. Following 
reperfusion, the chest wall and the skin incision will be carefully closed with 5-0 Polysorb® 
(Braided Lactomer 9-1) suture mated to a CV-23 (1/2 inch, 17 mm) tapered needle.  
The duration of myocardial ischemia was for 45 min in all experiments and the duration of 
the reperfusion was 24 hours. 5 mins prior to reperfusion, experimental compound or vehicle was 
administered via intracardiac injection.  
           In the myocardial ischemia-reperfusion experiments blood (~50 μL) was collected 
from a subset of mice via tail vein at 4 hours of reperfusion for the subsequent measurement of 
plasma markers of cardiac injury (Troponin-I).  
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           At 24 hours of reperfusion, mice were anesthetized as previously descried. An 
endotracheal tube was placed in the trachea following a tracheostomy and the mice were ventilated 
as described previously. The common carotid artery was fully dissected and then cannulated with 
PE-10 tubing for injection of Evan’s blue dye to delineate the area of myocardium at risk. Next, 
the left coronary artery was fully ligated again at the same location as in ischemic phase. Then 
Evan’s blue dye (0.5 mL) was injected in the to the carotid artery catheter.  
The Evan’s blue dye was only distributed in regions of the heart that receive normal blood 
flow and therefore provided a very accurate method to delineate the non-ischemic (normal) 
myocardium from the ischemic myocardium (area at risk). The heart then was rapidly excised and 
sliced for further analysis with 2,3,5-triphenyltetrazolium (TTC). In non-infarcted myocardium, 
TTC was enzymatically reduced to 1,3,5-triphenylformazan, which is in red color. In the necrosis 
core (Infarction), TTC remained in white color. In general, on the slices of a properly stained heart, 
the left ventricle (LV) was divided into three regions: the dark-blue region as the normal 
myocardium, the non-blue region as the area at risk (AAR), and the white region as the infarction 
(INF). Pictures of each slice were taken and analyzed using ImageJ software (NIH) in a blinded 
manner.  
2.4.8 Sulfane Sulfur Measurement Protocol 
Male c57bl/6j mice (Jaxon Laboratory) were used at 10-12 weeks of age. The mice were 
anesthetized with intraperitoneal injections of ketamine (50 mg/kg) and sodium pentobarbital (60 
mg/kg). An incision was made in the skin along the midline to expose the sternum. A median 
sternotomy was performed and the wound edges were cauterized with an electrocautery device. 
Experimental compound solution or vehicle was administered through intracardiac injection. 5-
min post injection, blood was collected for further analysis.  
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For sulfane sulfur measurement, 50 uL of plasma sample was mixed with equal volume of 
15 mM DTT in 0.1 mM Tris/HCl, pH 9.0 in a small glass vial (5182-0553, Agilent), sealed with a 
rubber top, and incubated at 37 °C for 50 minutes. After the incubation, 200 μL of 1M sodium 
citrate (pH 6.0) was injected into the vial through the rubber top. Then the mixture was incubated 
at 37 °C for 10 minutes with shaking at 125 rpm. After shaking, 200 μL of head-space gas was 
applied to a gas-chromatograph (7890A GC System, Agilent) equipped with a dual plasma 
controller and sulfur chemiluminescence detector (355, Agilent). Chromatographs were captured 
and analyzed with Agilent ChemStation software (B.04.03). 
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3 AN ENRICHMENT-TRIGGERED PRODRUG ACTIVATION STRATEGY 
DEMONSTRATED USING A CLICK, CYCLIZE, AND RELEASE  SYSTEM FOR 
DELIVERY OF DOXORUBICIN IN MITOCHONDRIA 
Abstract: This chapter is mainly based on my publications: Nat. Chem. 2017 in revision. 
A critical component of an effective prodrug approach is achieving delivery to and drug release at 
the desired site. Through the use of targeting molecules such as antibodies, selective delivery of a 
drug to the desired site can be readily achieved. However, achieving triggered drug release only at 
the site of action while ensuring prodrug stability in the general circulation is a challenging task. 
We desgined a novel approach of prodrug activation through enrichment by taking advantage of 
reaction kinetics, which is directly correlated with concentration. Specifically, we have designed 
a “Click, Cyclize and Release” (CCR) system for drug delivery using tetrazine-alkyne pairs as a 
model system to initiate the release cascade. In demonstrating the feasibility of this prodrug system, 
we prepared prodrugs of doxorubicin conjugated to triphenylphosphonium for targeted enrichment 
in mitochondria. It was found that indeed, enrichment allowed the proper chemistry to happen, 
leading to doxorubicin release and thus cytotoxicity. This method should be generally applicable 
to targeted drug delivery using a variety of targeting molecules. 
3.1  Introduction  
Prodrug strategies have been widely used to address delivery problems with 
pharmaceuticals.80, 153-160 Essentially all such approaches have one goal, i.e. to deliver the drug to 
the desired location at a sufficiently high concentration. Prodrug efforts focused on improving 
physicochemical properties allow for enhanced permeability and solubility. Site-selective 
activations allow for targeting based on environmental factors such as pH,161-162 unique redox 
chemistry including levels of H2O2
163-165 glutathione166-170 and other thiol species,171-172 and 
96 
elevated levels of enzymes such as esterases,116, 173-174 proteases,175-177 and phosphatases.178-179 In 
addition, gut bacteria also present unique redox chemistry and an active enzymatic environment 
for site-selective targeting.180 In recent years, targeted drug delivery has quickly gained attention 
with some remarkable success,181 especially in the field of cancer with the goal being minimizing 
toxicity.182 For example, antibody-drug conjugates allow for targeted delivery of drugs to the 
desired site.181, 183-184 There are many other targeting molecules that can be used to hone in on 
biomarkers such as the high affinity folate receptor,185-186 carbohydrate biomarkers,187 and 
prostate-specific membrane antigen (PSMA).188-190 Such targeted approaches work very well in 
enriching the concentration of the drug conjugates and prodrugs at the desired site. However, 
targeted release after enrichment is still a significant challenge.  
  Herein we describe a novel concentration-sensitive platform approach to prodrug 
activation based on controls by reaction kinetics using bioorthogonal click chemistry, which has 
been applied in prodrug preparation with excellent success.130, 156-157, 191-197 Ideally, one would like 
to use linker chemistry that tethers the active drug to the targeting molecule in a stable fashion, 
and allow for selective cleavage at the desired site of action.157, 198-201 Through the use of click 
chemistry and the concept of co-localization,202-204 the linker can be very stable until enrichment-
triggered release (ETR). The applicability of the approach is not limited to cell surface as in the 
case of antibody-mediated delivery because of the use of small molecules for both targeting and 
cleavage.  
 
Scheme  3.1.General concept of the CCR system. 
97 
3.2 Results and Discussions 
To establish the proof of concept, we designed a pair of prodrug-release trigger partners 
that can undergo a bioorthogonal reaction with tunable release rates, which should set the stage for 
subsequent release of a drug moiety. Specifically, we used the tetrazine-cyclooctyne chemistry as 
the prodrug-trigger pair for the click reaction,205-206 a lactonization reaction of the cycloaddition 
intermediate (CI) for drug release (Scheme 3.1),97 and mitochondria-targeting as a way to achieve 
enrichment, which is discussed later.207 Tetrazines are known to react with transcyclooctene208-209 
and strained cyclooctyne205-206 with second order rate constants ranging from 0.0001 M-1s-1 to more 
than 1000 M-1s-1. As a proof of principle study, we contemplated a scenario where the prodrug 
could be used at a concentration of 10 μM in cell culture without cytotoxicity until triggered release 
is achieved based on control by reaction kinetics. For this design, we desire the second order rate 
constant to be below 0.25 M-1s-1, which would result in the first half-life being over 100 h without 
enrichment at 10 μM. Triphenylphosphine conjugation is known to enrich its “payload” to about 
500μM or higher in mitochondria,207, 210 which would lead to a decrease in its first half-life to about 
2.2 h. What this means is that the prodrug would be non-toxic to cells until enrichment-triggered 
release. The general idea is presented in Figure 3.1, which depicts a trigger-prodrug pair going 





Figure 3.1.General approach for drug release based on reaction kinetics, leading to 
enrichment triggered release (ETR) 
 
 First, we studied the chemical feasibility of the designed system using Dox. Thus, we 
synthesized the two components of this drug release system: alkyne triggers (AT, 51-53) with an 
appropriately positioned hydroxyl group to initiate lactonization, model tetrazine-prodrugs (TP, 
54 and 55), and tetrazine-linked prodrugs of Dox (56 and 59; Table 3.1). The reason that we also 
prepared a tetrazine conjugate (55) with dansyl amine was to take advantage of the strong 
fluorescence of dansyl amine as a marker to easily monitor and also check feasibility of the click, 
cyclization and release (CCR) sequence of events for amine containing prodrugs.  
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Table 3.1 Evaluation of the reaction kinetics of the CCR system.All reactions were 
conducted in PBS containing 10% DMSO. *not detectable because of the slow second order 
reaction and fast lactonization reaction. No intermediates were observed. ∆: not detectable 
because of Dox decomposition in PBS. (n = 3, p= 0.95).  
Tetrazine Alkyne k2 at r.t (M
-1s-1) k2 at 37 
oC (M-1s-1) k1 at r.t (h
-1) Dox Peak % 
within 48 h, 
at r.t (%)  
55 51 0.25± 0.06 1.9± 0.4 0.029± 0.006 60± 6 (48 h) 
52 0.0075± 0.0009 0.021± 0.005 * 90± 5 (20 h) 
53b 0.042± 0.012 0.14± 0.04 0.16±0.04 90 ±3 (16 h) 
56 51 0.36± 0.07 2.1 ±0.4 ∆ 20±5 (48 h) 
52 0.0078±0.0009 0.025±0.006 * 85±5 (21 h) 
53b 0.065±0.013 0.19±0.04 0.20±0.04 80±5 (18 h) 
53a 0.061±0.013 0.17±0.05 0.21±0.04 80±5 (19 h) 
100 
59 53b 0.091±0.013 0.25±0.05 0.22±0.05 78±6 (18 h) 
 
                                                                                                                       
As the first step, we studied the basic chemical feasibility of the proposed approach. Thus, 
we treated 25 μM of the prodrugs 55 or 56 with alkynes 51, 52 or 53 at different concentrations at 
room temperature (r.t.) or 37 °C respectively, and monitored prodrug consumption and the release 
of the parent drug by HPLC (Table 3.1). There are three issues in this study: i.) cycloaddition 
regiochemistry, ii.) substituent effect at the R1 position, and iii.) the effect of the “drug” on the 
reaction rates and regiochemistry.  
On the issue of regiochemistry, one can see from Scheme 1 that the cycloaddition chemistry 
has two possible regioisomeric products, but only one would lead to lactonization and drug release. 
For the strategy to work, it is critical that the correct regioisomer (57b) is the predominant product. 
Fortuitously, it was found that more than 80% Dox or dansyl amine was released within 48 h of 
the prodrug treatment with alkyne 52 or 53. Such results indicate that the regiochemistry of the 
Inverse Electron Demand Diels-Alder reaction (DAinv) is such that it favors the reaction leading to 
57b with the hydroxyl group on the cyclooctyne positioned on the same side of the amide group 
linked to the parent drug. This allows for subsequent lactonization and drug release. To acquire 
initial insight into the observed regiochemistry, we performed theoretical calculations. 
Specifically, we used reported methods to calculate possible transition state(s) and activation 
energies for two regio-isomers.205 Schematic representations of the energy profiles for the tetrazine 
alkyne reactions are shown in Scheme 3.2. All of the QM energies are in kcal· mol-1. To simplify 
the calculation process, we used tetrazine 60 and alkyne 52 as models.205 The results showed that 
the activation energy for the first step of the DAinv between 60 and 52 via transition state TS1b is 
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17.1 kcal·mol-1 as compared to 19.0 kcal·mol-1 for the reaction via transition state TS1a. The 




Scheme  3.2.  Schematic representations of the reaction between tetrazine 60 and alkyne 
52 (kcal·mol-1) 
 
There are several reasons that we needed to understand the effect of the R1 group on the 
alkyne trigger for this project. First, we are interested in understanding factors that would allow us 
to tune the reaction rate. It is easy to intuitively understand that the R1 group would have an effect 
on both the DAinv reaction and the subsequent lactonization. Second, for eventual applications, we 
need to conjugate both the tetrazine and alkyne to a targeting moiety. This means that we need a 
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“handle” for such conjugation chemistry. For the tetrazine part, this can be easily accomplished 
through the phenolic hydroxyl group. For the cyclooctyne, we need to introduce an additional 
“handle” for such conjugations. For this reason, the R1 group is essential as a handle for further 
conjugation. Thus, we need to understand the substituent effect at this position. It was found that 
a methyl group or a benzyl group significantly reduced the rate of the DAinv reaction. For example, 
when R1 was a hydrogen, the second order rate constant was 0.25 M
-1s-1 at r.t and 1.9 M-1s-1 at 37 
C when dansyl amine-prodrug 55 was used. In comparison, the second order rate constant was 
0.0075 M-1s-1 and 0.021 M-1s-1 at r.t and 37 C, respectively, for alkyne 52 with a methyl 
substituent; and 0.042 M-1s-1 and 0.14 M-1s-1 at r.t and 37 C, respectively, for alkyne 53 with a 
phenyl substituent. Such results indicate that the DAinv reaction rates can easily be tuned over a 
range of more than 30-fold by using different R1 groups on the alkyne. Additionally, varying the 
temperature from r.t to 37 °C can afford another 3- to 10-fold of reaction rate variations. Besides, 
the reaction rate (0.25 M-1s-1) between 59 and 53b is similar to that for the reaction between 56 
and 53a (0.17 M-1 s-1), confirming that the introduction of the TPP moiety would not significantly 
affect the reaction kinetics. As discussed earlier, the second order rate constant was targeted to be 
below 0.25 M-1s-1. The range of second order rate constants that can be tuned falls exactly where 
needed. It should also be noted that the R1 substituent accelerated the rate of the lactonization, as 
expected due to added conformational constraints. Therefore, all the reaction studies thus far 
clearly demonstrate one thing, i.e., the designed CCR system can be used for prodrug release for 
the intended purpose.  
Regarding the third issue of the effect of the “drug” moiety on the reaction outcomes, it 
was found that dansylamine-prodrug 55 and Dox-prodrug 56 did not show statistically significant 
differences in terms of reaction rates. For example, the second order rate constant for the reaction 
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of alkyne 51 with tetrazine 55 or 56 at 37 ºC is 1.9 or 2.1 M-1s-1, respectively. Similarly, the second 
order rate constant for the reaction of alkyne 53b with tetrazine 55 or 56 at 37 ºC is 0.14 or 0.19 
M-1s-1, respectively. Such results are expected since the “drug” portion is positioned away from all 
reaction centers, and thus would not be expected to have a major effect on reaction rates. The only 
issue is that if the lactonization rate is slow, it may only lead to partial drug release within a 
reasonable period of time. This is the case with alkyne trigger 51. For example, only 60% 
dansylamine and 20% Dox was detected after treating prodrugs with alkyne 51 (1 mM) for 48 h. 
This low percentage Dox recovery was likely because of the slow lactonization rate of 57b (t1/2 = 
24 h) when R1 was hydrogen, and decomposition of Dox in PBS (t1/2= 50 h).
211 In contrast, with 
alkyne 52, the lactonization rate was so fast that the HPLC method did not detect the accumulation 
of the intermediate (CI). This also led to 85-90% release of the active drug at the 48-h point. For 
alkyne 53, the situation was similar with 80-90% drug release. All such results indicate the 
importance of the R1 group not only for tethering a targeting molecule, but also for an improved 
lactonization rate.   
In addition to the three chemical feasibility issues discussed above, we were also interested 
in understanding the stability of the tetrazine-linked prodrugs in the presence of high 
concentrations of thiol species, due to the electron deficient nature of the tetrazine moiety. It is 
important to note that we did not encounter stability problems. 
   Next, we were interested in testing the drug delivery system in a cellular environment. 
We first chose the alkyne 51 and 53b. HeLa cells were incubated with different concentrations of 
Dox-prodrug and alkynes, or doxorubicin, for 48 hours at 37 C. The IC50 values are shown in 
Table 3.2. After modification, the Dox-prodrug 56 lost its activity with IC50 well over 100 μM, 
while the IC50 of the parent drug Dox was about 1.0 μM. Such results were expected and desirable 
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because the activity of the prodrug means that it would not be cytotoxic before Dox is released 
through the CCR process. As designed, the IC50 of Dox-prodrug 56 is about 1.5 μM in the presence 
of 50 μM alkyne 51 and 2.0 μM in the presence of 50 μM alkyne 53b. Such results indicate efficient 
release of the parent drug, Dox, by alkynes 51 and 53b.  
Table 3.2 IC50 in Hela cell line. (n = 3, p = 0.95) 
 
Compounds IC50 (μM) 
Dox-prodrug 56 >100  
Alkyne 51 >100  
Alkyne 53b >50 
Dox 1.0±0.2 
Dox-prodrug 56 + 50 μM 51 1.5±0.3 
Dox-prodrug 56 + 100 μM 51 1.3±0.2 
Dox-prodrug 56 + 50 μM 53b 2.3±0.4 
Tetrazine 54+ 100 μM 51 >100 
 
Having established a well-defined release system, we next examined the feasibility of using 
reaction kinetics to control drug release.  Our goal was thus to target and enrich the prodrug at a 
particular location within the mammalian cell. It is well-known that folic acid, Arg-Asp-Asp 
(RGD), and many other molecules can target cancer, and be used for drug delivery.212 We chose 
mitochondrion-targeting through the use of a well-known triphenylphosphonium (TPP) moiety, 
which is known to enrich in mitochondria by approximately 100 to 500 fold.210  We elected to use 
mitochondria targeting because this can easily be assessed in a cell culture system. Thus, we 
conjugated the tetrazine prodrug and the alkyne trigger with triphenylphosphine to give 59 and 
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53b, respectively. HeLa cells were treated with 10 μM or 20 μM TPP-alkyne 53b and various 
concentrations of TPP-Dox-prodrug 59 (0, 1.2, 2.5, 5 and 10 μM) for 48 hours. It is clear that the 
IC50 (~1.5 μM) for TPP-Dox 59 in the presence of 20 μM of TPP-alkyne 53b is much lower than 
that of its non-TPP conjugated counterpart Dox prodrug 56 (~10 μM) in the presence of 20 μM 
alkyne 53a (Figure 3.2a). We see a similar trend when the alkyne concentration was decreased to 
10 μM. For example, the IC50 for TPP-Dox prodrug 59 was about 2 μM in the presence of 53b, 
while the IC50 for Dox prodrug 56 was well over 10 μM in the presence of 10 μM of the alkyne 
trigger 53a (Figure 3.2b). As controls, both the IC50 values of 59 and 53b alone are higher than 
40 μM, and the treatment of 20 μM of alkyne 53a or 53b alone had no effect on cell viability. Such 
dose-dependent results strongly support the underlying hypothesis that conjugation with TPP (53b 
and 59) allows for the enhanced release of Dox through enrichment of the prodrug in mitochondria, 
which subsequently led to an enhanced bimolecular reaction rate and facilitated CCR-mediated 
activation of the prodrug. Without such an enrichment, the reaction is expected to be slow, 
resulting in a lower level of active Dox being released. Specifically, the second order rate constant 
of the reaction between the Dox-prodrug 56 and alkyne 53a was determined to be 0.17 M-1s-1, with 
the first half-life at 10 μM concentration of 56 and 10 μM concentration of 53a being about 163 h. 
Such results also mean that only 22% of the drug is released at the 48-h time point. If the 
concentrations of both the tetrazine prodrug (59) and alkyne (53b) are enriched to 500 μM in the 
mitochondria, the first half-life of the reaction would be 2.0 h (confirmed by experiments), which 
means almost complete Dox release at the 48-h time point. As a consequence, major differences 
in the apparent potency of the two prodrugs was observed with and without conjugation to TPP. 
Therefore, we conclude that enrichment in the mitochondria indeed led to triggered release of the 
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drug, as designed. The same concept is applicable to the delivery of drugs through other targeting 
approaches such as receptor-mediated drug delivery.  
 
  
Figure 3.2. Cytotoxicity evaluation of various prodrugs(n = 4, p = 0.95) 
 
3.3 Conclusion 
In conclusion, in targeted therapy, there is a strong need for the development of new 
chemistry to achieve selective delivery, which would complement existing ones. In this study, we 
have developed a new concept and a platform approach, which relies on concentration-sensitive 
chemistry to allow for selective drug release upon enrichment. This is achieved by taking 
advantage of reaction kinetics, which allows for accelerated cleavage at an elevated concentration. 
Such an approach will be very useful in delivering small molecules through targeting including 
the use of antibody drug conjugates and receptor-mediated drug delivery. As a result, the delivery 
is not limited to cell surface and can be used for sub-cellular delivery, with enriched concentrations, 
which could not be achieved by ADC based delivery. Collectively, we describe a method that 
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3.4 Experiment part 
General Information. All reagents and solvents were of reagent grade and were purchased 
from Aldrich. 1H-NMR (400 MHz) and 13C-NMR (100 MHz) spectra were recorded on a Bruker 
Avance 400 MHz NMR spectrometer. Mass spectral analyses were performed on an ABI API 
3200 (ESI-Triple Quadruple) instrument. HPLC was performed on a Shimadzu Prominence UFLC 
(column: Waters C18 3.5 μM, 4.6×100 mm). UV-Vis absorption spectra were recorded on a 
Shimadzu PharmaSpec UV-1700 UV-Visible spectrophotometer. Fluorescence spectra were 
recorded on a Shimadzu RF-5301PC fluorometer. 96-Well plates were read and recorded on a 




Reagents and conditions (i). (1) N2H4, Zn(OTf)2, 60 ℃ , 24 h, (2) NaNO2, H2O, HCl; (ii). 
dichloromethane (DCM), BBr3, 0 ℃, 0.5 h; (iii) propargyl bromide, acetonitrile, K2CO3, 60 ℃, 3 
h; (iv). (1) DCM, Dess–Martin periodinane, room temperature (r.t.), 10 min; (2) 
NaClO2/NaH2PO4, 2-methylbut-2-ene, t-BuOH, r.t, 2h; (v). (1) C2O2Cl2, DMF, DCM. r.t., (2) NHS, 
Et3N, DCM, r.t. 1h (3) Dox, Et3N, DMF, DCM.r.t.. (vi). CuSO4 5H2O, sodium ascorbate, DMSO, 
t-BuOH, N3(CH2)9PPh3Br, TBTA, 6 h r.t. 
Scheme  3.3 Synthesis of 59. 
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Synthesis of 4-(6-(methoxymethyl)-1,2,4,5-tetrazin-3-yl)phenol (103): To a solution of 4-
hydroxybenzonitrile (101, 1.785 g, 15.0 mmol) and 2-methoxyacetonitrile (102, 3.195 g, 45.0 
mmol) in N2H4 (13.5 ml) was added Zn(OTf) (1.812 g, 6 mmol). The reaction mixture was stirred 
at 60 ℃ for 24 h and cooled down to the room temperature (r.t). Then 40 mL of ethyl acetate 
(EtOAc), 20mL H2O, and NaNO2 (10 g, 145 mmol) were added to the mixture. HCl (10 M, 10 ml) 
was added slowly to the mixture over a period of 1 h. The reaction mixture was extracted with 
EtOAc (3 × 40 ml). The combined organic layer was washed with brine (50 mL), and dried over 
Na2SO4. The solvent was removed under reduced pressure to afford the crude product. The final 
product was obtained as a purple solid by recrystallization with hexane and EtOAc (2.18 g, 67%). 
1H NMR (CD3OD): δ 8.41 (d, J = 8.8 Hz, 2H), 6.96 (d, J = 8.8 Hz, 2H), 4.99 (s, 2H), 3.56 (s, 3H). 
13C NMR (CD3OD): δ166.8, 166.0, 163.5, 131.1, 124.0, 117.2, 73.2, 59.6. HRMS (ESI): m/z [M 
+ H]+ calcd for C10H11N4O2 219.0882; found, 219.0898. 
 
Synthesis of 4-(6-(hydroxymethyl)-1,2,4,5-tetrazin-3-yl)phenol (104): To a solution of 
compound 103 (410 mg, 1.9 mmol) in dichloromethane (DCM, 20 ml) was added BBr3 solution 
(1 M, 5 ml, 5.0 mmol) dropwise. The mixture was stirred at 0 ℃ for 30 min, and then the reaction 
was quenched with water (20 ml) and extracted with EtOAc (3 × 30 ml). The combined organic 
phase was dried over Na2SO4 and evaporated under reduced pressure. The pure product was 
achieved by chromatography as a purple solid (230 mg, 60%). 1H NMR (CD3OD): δ8.45 (d, J = 
8.8 Hz, 2H), 7.00 (d, J = 8.8 Hz, 2H), 5.14 (s, 2H). 13C NMR (CD3OD): δ168.8, 166.1, 163.4, 




Synthesis of (6-(4-(prop-2-yn-1-yloxy)phenyl)-1,2,4,5-tetrazin-3-yl)methanol (105): To a 
solution of compound 104 (230 mg, 1.1 mmol) in acetonitrile (ACN) (10 ml), 3-bromoprop-1-yne 
(250 mg, 2.1 mmol) and K2CO3 (690 mg, 5.0 mmol) were added at r. t. The reaction was stirred at 
60 oC for 2 h, cooled down to r.t, quenched with the HCl solution (1M, 10 ml), and then extracted 
with EtOAC (2 × 50 ml). The combined organic phase was dried over Na2SO4 and evaporated 
under reduced pressure. The pure product was achieved by chromatography as a purple solid (230 
mg, 86%). 1H NMR (CD3OD): δ 8.46 (d, J = 8.8 Hz, 2H), 7.26 (d, J = 8.8 Hz, 2H), 5.99 (t, J = 6.4 
Hz, 1H), 5.02 (d, J = 6.4 Hz, 2H), 4.95 (d, J = 2.4 Hz, 2H), 3.64 (t, J = 2.4 Hz, 1H). 13C NMR 
(CD3OD): δ168.0, 163.7, 160.8, 129.5, 124.7, 115.8, 78.8, 78.7, 62.0, 55.8. [M + H]+ calcd for 
C12H11N4O2, 243.0882; found, 243.0895. 
 
Synthesis of 6-(4-(prop-2-yn-1-yloxy)phenyl)-1,2,4,5-tetrazine-3-carboxylic acid (54):  To 
a solution of compound 105 (100 mg, 0.41 mmol) in DCM (5 ml) was added Dess–Martin 
periodinane (260 mg, 0.62 mmol) at r.t. After 20 min, the mixture was loaded into a silica column 
and eluted with DCM/EtOAC (2/1) to afford a purple solid (98 mg). The solid was dissolved in a 
solution of t-BuOH (3 mL) and 2-methylbut -2-ene (0.5 mL). Then a solution of NaClO2 (74 mg, 
0.82 mmol) in 0.67M NaH2PO4 (0.7 mL) was added slowly to the reaction mixture at r.t. After 2 
h, the reaction mixture was quenched with HCl (1 M, 10 mL), and extracted with ethyl acetate (2 
× 20 mL). The combined organic phase was dried over Na2SO4 and then evaporated under reduced 
pressure to give the crude product, which was purified by column chromatography to yield a purple 
solid (73 mg, 70%). 1H NMR (DMSO-D6): δ 8.53 (d, J = 8.8 Hz, 2H), 7.29 (d, J = 8.8 Hz, 2H), 
4.97 (d, J = 2.4 Hz, 2H), 3.63 (t, J = 2.4 Hz, 1H). 13C NMR (DMSO-D6): δ 163.5, 163.2., 161.3, 
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(prop-2-yn-1-yloxy)phenyl)-1,2,4,5-tetrazine-3-carboxamide (56): To a solution of 54 (32 mg, 
0.125 mmol) in 1.5 ml DCM was added oxalyl chloride (32 mg, 0.25 mmol); then DMF (2 μL) 
was added. The reaction was stirred at r.t. for 20 min. The solvent was removed by rotavapor. The 
residue was dissolved in 1 ml DCM. A solution of N-hydroxysuccinimide (NHS, 29 mg, 0.25 
mmol) in 2 mL DCM was added to the reaction mixture, followed by triethylamine (Et3N, 16 μL). 
The reaction mixture was stirred at r.t. for 1 h; then a solution of doxorubicin hydrochloride (68 
mg, 0.125 mmol) in 2 mL DMF was added to the reaction mixture. Then Et3N (16 μL) was added 
to the mixture. The reaction was stirred at r.t. for 20 min and diluted with 20 mL DCM, and washed 
with H2O (10 mL) and brine (10 mL). The organic layer was dried over Na2SO4, and then 
evaporated under reduced pressure to give the crude product, which was purified by column 
chromatography to yield a red solid (50 mg, 51%). 1H NMR (CDCl3): δ 13.97 (s, 1H), 13.21 (s, 
1H), 8.56 (d, J = 8.8 Hz, 2H), 8.19 (d, J = 8.8 Hz, 1H), 8.00 (d, J = 8.0 Hz, 1H), 7.76 (t, J = 8.0 Hz, 
2H), 7.36 (d, J = 8.0 Hz, 2H), 7.13 (d, J = 8.8 Hz, 2H), 5.57 (d, J = 3.2 Hz, 1H), 5.30 (d, J = 1.6 
Hz, 1H), 4.80-4.79 (m, 4H), 4.54 (s, 1H), 4.52-4.48 (m, 1H), 4.27 (q, J = 6.4 Hz, 1H), 4.05 (s, 3H), 
3.84 (d, J = 5.6 Hz, 1H), 3.26-3.28 (m 1H), 2.98-3.02 (m, 2H), 2.59 (t, J = 2.4 Hz, 1H), 2.42-2.37 
(m, 2H), 2.22-1.99 (m, 3H), 1.34 (d, J = 9.6 Hz, 3H). 13C NMR (CDCl3): δ 214.0, 187.2, 186.8, 
164.9, 162.3, 161.2, 158.7, 157.4, 156.3, 155.8, 135.9, 135.6, 133.8, 133.6, 131.0, 124.1, 121.0 
111 
120.0, 118.6, 116.0, 111.8, 111.6, 100.7, 100.1, 77.7, 77.4, 76.8, 76.6, 70.0, 69.3, 67.3, 65.7, 56.8, 
56.1, 46.3, 35.8, 34.1, 29.9, 17.0. [M - H]- calcd for C39H34N5O13. 780.2159. found; 780.2140. 
 
Synthesis of (9-azidononyl)triphenylphosphonium bromide (109). To a solution of 1, 9-
dibromononane (2 ml, 10 mmol) in toluene (5 ml) was added triphenylphosphine (262 mg). The 
reaction with stirred at 110 °C for 24 h, and then cooled down to r.t. The solvent was removed 
under reduce pressure, and the residue was purified by column (DCM/MeOH= 50/1) to afford 
colorless oil (400 mg). Then the oil was dissolved in ethanol (5 ml), and followed by addition of 
NaN3 (325 mg, 5 mmol). The reaction was stirred at 70 °C for 48 h, and cooled down to r.t. The 
solvent was removed under reduce pressure, and the residue was washed with H2O (10 ml), and 
extracted with EtOAc (3 × 20 ml). The combined organic phase was washed with brine (10 ml) 
and dried over Na2SO4, and then evaporated under reduced pressure to give the crude product, 
which was purified by column chromatography (DCM/MeOH= 20/1) to yield a red solid (300 
mg, 62%). 1H NMR (CDCl3): δ 7.65-7.85 (m, 15H), 3.78-3.70 (m, 2H), 3.20 (t, J = 7.0 Hz, 2H), 
1.46-1.58 (m, 6H), 1.13-1.25 (m, 8H). 13C NMR (CDCl3): δ 135.0 (d, J = 3 Hz), 133.7 (d, J = 10 
Hz), 130.5 (d, J = 12 Hz), 118.4 (d, J = 85 Hz ), 51.4, 30.4 (d, J = 15 Hz ), 29.0, 28.9, 28.8, 26.6, 
22.7, 22.6 (d, J = 50 Hz) 22.6, [M - Br]






yl)heptyl)triphenylphosphonium bromide(59): To a solution of 56 (30 mg, 0.038 mmol), 109 (39 
112 
mg, 0.076 mmol), tris[(1-benzyl-1H-1,2,3-triazol-4-yl)methyl]amine (TBTA, 1 mg) in t-BuOH 
(1.5 mL), and DMSO (0.5 mL) was added a solution of CuSO4 5H2O (1 mg) and sodium ascorbate 
(1.5 mg) in 0.5 mL H2O. The reaction mixture was stirred at r.t. for 6 h, diluted with DCM (20 mL) 
and H2O (10 mL), and extracted with DCM (2 × 20 ml). The combined organic layer was washed 
with EDTA (20 mM, 10 mL) and brine (10 mL), dried over Na2SO4, and then evaporated under 
reduced pressure to give the crude product, which was purified by column chromatography 
(DCM/MeOH= 9/1) to yield a red solid (28 mg, 57%). 1H NMR (DMSO-D6): δ 14.07 (s, 1H), 
13.29 (s, 1H), 8.63 (d, J = 8.4 Hz, 1H), 8.48 (d, J = 8.0 Hz, 2H), 8.29 (s,1H), 7.60-7.90 (m, 18H), 
7.33 (d, J = 8.0 Hz, 2H), 5.57 (s, 1H), 5.25-5.30 (m, 3H), 5.20 (d, J = 6.0 Hz, 1H), 4.94-5.02 (m, 
1H), 4.89 (t, J = 6.0 Hz, 1H), 4.61 (d, J = 6.0 Hz, 2H), 4.30-4.37 (m, 3H), 3.97 (s, 3H), 3.50-3.60 
(m, 2H), 2.94-3.07 (m, 2H), 2.00-2.33 (m, 4H), 1.71-1.78 (m, 4H), 1.41-1.50 (m, 4H), 1.16-1.23 
(m, 11H). 13C NMR (DMSO-D6): δ 213.9, 186.5, 186.5, 163.9, 162.3, 160.8, 158.9, 158.1, 156.2, 
154.6, 142.0, 136.2, 135.5, 134.9 (d, J = 3.0Hz ), 134.7, 134.2, 133.6 (d, J = 10 Hz ), 133.4, 130.2 
(d, J = 12 Hz), 130.2, 124.7, 123.7, 120.0, 119.8, 118.6 (d, J = 85 Hz ), 115.9, 110.8, 110.7, 100.1, 
75.0, 70.1, 67.8, 66.6, 63.7, 61.5, 56.6, 49.4, 46.0, 36.7, 32.1, 29.8, 29.8, 29.6, 28.5, 28.2, 27.9, 




Reagents and conditions: (i) DCM, Et3N, r.t 1 h; (ii) DCM, TFA, 30 min. r.t.; (iii) (1) C2O2Cl2, 
DMF, DCM. r.t. 30 min; (2) NHS, Et3N, DCM, 1 h, r.t., (3) 113, Et3N, DCM, r.t. 20 min.  
Scheme  3.4 Synthesis of Dansylamine prodrugs. 
 
Synthesis of tert-butyl(3-(2-(2-(3-((5-(dimethylamino)naphthalene)-1-
sulfonamido)propoxy)-ethoxy)ethoxy)propyl)carbamate (112). To a solution of dansyl chloride 
(110, 270 mg, 1 mmol) in DCM (2 mL) was add a solution of NH2-PEG-NHBoc (111, 352 mg, 
1.1 mmol) and then Et3N (180 uL). The reaction mixture was stirred at r.t. for 30 min and 
evaporated under reduced pressure to give the crude product, which was purified by column 
chromatography (DCM/MeOH= 50/1) to give a yellow oil (590 mg). 1H NMR (CDCl3): δ 8.51 (d, 
J = 8.4 Hz, 1H), 8.31 (d, J = 8.4 Hz, 1H), 8.22 (dd, J1 = 7.2 Hz, J2 = 1.2 Hz, 1H), 7.50-7.54 (m, 
2H), 7.16 (d, J = 7.6 Hz, 1H), 5.70-5.78 (m, 1H), 4.90-4.98(m, 1H ), 3.40-3.65 (m, 12H), 3.13-
3.23 (m 2H), 3.02(q, J = 6.4 Hz), 2.87 (s, 6H), 1.65-1.75 (m, 2H), 1.58-1.64 (m, 2H), 1.44 (s, 9H). 
13C NMR (CDCl3): δ 156.14 152.0, 135.0, 130.2, 130.0, 129.8, 129.6, 128.3, 123.3, 119.2, 115.2, 
78.9, 70.7, 70.7, 70.6, 70.4, 70.2, 70.0, 45.5, 42.2, 38.6, 29.7, 28.8, 28.6. [M +H]+ calcd for 




(dimethylamino)naphthalene-1-sulfonamide (113). To a solution of 112 (300 mg) in DCM (2 mL) 
was added TFA (2 mL) at r.t. The reaction mixture was stirred at r.t for 30 min and then the solvent 
was evaporated under reduced pressure to give the crude product, which was purified by column 
chromatography (DCM/MeOH= 10/1) to afford a green oil (292 mg, 95%). 1H NMR (CDCl3): δ 
8.51 (d, J = 8.4 Hz, 1H), 8.32 (d, J = 8.4 Hz, 1H), 8.21 (dd, J1 = 7.2 Hz, J2= 0.8Hz, 1H), 7.82-7.95 
(m, 2H), 7.48-7.56 (m, 2H), 7.18 (d, J = 7.6 Hz, 1H ) 6.48-6.55 (m, 1H), 3.55-3.68 (m, 8H), 3.44-
3.50 (m, 4H), 3.15-3.22 (m, 2h), 2.95-3.00 (m 2H), 2.88(s, 6H), 1.90-1.95(m, 2H), 1.62-1.69(m, 
2H). 13C NMR (CDCl3) δ 151.6, 135.0, 130.2, 129.9, 129.8, 129.5, 128.4, 123.4, 119.5, 115.5, 
70.4, 70.4, 70.0, 69.9, 69.8, 69.6, 45.6, 41.7, 40.0, 28.8, 26.4. [M +H]+ calcd for C22H36N3O5S 




3-carboxamide(55). To a solution of 54 (16 mg, 0.0625 mmol) in 1ml DCM was added oxalyl 
chloride (16 mg, 0.125 mmol) and DMF (2 μL). The reaction was stirred at r.t for 20 min. Then 
the solvent was removed by rotavapor. The residue was dissolved in 1 mL DCM. A solution of 
NHS in 2 mL DCM was added to the reaction mixture, followed by the addition of Et3N (16 μL). 
The reaction mixture was stirred at r.t for 1 h; then a solution of dansyzlamine (96 mg, 0.125 mmol) 
in 2 mL DCM was added, followed by the addition of Et3N (32 μL). The reaction was stirred at r.t 
for 20 min, diluted with 20 mL DCM, and washed with H2O (10 mL) and brine (10 mL). The 
organic layer was separated, dried over Na2SO4, and evaporated under reduced pressure. The 
residue was purified by column (DCM/MeOH= 50/1) to afford a purple solid 25 mg (60%). 1H 
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NMR (CDCl3): δ 8.63 (dd, J1 = 6.8 Hz, J2 = 2 Hz, 2H), 8.55-8.61 (m 1H), 8.49 (d, J = 8.4 Hz, 1H), 
8.31 (d, J = 8.4 Hz, 1H), 8.21 (dd, J1 = 7.2 Hz, J2= 1.2 Hz, 1H), 7.46-7.54 (m, 2H), 7.18 (dd, J1 = 
6.8 Hz, J2 = 2 Hz, 2H), 7.14 (d, J = 7.2, 1H), 5.73-5.78 (m, 1H), 4.82 (d, J = 2.4 Hz, 2H ), 3.64-
3.76 (m, 10H), 3.47-3.49 (m 2H), 3.40 (t, J = 6.4 Hz 2H), 3.02 (q, J = 6.0 Hz, 2H), 2.87 (s, 6H), 
2.59 (t, J = 2.4 Hz, 1H), 1.92-1.99 (m, 2H), 1.58-1.64 (m, 2H). 13C NMR (CDCl3): δ 164.9, 162.2, 
159.32, 157.8, 152.0, 135.1, 131.0, 130.3, 123.0, 129.8, 129.6, 128.3, 124.3, 123.3, 119.3, 116.0, 
115.2, 77.4, 76.5, 70.9, 70.7, 70.6, 70.3, 70.2, 70.1, 56.1, 45.5, 42.3, 39.0, 28.9, 28.7. [M +H]+ 
calcd for C34H42N7O7S, 692.2861 found: 692.2846. 
 
 
Reagents and conditions: (i) Cs2CO3, P(OMe)3, DMSO, O2, r.t, 24 h; (ii) TBDMSOTf, Et3N, DCM, 
r.t, 6 h; (iii) (1) KHMDS, THF, -78 oC, 1 h; (2) Tf2NPh, THF, -78
oC-r.t., 1h; (iv). LDA, THF, 0 oC, 
2.5 h. (v) LiOH, dioxane/H2O (5:1), 60 
oC, 3 h; (vi). TBAF, THF, r.t, 2 h; (vii) (1) EDC, NHS, 
DCM, r.t., 1 h; (2) 122, DCM, Et3N, r.t., 3 h.  
Scheme  3.5 Synthesis of TPP-Alkyne. 
 
Compound 115213 and 122214 are known compounds.  
 
Synthesis of methyl 4-((1-hydroxy-2-oxocyclooctyl)methyl)benzoate (116):  To the solution 
of 115 (4.6 g, 16.8 mmol) in 20 ml of DMSO was added Cs2CO3 (821 mg, 2.52 mmol) and 
P(OMe)3 (5.2 g, 42 mmol). The reaction was stirred at r.t under O2 for 24 h, quenched with H2O 
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(40 mL), and extracted with EtOAc (2 × 200 ml). The combined organic phase was dried over 
Na2SO4 and then evaporated under reduced pressure to give the crude product, which was purified 
by column chromatography to yield a white solid (3.1 g, 64%).215 1H NMR (CDCl3): δ 7.91 (d, J 
= 8.3 Hz, 2H), 7.18 (d, J = 8.3 Hz, 2H), 3.88 (s, 3H), 3.84 (d, J = 1.2 Hz, 1H), 2.94 – 2.82 (m, 3H), 
2.42 – 2.31 (m, 1H), 2.22-2.27 (m, 1H), 2.00 – 1.86 (m, 2H), 1.83 – 1.54 (m, 4H), 1.47 – 1.20 (m, 
2H), 0.98 – 0.78 (m, 1H). 13C NMR (CDCl3): δ 218.1, 167.1, 140.9, 1302, 129.5, 128.9, 81.0, 52.1, 
46.3, 36.8, 33.3, 30.5, 25.5, 24.5, 23.0. [M +H]+ calcd for C17H23O4,  291.1591 found: 291.1586.  
 
Synthesis of methyl 4-((1-((tert-butyldimethylsilyl)oxy)-2-oxocyclooctyl)methyl)-
benzoate(117). To a solution of 116 (3.1 g, 10.7 mmol) in 50 ml of DCM, was added TBDMSOTf 
(3.4 g, 12.84 mmol) and Et3N (1.3 g, 12.84 mmol). The reaction was stirred at r.t for 6 h. Then 
solvent was evaporated under reduced pressure to give the crude product, which was purified by 
column chromatography to yield a white solid (1.7 g, 33%). 1H NMR (CDCl3): δ 7.91 (d, J = 7.2 
Hz, 2H), 7.16 (d, J = 7.6 Hz, 2H), 3.90 (d, J = 1.0 Hz, 3H), 3.05 (d, J = 13.6 Hz, 1H), 2.90 (d, J = 
13.6 Hz, 1H), 2.56 – 2.15 (m, 3H), 1.92 – 1.20 (m, 8H), 1.11 – 1.01 (m, 1H), 0.86 (d, J = 0.9 Hz, 
9H), 0.05 (s, 3H), -0.12 (s, 3H). 13C NMR (CDCl3): δ 216.3, 167.2, 141.6, 130.8, 129.4, 128.8, 
85.1, 52.2, 47.8, 38.7, 35.9, 30.5, 26.6, 25.7, 24.8, 23.4, 19.4, -2.1, -2.4. [M +H]+ calcd for 
C23H37O4Si, 405.2456 found: 405.2468.  
 
Synthesis of methyl (E)-4-((1-((tert-butyldimethylsilyl)oxy)-2-(((trifluoromethyl)-
sulfonyl)oxy)cyclooct-2-en-1-yl)methyl)benzoate(118). To a solution of 117(1.7 g, 4.2 mmol) in 
50 ml of THF was added a solution of potassium bis(trimethylsilyl)amide(KHMDS) in THF (0.5 
M, 9.2 ml) over a period of 10 min under the protection of argon at -78 oC. The reaction was stirred 
117 
at -78 oC for 1 h, and a solution of N-phenyl-bis(trifluoromethanesulfonimide) (Tf2NPh, 1.6 g, 4.62 
mmol) in 20 ml of THF was added slowly over 10 min. The reaction was stirred for another 10 
min at -78 oC, then warmed to r.t, and then stirred for another 30 min. The solvent was removed 
by a rotavapor and the residue was purified by chromatography to give a colorless oil (1.0 g, 47%). 
1H NMR (CDCl3): δ 7.93 (d, J = 8.1 Hz, 2H), 7.22 (d, J = 8.1 Hz, 2H), 5.57 (t, J = 9.4 Hz, 1H), 
3.91 (s, 3H), 3.36 (d, J = 12.4 Hz, 1H), 2.91 (d, J = 12.4 Hz, 1H), 1.69-2.01 (m, 6H), 1.53 – 1.32 
(m, 4H), 0.96 (s, 9H), 0.27 (m, 6H). 13C NMR (CDCl3) δ 167.1, 152.3, 141.6, 130.5, 129.4, 128.7, 
120.5, 118. 6(q, J= 317 Hz), 80.1, 52.2, 35.9, 26.5, 25.4, 23.5, 23.4, 22.1, 19.0, -1.3, -1.5. [M +H]+ 
calcd for C24H36F3O6SSi, 537.1948 found: 537.1970.  
 
 
Synthesis of methyl 4-((1-((tert-butyldimethylsilyl)oxy)cyclooct-2-yn-1-
yl)methyl)benzoate(119) To a solution of 118 (450 mg, 0.84 mmol) in 10 ml of THF was added a 
solution of LDA in THF (2M, 0.53 ml) drop-wise over a period of 2.5 h under the protection of 
argon at 0 oC.  Then the reaction was quenched with H2O (40 mL), and extracted with ethyl acetate 
(2 × 50 ml). The combined organic phase was dried over Na2SO4 and then evaporated under 
reduced pressure to give the crude product, which was purified by column chromatography to yield 
a colorless oil (200 mg, 62%).  1H NMR (CDCl3): δ 7.93 (d, J = 8.0 Hz, 2H), 7.37 (d, J = 8.0 Hz, 
2H), 3.89 (s. 3H), 2.97 (d, J = 13.0 Hz, 1H), 2.78 (d, J = 13.0 Hz, 1H), 1.36-2.32 (m, 10H), 0.83 
(s, 9H), 0.12 (s, 3H), -0.26 (s, 3H).  13C NMR (CDCl3): δ 167.6, 143.6, 131.2, 129.0, 128.3, 99.5, 
94.9, 75.9, 52.1, 52.0, 48.3, 34.5, 30.1, 27.2, 26.1, 20.7, 18.3, -2.7, -3.6. [M +H]+ calcd C23H35O3Si 
387.2350 found: 387.2365.  
118 
Synthesis of 4-((1-((tert-butyldimethylsilyl)oxy)cyclooct-2-yn-1-yl)methyl)benzoic acid 
(120). To a solution of 119 (100 mg, 0.26 mmol) in dioxane (3 mL) and H2O (0.75 mL) was added 
finely crushed LiOH (200 mg, 8.3 mmol). The suspension was heated to 50 ºC and then stirred for 
3 h. The dioxane was removed on a rotary evaporator and the reaction mixture was diluted with 
DCM (20 mL). The organic layer was washed with 1 N HCl (2 × 10 mL), H2O (3 x 10 mL), and 
brine (1 × 10 mL), and dried over Na2SO4, yielding a white solid (86 mg 89%). 
1H NMR (CDCl3): 
δ 8.02 (d, J = 8.0 Hz, 2H), 7.42 (d, J = 8.0 Hz, 2H), 3.00 (d, J = 13Hz, 1H), 2.82 (d, J = 13Hz, 1H), 
2.05- 2.28 (m, 2H), 1.51-2.01 (m, 6H), 1.26-1.50 (m, 2H), 0.84 (s, 9H), 0.13 (s, 3H), -0.25 (s, 3H)  
13C NMR (CDCl3): δ 172.4, 144.6, 131.3, 129.6, 127.4, 99.6, 94.6, 75.7, 52.1, 48.4, 34.5, 30.1, 
27.2, 26.0, 20.7, 18.2, -2.7, -3.6. [M +H]+ calcd C22H33O3Si 373.2193 found: 373.2204. 
 
Synthesis of 4-((1-hydroxycyclooct-2-yn-1-yl)methyl)benzoic acid (53a). To a solution of 
120 (68 mg, 0.18 mmol) in 0.2 ml of THF was added tetra-n-butylammonium fluoride (TBAF) 
solution (2M in THF/hexane, 1 mL). The reaction was stirred at r.t for 2 h, and then the solvent 
was removed under reduced pressure. The residue was purified by chromatography 
(DCM/EtOAc=2/1) to give a white sticky solid (46 mg, 99%). 1H NMR (CDCl3): δ 8.03 (d, J = 
8.0 Hz, 2H), 7.44 (d, J = 8.0 Hz, 2H), 3.01 (d, J=13 Hz, 1H), 2.88 (d, J=13 Hz, 1H), 2.08-2.21(m, 
3H), 1.72-2.03 (m, 6H), 1.36-1.44 (m, 1H). 13C NMR (CDCl3): δ 172.0, 143.6, 130.7, 130.1, 127.9, 




triphenylphosphonium bromide (53b). To a solution of 53a (38 mg, 0.15 mmol) in DCM, was 
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added N-(3-dimethylaminopropyl)-N-ethylcarbodiimide hydrochloride (EDC 42 mg, 0.225 mmol) 
and NHS (35 mg, 0.3 mmol). The reaction was stirred at r.t for 1 h, diluted with DCM (10 mL), 
and then washed with H2O (5 mL) and brine (5 mL). The organic phase was dried over Na2SO4, 
and evaporated under reduced pressure to afford a white solid. The solid was dissolved in 2mL 
DCM, followed by the addition of a solution of 122 (90 mg, 0.225 mmol) in 2mL DCM. Then 
Et3N (30 mg, 0.3 mmol) was added into the reaction mixture. The reaction was stirred at r.t for 3 
h, and diluted with DCM (15 mL). The organic layer was washed with H2O (5 mL) and brine (5 
mL), dried over Na2SO4, and evaporated under reduced pressure to afford the crude product, which 
was purified by chromatography (DCM/MeOH =10/1) to give a white solid (57 mg, 60 %). 1H 
NMR (CDCl3): δ 9.43 (t, J = 6.0 Hz, 1H), 8.14 (d, J = 8.0 Hz, 2H) 7.69-7.74 (m, 9H), 7.56-7.61 
(m, 6H), 7.39 (d, J = 8.0 Hz, 2H), 3.89-3.82 (m, 2H), 3.71-3.70 (m, 2H), 2.97 (d, J=13 Hz, 1H), 
2.82 (d, J=13 Hz, 1H), 2.16 (t, J = 6.0 Hz, 2H), 2.12-1.67 (m, 10H), 1.43-1.38 (m, 1H). 13C NMR 
(CDCl3): δ 167.8, 140.6, 135.1 (d, J = 3 Hz), 133.5 (d, J = 10 Hz), 132.4, 130.6, 130.6 (d, J = 12 
Hz), 127.9, 118.4 (d, J = 85 Hz), 100.1, 99.7, 94.9, 74.3, 50.8, 46.9, 39.4 (d, J = 17 Hz), 34.6, 30.0, 




Reagents and conditions: (i) 1) LDA, THF, -78 °C, 1h; 2) methyliodide, THF, r.t, 40 min; (ii) 
Cs2CO3, P(OEt)3, DMSO, O2 (1.0 atm), r.t, 36 h; (iii) TBDMSOTf, Et3N, DCM, r.t, 6 h; (iv) 1) 
KHMDS, THF, 46 °C, 1 h; 2) Tf2NPh, THF, r.t, 1 h; (v) LDA, THF, 0 
°C, 2.5 h, 89%; (vi) TBAF, 
THF, r.t, 2 h.  
Scheme  3.6 Synthesis of Alkyne 52. 
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Compound 124 is commercially available, and compound 51216 is a known compound.  
 
Synthesis of 2-methylcyclooctan-1-one (125). To a solution of cyclooctanone (124, 3.2g, 
25.3 mmol) in 50 ml of THF, a solution of LDA in THF (2M, 15.1 mL) was added dropwise under 
the protection of argon at -78 °C. The reaction was stirred at -78 °C for 1 h, and then methyliodide 
(1.6 ml, 25.7 mmol) was added slowly over 10 min. The reaction was stirred for another 30 min 
after being warmed to r.t. The solvent was removed on a rotavapor, and the residue was purified 
by chromatography to give a colorless oil (1.9 g, 56%). 1H NMR (CDCl3): δ2.63-2.52 (m, 1H), 
2.43-2.30 (m, 2H), 1.33-1.95 (m, 9H), 1.25-1.12 (m, 1H), 1.01 (d, J=6.8 Hz, 3H). 13C NMR 
(CDCl3): δ 220.4, 45.3, 40.4, 33.1, 26.9, 26.6, 25.7, 24.6, 16.6. [M +H]+ calcd: C9H17O 141.1274 
found: 141.1286 
 
Synthesis of 2-hydroxy-2-methylcyclooctan-1-one (126). The mixture of 125 (1.9 g, 13.5 
mmol), Cs2CO3 (1.3 g, 4.0 mmol) and P(OEt)3 (6.9 ml, 40.5 mmol) in 20 ml of DMSO was stirred 
at r.t under O2 for 36 h. Then the reaction was quenched with H2O (40 mL), and extracted with 
EtOAc (2 × 200 ml). The combined organic phase was dried over Na2SO4 and then evaporated 
under reduced pressure to give the crude product, which was purified by column chromatography 
to yield a colorless liquid (0.75 g, 35%). 1H NMR (CDCl3): δ 3.91 (s, 1H), 2.83-2.72 (m, 1H), 
2.35-2.24 (m, 2H), 1.99-1.83 (m, 2H), 1.82-1.67 (m, 3H), 1.67-1.56 (m, 1H), 1.39-1.28 (m, 2H), 
1.27 (s, 3H), 0.96-0.83 (m, 1H). 13C NMR (CDCl3): δ 219.8, 77.8, 35.8, 34.4, 30.3, 27.4, 25.4, 
24.3, 23.1. [M +Na]+ calcd: C9H16NaO2, 179.1048 found:179.1055.  
. 
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Synthesis of 2-((tert-butyldimethylsilyl)oxy)-2-methylcyclooctan-1-one (127). To a solution 
of 126 (0.75 g, 4.8 mmol) in 50 ml of DCM were added TBDMSOTf (1.6ml, 7.2 mmol) and Et3N 
(0.73 ml, 5.3 mmol). The reaction was stirred at r.t for 6 h before solvent evaporation under reduced 
pressure to give the crude product, which was purified by column chromatography to yield a white 
solid (0.42 g, 33%). 1H NMR (CDCl3): δ 2.71-2.61 (m, 1H), 2.44-2.35 (m, 1H), 2.08-1.99 (m, 1H), 
1.96-1.78 (m, 3H), 1.77-1.54 (m, 1H), 1.53-1.37 (m, 2H), 1.37-1.29 (m, 5H), 0.90 (s, 9H), 0.14 (d, 
J = 6.7 Hz, 6H). 13C NMR (CDCl3): δ 217.4, 80.8, 38.6, 36.9, 29.3, 26.2, 25.9, 25.6, 24.6, 23.1, 
18.5, -2.3, -2.6. [M +Na]+ calcd: C15H30NaO2Si, 293.1913 found: 293.1913. 
 
Synthesis of (E)-8-((tert-butyldimethylsilyl)oxy)-8-methylcyclooct-1-en-1-yl 
trifluoromethanesulfonate (128). To a solution of 127 (0.42 g, 1.58 mmol) in 50 ml of THF was 
added a solution of KHMDS in THF (0.5 M, 3.4 mL) slowly over 10 min under the protection of 
argon at -78 °C. After the reaction was stirred at -78 °C for 1 h, a solution of Tf2NPh, (0.62 g, 1.73 
mmol) in 10 ml of THF was added slowly over 10 min. The reaction was stirred for another 1 h 
after warming to r.t. The solvent was removed on a rotavapor and the residue was purified by 
column chromatography to give a colorless oil (0.32 g, 50%). 1H NMR (CDCl3): δ6.18 (dd, J =12.8, 
4.7 Hz, 1H), 2.65-2.47 (m, 1H), 2.30-2.20 (m, 1H), 2.11-1.99 (m, 1H), 1.92-1.65 (m, 4H), 1.57-
1.42 (m, 4H), 1.24-1.08 (m, 1H), 0.95 (s, 9H), 0.84-0.71 (m, 1H), 0.15 (d, J = 6.6 Hz, 6H). 13C 
NMR (CDCl3): δ 155.5, 118.6 (q, J = 318 Hz), 118.0, 76.6, 40.1, 28.8, 26.3, 26.2, 23.7, 23.5, 22.1, 
18.7, -2.0, -2.0. [M +H]+ calcd: C16H30F3O4SSi, 403.1586; found 403.1575. 
 
Synthesis of tert-butyldimethyl((1-methylcyclooct-2-yn-1-yl)oxy)silane (129). To a solution 
of 128 (0.32, 0.80 mmol) in 10 ml of THF, a solution of LDA in THF (2 M, 0.8 ml) was added 
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drop-wise over a period of 20 minutes under the protection of argon at 0 °C. After being warmed 
to r.t., the reaction was quenched with H2O (10 mL), and extracted with ethyl acetate (2 × 30 ml). 
The combined organic phase was dried over Na2SO4 and then evaporated under reduced pressure 
to give the crude product, which was purified by column chromatography to yield a colorless oil 
(179 mg, 89%).1H NMR (CDCl3): δ 2.29-2.10 (m, 2H), 2.08-1.98 (m, 1H), 1.92-1.82 (m, 3H), 
1.80-1.68 (m, 2H), 1.61-1.51 (m, 2H), 1.36 (s, 3H), 0.88 (s, 9H), 0.19 (d, J=16.6Hz, 6H). 13C NMR 
(CDCl3): δ97.7, 96.8, 71.9, 53.9, 34.8, 30.2, 29.6, 27.1, 25.9, 20.8, 18.1, -3.0, -3.0. [M +H]+ calcd: 
C15H29OSi, 253.1988, found: 253.1972 
 
Synthesis of 1-methylcyclooct-2-yn-1-ol (52). To a solution of 129 (179 mg, 0.71 mmol), 
TBAF (1 M, 2.1 ml) was added. After stirring at r.t. for 2 h, the solvent was removed under reduced 
pressure and was purified by chromatography to give a colorless oil (51 mg, 52%). 1H NMR 
(CDCl3): δ2.29-2.12 (m, 2H), 2.10-2.01 (m, 1H), 1.99-1.75 (m, 5H), 1.74-1.61 (m, 2H), 1.58-1.47 
(m, 1H), 1.42(s, 3H). 13C NMR (CDCl3): δ 98.3, 96.1, 70.9, 52.5, 34.7, 30.0, 28.2, 27.0, 20.7. M 
+H]+ calcd: C9H15O, 139.1117 found 139.1109. 
 
3.4.2 Kinetic studies of the CCR system 
Stock solution preparation. 
Each of the tetrazine prodrugs (compounds 55, 56 and 59) was dissolved in DMSO to 
afford a 500-µM stock solution. Each of the alkynes (compounds 51, 52, 53a and 53b) was 
dissolved in DMSO to afford a 50-mM stock solution. Doxorubicin (Dox) and dansylamino 
compound (DA) 113 were each dissolved in DMSO to afford 1mM stock solutions 
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HPLC method A: mobile phase A (10 mM NaH2PO4 in water, pH = 5.0) and mobile phase 
B (ACN), flow rate: 1 mL/min, running time: 30 min, the gradient elution method: 25% B from 0 
to 6 min, 25% to 50 % B from 6 to 8 min, 50% B from 8 to 15 min, 50% to 99% B from 15 to 20 
min, 99% B from 20 to 25 min, 99% to 25% B from 25 to 30 min. Detection wavelength: 256 nm. 
Column: Waters C18 3.5 μM, 4.6 × 100 mm. Injection volume: 20 µL.   
HPLC method B: mobile phase A (10 mM NaH2PO4 in water, pH = 5.0) and mobile phase 
B (ACN), flow rate: 1 mL/min, running time: 30 min, the gradient elution method: 30% B from 0 
to 6 min, 30% to 50 % B from 6 to 8 min, 50% B from 8 to 15 min, 50% to 99% B from 15 to 20 
min, 99% B from 20 to 25 min. 99% to 30 % B from 25 to 30 min. Detection wavelength 1: 256, 
detection wavelength 2: 337 nm. Column: Waters C18 3.5 μM, 4.6 × 100 mm. Injection volume: 
20 µL.  
Standard curve of Dox concentration measurement.  
To four HPLC vials containing 0.9 mL PBS (size: 1.5 mL) were added 25, 15, 20, 10 µL 
Dox stock solution (1 mM) respectively. Then defined amounts DMSO (975, 985, 980, and 990 
µL) were added to each vial to afford final concentration of four vials were 25, 15, 20, 10 µM in 
PBS (10% DMSO), respectively. The samples were analyzed with HPLC method A. Dox retention 
time: 4.0 min.  
Standard curve for DA concentration measurement.  
To four HPLC vials containing 0.9 mL PBS (size: 1.5 mL) were added 25, 15, 20, 10 µL 
Dox stock solution (1 mM) respectively. Then defined amounts DMSO (975, 985, 980, and 990 
µL) were added to each vial to afford final concentration of four vials were 25, 15, 20, 10 µM in 
PBS (10% DMSO), respectively. The samples were analyzed with HPLC method B. DA retention 
time: 5.8 min. 
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General procedures HPLC studies of reaction kinetic. 
To three 20-ml vials with 9 mL PBS were added a solution of tetrazine prodrug (500 µL, 
500µM). 350 µL, 300 µL and 250 µL DMSO were added to vial respectively, and then 150 µL, 
200 µL and 250 µL of the alkyne solution (50 mM in DMSO) were added to the vials to afford 
final concentrations of alkyne 0.75 mM, 1 mM and 1.25 mM in PBS (10% DMSO, 25 µM prodrug) 
respectively. The reaction was stirred at r.t or 37 ºC respectively. Every 30 min about 500 µL 
reaction mixtures were taken out and 20 µL of them were injected into the HPLC by the 
autosampler; the rest of them were poured back to the reaction mixture. (Note: In the cases of 
prodrugs 55 or 56 reacting with alkyne 51 at 37 °C, the final concentrations of 51 in the kinetic 
studies were 250 µM, 300 µM and 350 µM).  
Table 3.3 Retention time from the kinetic studies 







retention time (min) 
A 6 1 13.7 3.9 13.9/14.5 
2 13.7 3.9 NO 
3a 13.7 4.0 18.5 
3b 13.7 4.0 22.8 
9 3b 11.0 4.0 23.1 
B 5 1 11.7 5.7 11.5/12.1 
2 11.7 5.7 no 
3b 11.7 5.7 23.5 
.  
Determination of second-order rate constants: 
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The reaction rate constant, kobs, was calculated for each concentration of the alkyne by 
fitting the prodrug areas versus time using eq. 1 
Y=Aexp(-kobst) eq. 1                                                            
Where Y is the prodrug area, and t is time. The pseudo-first-order rate constant, kobs, was 
then plotted against the concentration of alkyne to yield the second-order rate constant using eq 2. 
kobs = k2[Alkyne] eq. 1                                                                 
where k2 is the second-order rate constant. The results are shown in Table 3.4. 






n of Alkyne 
(mM) 
Expt. 1 Expt. 2 Expt. 3 
Kobs (h
-1) 
r.t 55 51 0.75 0.752 0.704 0.756 
51 1.00 0.980 0.802 1.01 
51 1.25 1.20 1.10 1.26 
37 °C 55 51 0.25 1.82 1.64 1.90 
51 0.3 2.15 1.94 2.26 
51 0.35 2.53 2.25 2.65 
r.t 55 52 0.75 0.0203 0.0201 0.0217 
52 1.00 0.0273 0.0269 0.0289 
52 1.25 0.0339 0.0324 0.0359 
37 °C 55 52 0.75 0.0506 0.0584 0.0599 
52 1.00 0.0670 0.0781 0.0801 




53b 0.75 0.125 0.115 0.13 
53b 1.00 0.155 0.148 0.175 
53b 1.25 0.199 0.180 0.22 
37 °C 55 53b 0.75 0.411 0.388 0.353 
53b 1.00 0.548 0.511 0.453 
53b 1.25 0.695 0.636 0.561 
r.t 56 51 0.75 0.894 0.976 0.993 
51 1.00 1.18 1.30 1.34 
51 1.25 1.47 1.62 1.69 
37 °C 56 51 0.25 1.90 1.81 1.97 
51 0.3 2.28 2.15 2.38 
51 0.35 2.65 2.48 2.78 
r.t 56 52 0.75 0.0202 0.0209 0.0207 
52 1.00 0.0282 0.0262 0.0278 
52 1.25 0.0353 0.0341 0.0344 
37 °C 56 52 0.75 0.0607 0.0671 0.0696 
52 1.00 0.0798 0.0895 0.0941 
52 1.25 0.0986 0.112 0.119 
r.t 56 53b 0.75 0.201 0.195 0.197 
53b 1.00 0.261 0.257 0.261 
53b 1.25 0.309 0.318 0.326 
37 °C 56 53b 0.75 0.486 0.503 0.533 
53b 1.00 0.635 0.672 0.622 
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53b 1.25 0.783 0.846 0.905 
r.t 56 53a 0.75 0.183 0.191 0.185 
53a 1.00 0.235 0.246 0.247 
53a 1.25 0.289 0.295 0.307 
37 °C 56 53a 0.75 0.418 0.438 0.495 
53a 1.00 0.546 0.598 0.678 
53a 1.25 0.673 0.739 0.857 
r.t 59 53b 0.75 0.296 0.305 0.291 
53b 1.00 0.331 0.356 0.359 
53b 1.25 0.445 0.465 0.474 
37 °C 59 53b 0.75 0.711 0.701 0.714 
53b 1.00 0.921 0.902 0.871 
53b 1.25 1.21 1.15 1.09 
.  
 
General procedure for the determination of the lactonization rate constants.  
To a 9 mL PBS in a 20-mL vial was added a solution of the respective tetrazine prodrug 
(500 µL, 500 µM). Then 1 mL of the respective alkyne (50 mM in DMSO) was added to afford a 
final concentration of 5 mM in PBS (15% DMSO). The reaction was stirred at r.t. Every 30 min 
about 500 µL the reaction mixture was taken out and 20 µL of them was injected into the HPLC 
by an autosampler; the rest of them was poured back to the reaction mixture. The reaction rate 
constant, k1, was determined by fitting the area in HPLC chromatogram of the intermediate versus 
time using eq. 3. 
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Y=Aexp(-k1 t)  eq. 3                                                            
Where Y is the intermediate areas, and t is the time. The results are shown in Table 3.5.  
 
Table 3.5 Lactonization rate constants 
Tetrazines 
prodrugs 
Alkyne First Data 
point time* 
         k1  (h
-1) 
Expt 1 Exp 2 Expt. 3 
55 51 1 h 0.0253 0.0291 0.0332 
55 53b 4 h 0.162 0.184 0.142 
56 53b 4 h 0.223 0.179 0.196 
56 53a 4 h 0.185 0.206 0.229 
59 53b 4h 0.225 0.191 0.265 
*: The time point that more that 90% prodrug were consumed. .  
General procedure of prodrug stability studies.  
To a 9.5 mL of PBS or 1 mM cysteine solution in PBS in a 20-mL vial was added a solution 
of tetrazine prodrug (500 µL, 500 µM). The solution was stirred at r.t. or 37 ºC for 24 h. The 
reaction solution was injected into HPLC, and analyzed with Method A for prodrugs 56 and 59, 
and Method B for prodrug 55. 
Prodrug (55 or 56, 25 μM in PBS alone or in the presence of 1 mM cysteine (Cys) in PBS) 
was incubated at r.t or 37 °C for 24 h. Then HPLC was used to monitor the concentration of the 
remaining prodrug (Table 3.6). (Note: there are literature reports of Dox decomposition by 
itself211).217   
Table 3.6 Stability studies of prodrugs 55 and 56 in PBS. (5% DMSO, n = 4, p = 0.95).  
Prodrugs 
remaining 
24 h in PBS 
at r.t (%) 
24 h in PBS 
at 37 °C (%) 
24 h in PBS with 
1mM Cys at r.t (%) 
24 h in PBS with 1mM 
Cys at 37 °C (%) 
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555 91±5 85±5 88±5 81±5 
56 85±5 78±5 80±5 76±5 
 
3.4.3 Cell culture 
Hela cells (ATCC) were used in the studies. Hela cells were maintained in DMEM 
(Dulbecco’s Modified Eagle’s Medium) supplemented with 10% fetal bovine serum (MidSci; 
S01520HI), and 1% penicillin-streptomycin (Sigma-Aldrich; P4333) at 37 °C with 5% CO2. 
3.4.3.1 Studies of cytotoxicity  
Test compound was dissolved in DMSO to afford a stock solution. The final concentration 
of DMSO in cell culture was 1% (v/v) in PBS. Hela cells were seeded in 96-well plates one day 
before the experiment. Different concentrations of prodrug was added into the cell culture. The 
cells were then incubated for 48 h at 37 °C with 5% CO2. The cell viability was tested by the MTT 
assay.218 Specifically, after 48 h of incubation, 5 mg/mL MTT (3-(4, 5-dimethylthiazol-2-yl)-2, 5-
diphenyltetrazolium bromide) was added into the cell culture. After incubation for 4 h, the 
supernatant was removed and 100 μL DMSO was added into the wells containing the cells. After 
shaking gently for 3 min, absorbance at 605 nm was read by a plate reader. Some of the result were 




Figure 3.3.Studies of cytotoxicity (n = 4). 
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3.4.4 Computational studies 
All calculations were performed using the Gaussian 09 program.219 Initial geometry 
optimizations were carried out by DFT calculations with use of the B3LYP220-221 with the standard 
6-31G(d,p) basis set. The transition state geometries were obtained using the QST3 method. 
Energies are shown in Table S4. The stationary points are characterized by frequency calculations 
to verify that TSs has one and only one imaginary frequency (Scheme S8). All calculations were 
conducted on Georgia State University cluster Orion with 8 CPU cores.222 
Coordinates and connections of 60 
N                 -3.33510000    1.54220000   -0.14430000 
 C                  4.67560000    0.52310000   -0.31910000 
 C                  5.21030000   -0.72150000    0.01340000 
 C                  4.36190000   -1.79170000    0.29720000 
 C                  2.97890000   -1.61720000    0.24860000 
 C                  2.44420000   -0.37260000   -0.08380000 
 C                  3.29260000    0.69760000   -0.36770000 
 C                  1.11850000   -0.20540000   -0.13030000 
 N                  0.63990000    1.04560000   -0.00410000 
 N                 -0.69490000    1.21400000   -0.05090000 
 C                 -1.45900000    0.11980000   -0.22080000 
 N                 -0.98040000   -1.13120000   -0.34700000 
 N                  0.35440000   -1.29960000   -0.30010000 
 C                 -2.79850000    0.28880000   -0.26790000 
 O                  6.55380000   -0.89100000    0.06070000 
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 C                  6.87730000   -2.20900000    0.41250000 
 C                  8.33880000   -2.36090000    0.45530000 
 C                  9.54380000   -2.48610000    0.49060000 
 O                 -3.52290000   -0.66600000   -0.41910000 
 C                 -4.77280000    1.72360000   -0.19480000 
 C                 -5.10480000    3.20130000   -0.03400000 
 H                 -2.72830000    2.34220000   -0.01760000 
 H                  5.34460000    1.36700000   -0.54300000 
 H                  4.78350000   -2.77330000    0.55940000 
 H                  2.30990000   -2.46120000    0.47240000 
 H                  2.87090000    1.67910000   -0.62990000 
 H                  6.45130000   -2.44030000    1.41440000 
 H                  6.45370000   -2.90890000   -0.34230000 
 H                 10.62750000   -2.59870000    0.52230000 
 H                 -5.15760000    1.36200000   -1.17460000 
 H                 -5.24880000    1.14490000    0.62820000 
 H                 -6.20830000    3.34050000   -0.07280000 
 H                 -4.72000000    3.56290000    0.94580000 
 H                 -4.62880000    3.78000000   -0.85700000 
 1 14 1.0 20 1.0 22 1.0 
 2 3 1.0 7 2.0 23 1.0 
 3 4 2.0 15 1.0 
 4 5 1.0 24 1.0 
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 5 6 2.0 25 1.0 
 6 7 1.0 8 1.0 
 7 26 1.0 
 8 9 1.0 13 2.0 
 9 10 2.0 
 10 11 1.0 
 11 12 2.0 14 1.0 
 12 13 1.0 
 13 
 14 19 2.0 
 15 16 1.0 
 16 17 1.0 27 1.0 28 1.0 
 17 18 3.0 
 18 29 1.0 
 19 
 20 21 1.0 30 1.0 31 1.0 















Coordinates and connections of 52 
 C                 -4.18010000   -2.30160000    0.09260000 
 C                 -5.19150000   -1.18990000   -0.25300000 
 C                 -4.97230000    0.16130000    0.47260000 
 C                 -4.06550000    1.19260000   -0.25130000 
 C                 -2.63920000    1.37760000    0.32480000 
 C                 -1.55430000    0.46390000   -0.28050000 
 C                 -2.01330000   -0.91580000   -0.20460000 
 C                 -2.83370000   -1.77920000   -0.09320000 
 C                 -0.25860000    0.61690000    0.50520000 
 O                 -1.32060000    0.81810000   -1.61670000 
 H                 -4.33910000   -3.17460000   -0.57920000 
 H                 -4.31920000   -2.62770000    1.14760000 
 H                 -6.20830000   -1.55850000    0.00950000 
 H                 -5.05560000   -0.97980000   -1.33750000 
 H                 -4.51330000   -0.05680000    1.46290000 
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 H                 -5.97760000    0.63600000    0.52550000 
 H                 -3.96310000    0.86830000   -1.31100000 
 H                 -4.56920000    2.17600000   -0.11720000 
 H                 -2.68330000    1.17830000    1.41890000 
 H                 -2.33920000    2.41850000    0.06930000 
 H                  0.54860000    0.97060000   -0.17450000 
 H                 -0.40610000    1.35810000    1.32230000 
 H                  0.02850000   -0.36580000    0.94190000 
 H                 -2.13710000    0.71350000   -2.07460000 
 1 2 1.0 8 1.0 11 1.0 12 1.0 
 2 3 1.0 13 1.0 14 1.0 
 3 4 1.0 15 1.0 16 1.0 
 4 5 1.0 17 1.0 18 1.0 
 5 6 1.0 19 1.0 20 1.0 
 6 7 1.0 9 1.0 10 1.0 
 7 8 3.0 
 8 
 9 21 1.0 22 1.0 23 1.0 


















Scheme  3.7. Unique imaginary frequencies. 
 
Table 3.7 Calculated energies. 
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In conclusion, we successfully investigated a new strategy of making H2S prodrugs by 
using an esterase catalyzed lactonization prodrug system. Compared to existing H2S 
prodrugs/donors, the new H2S prodrugs described show several unique features. First of all, they 
have controlled H2S release rates. This aspect seems to be the most challenging and important 
issue in the field of H2S donors.  Secondly, the trigger is an enzyme ubiquitous in the biological 
system.223 Thirdly, the prodrugs require a specific type of enzyme to trigger H2S release, which 
afford the potential for controlled release at preferred sites. Fourthly, as research tools, the 
prodrugs described have well-defined negative controls. Fifthly, this strategy provides the first 
H2S-NSAIDs hybrids with controllable release rates. We believe that these new H2S prodrugs will 
be very useful research tools to others working in this field. 
We have developed a series of persulfide prodrugs with controllable release rates. These 
persulfide prodrugs release persulfide through an esterase-mediated hydrolysis mechanism. In the 
presence of the PLE, the prodrugs efficiently released persulfides under near physiological 
conditions. Using the prodrug, we reaffirmed the reactivity between persulfide and MMTS. The 
protective effects of P2 in a murine model of MI/R injury have also been demonstrated.  All the 
studies above demonstrate that this novel type of persulfide prodrugs not only can be used as 
research tools, but also are possible therapeutic agents. 
 In targeted therapy, there is a strong need for the development of new chemistry to achieve 
selective delivery, which would complement existing ones. In the chapter 2 study, we have 
developed a new concept and a platform approach, which relies on concentration-sensitive 
chemistry to allow for selective drug release upon enrichment. This is achieved by taking 
advantage of reaction kinetics, which allows for accelerated cleavage at an elevated concentration. 
139 
Such an approach will be very useful in delivering small molecules through targeting including 
the use of antibody drug conjugates and receptor-mediated drug delivery. As a result, the delivery 
is not limited to cell surface and can be used for sub-cellular delivery, with enriched 
concentrations, which could not be achieved by ADC based delivery. Collectively, we describe a 
method that could be leveraged for biologic and medicinal efforts in treating disease.  
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Appendix C. 1H and 13C Spectra of compounds in chapter 3 
 
 

















































               
200 
 
      


































YBC_P67_ESIPOS_BWANG_12102014 #182-212 RT: 2.57-2.98 AV: 31 NL: 9.93E7
T: FTMS + p ESI Full ms [100.00-1000.00]





































YBC_P66_ESIPOS_BWANG_12102014 #172-199 RT: 2.45-2.82 AV: 28 NL: 3.54E5
T: FTMS + p ESI Full ms [100.00-1000.00]











































YBC_P65_II_ESIPOS_BWANG_12102014 #176-202 RT: 2.49-2.85 AV: 27 NL: 4.87E7
T: FTMS + p ESI Full ms [100.00-1000.00]







































YBC_P64_ESIPOS_BWANG_12102014 #171-188 RT: 2.43-2.66 AV: 18 NL: 7.65E7
T: FTMS + p ESI Full ms [100.00-1000.00]















































YBC_P12_ESINEG_BWANG_12102014_141210173548 #108-115 RT: 2.32-2.43 AV: 8 NL: 3.45E6
T: FTMS - p ESI Full ms [100.00-1000.00]





































QtofMicroACN+0.5%NH3 40ul, 1ul sample 09-Dec-201409:41:23
m/z












































19-Dec-201409:15:36ACN+0.5%NH3, 1ul sample, Na Format sol as ITSD QtofMicro















YBC_I_P115_ESIPOS_WILSON_02112015 #183-193 RT: 2.49-2.63 AV: 11 NL: 4.73E5
T: FTMS + p ESI Full ms [100.00-1000.00]










































YBC_I_P113_ESIPOS_WILSON_02112015 #181-190 RT: 2.47-2.59 AV: 10 NL: 1.74E7
T: FTMS + p ESI Full ms [100.00-1000.00]





































YBC_I_P114_ESIPOS_WILSON_02112015 #171-189 RT: 2.33-2.57 AV: 19 NL: 3.21E5
T: FTMS + p ESI Full ms [100.00-1000.00]









































YBC_I_P118_ESIPOS_WILSON_02112015 #184-196 RT: 2.50-2.67 AV: 13 NL: 2.74E7
T: FTMS + p ESI Full ms [100.00-1000.00]
















































YBC_I_P119_ESIPOS_WILSON_02112015 #185-200 RT: 2.52-2.72 AV: 16 NL: 2.62E6
T: FTMS + p ESI Full ms [100.00-1000.00]





































Bingchen_YBC_I_P136_ESIPOS_BWANG_04292015 #182-190 RT: 2.56-2.67 AV: 9 NL: 5.62E7
T: FTMS + p ESI Full ms [100.00-1000.00]











































Bingchen_YBC_I_P140_ESIPOS_BWANG_04292015 #187-199 RT: 2.66-2.82 AV: 13 NL: 1.60E7
T: FTMS + p ESI Full ms [100.00-1000.00]












































Bingchen_YBC_I_P141_ESIPOS_BWANG_04292015 #187-193 RT: 2.68-2.76 AV: 7 NL: 1.68E7
T: FTMS + p ESI Full ms [100.00-1000.00]





































Bingchen_YBC_I_P142_ESIPOS_BWANG_04292015 #177-185 RT: 2.53-2.64 AV: 9 NL: 3.51E7
T: FTMS + p ESI Full ms [100.00-1000.00]














































Bingchen_YBC_I_P143_ESIPOS_BWANG_04292015 #180-193 RT: 2.57-2.75 AV: 14 NL: 4.13E6
T: FTMS + p ESI Full ms [100.00-1000.00]









































Bingchen_YBC_II_P60_ESIPOS_BWANG_05062015 #170-184 RT: 2.35-2.54 AV: 15 NL: 6.85E6
T: FTMS + p ESI Full ms [100.00-1000.00]







































Bingchen_YBC_II_P61_ESIPOS_BWANG_05062015 #147-164 RT: 2.05-2.28 AV: 18 NL: 3.58E8
T: FTMS + p ESI Full ms [100.00-1000.00]









































Bingchen_YBC_II_P63_ESIPOS_BWANG_05062015 #181-193 RT: 2.50-2.67 AV: 13 NL: 2.54E9
T: FTMS + p ESI Full ms [100.00-1000.00]














































YU_6_P42_ESIPOS_BWang_10272016 #116-155 RT: 1.90-2.45 AV: 40 NL: 6.25E5
T: FTMS + p ESI Full ms [50.00-1000.00]
































































YU_6_64_ESIPOS_BWang_10272016_161027105256 #159-191 RT: 2.53-2.97 AV: 33 NL: 1.61E4
T: FTMS + p ESI Full ms [50.00-1000.00]
















































YU_6_52_ESIPOS_BWang_10272016 #171-184 RT: 2.72-2.91 AV: 14 NL: 8.79E5
T: FTMS + p ESI Full ms [50.00-1000.00]



























































YU_7_26_ESIPOS_BWANG_11032016 #156-167 RT: 2.34-2.50 AV: 12 NL: 5.07E3
T: FTMS + p ESI Full ms [50.00-1000.00]













































in ACN+0.5%NH3  792.8593 as ITSD






































in ACN+0.5%NH3  792.8593 as ITSD
m/z

















YU_7_22_ESIPOS_BWang_10272016_161027123156 #160-171 RT: 2.24-2.39 AV: 12 NL: 1.82E5
T: FTMS + p ESI Full ms [100.00-2000.00]
























































YZ__4_79_1_BWANG_120116 #111-150 RT: 1.57-2.13 AV: 40 NL: 2.52E6
T: FTMS + p ESI Full ms [100.00-1000.00]














































YZ__4_78_1_BWANG_120116 #153-157 RT: 2.14-2.20 AV: 5 NL: 3.19E8
T: FTMS + p ESI Full ms [100.00-1000.00]












































YZ__4_77_1_BWANG_120116 #143-152 RT: 1.99-2.11 AV: 10 NL: 7.22E7
T: FTMS + p ESI Full ms [100.00-1000.00]










































































MJS_1_146_ESIPOS_BWANG_082616_2 360 (6.695) AM (Cen,4, 80.00, Ht,5000.0,226.95,0.80); Cm (355:361)







254.9860240.9720186.9978 226.9520221.1182193.1268 404.9711269.0018 387.0909335.2171307.1530 322.9826 472.9791437.2460 458.9359
m/z




MJS_1_147_ESIPOS_BWANG_082616_2 419 (7.781) AM (Cen,4, 80.00, Ht,5000.0,226.95,0.80); Cm (415:419)








































MJS_1_147_ESIPOS_BWANG_082616_2 419 (7.781) AM (Cen,4, 80.00, Ht,5000.0,226.95,0.80); Cm (415:419)






MIS_1_154_ESIPOS_BWang_09152016 #173-255 RT: 2.90-4.29 AV: 83 NL: 1.64E5
T: FTMS + p ESI Full ms [50.00-1000.00]














































































































MIS_1_155_ESIPOS_BWang_09152016 #127-166 RT: 2.13-2.79 AV: 40 NL: 6.12E5
T: FTMS + p ESI Full ms [50.00-1000.00]












































MIS_1_155_ESIPOS_BWang_09152016 #200 RT: 3.36 AV: 1 NL: 1.58E5
T: FTMS + p ESI Full ms [50.00-1000.00]





















































YU_A_1_ESIPOS_BWANG_11032016 #129-163 RT: 2.01-2.48 AV: 35 NL: 1.30E5
T: FTMS + p ESI Full ms [50.00-1000.00]












































YU_A_2_ESIPOS_BWANG_11032016 #133-217 RT: 2.01-3.19 AV: 85 NL: 6.14E5
T: FTMS + p ESI Full ms [50.00-1000.00]



















































YU_A_2_ESIPOS_BWANG_11032016 #133-217 RT: 2.01-3.19 AV: 85 NL: 1.10E7
T: FTMS + p ESI Full ms [50.00-1000.00]




















































































in ACN+0.5%NH3  792.8593 as ITSD



















ZYQ_A_2_ESIPOS_BWANG_11102016 #139-148 RT: 2.14-2.26 AV: 10 NL: 9.53E6
T: FTMS + p ESI Full ms [50.00-1000.00]





















































ZYQ_4_TPP_N3_ESIPOS_BWANG_121516_2 156 (2.905) Cm (152:157) TOF MS ES+ 
949430.4652
431.4799
432.4621
